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Abstract 
Sun exposure, specifically solar ultraviolet radiation (UVR), is adversely associated 
with melanoma incidence, yet exposure to ultraviolet radiation is an important step in 
the pathway to vitamin D synthesis. In vitro studies suggest that cultured melanoma 
cells proliferate at a slower rate in response to the hormonal form of vitamin D, 1,25-
dihydroxyvitamin D (1,25(OH)2D), and can synthesise 1,25(OH)2D from the main 
circulating form of vitamin D, 25-hydroxyvitamin D (25(OH)D). Similarly, in vivo 
trials have found that calcitriol (1,25(OH)2D) can suppress melanoma growth and 
inhibit metastasis in immunosuppressed rodents. Several epidemiological studies 
have suggested a link between higher sun exposure and improved melanoma 
prognosis, yet only a small body of research has been conducted to investigate if 
there is a relationship between vitamin D status and melanoma prognosis.  
The QUT Melanoma Study examined the relationship between serum 25(OH)D 
concentration at time of diagnosis and the histopathological features of melanoma 
that are associated with prognosis. Prior to wider-excision surgery, 100 eligible 
melanoma patients were recruited to this cross-sectional study in Brisbane, Australia. 
Blood was obtained for serum 25(OH)D analysis at time of recruitment and each 
patient completed a self–report questionnaire and consented to a physical 
examination to collect data on known risk factors for melanoma. Logistic regression 
modelling was used to obtain odds ratios for associations between vitamin D 
(continuous, lowest quartile, 50 nmol/L, highest quartile) and the prognostic 
indicators for melanoma of Breslow thickness, Clark level and mitotic activity, while 
controlling for potential confounders. 
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In multivariable analysis adjusted for age, sex, ITA (Individual Topography Angle) 
value, BMI (Body Mass Index) and season at time of diagnosis, a statistically 
significant association was observed between vitamin D status at the time of 
melanoma diagnosis and Breslow thickness. Melanomas with Breslow thickness of 
0.75mm or greater were considerably more common in patients with insufficient 
vitamin D status (< 50 nmol/L) compared to those with sufficient vitamin D status (≥ 
50 nmol/l) (OR = 3.82, 95% CI: 1.03, 14.14, P = 0.04). This association 
strengthened when the lower quartile of serum 25(OH)D (< 45.25 nmol/L) was 
compared to all other quartiles (OR = 5.03, 95% CI: 1.32, 19.09, P = 0.02). No 
significant relationships were found between vitamin D status (insufficient versus 
sufficient) and either Clark level (Level 2–5 versus Level 1) or mitosis (present 
versus absent), and there was no evidence that higher levels of serum 25(OH)D (≥ 
69.8 nmol/L) were protective for prognosis compared to lower levels   (< 69.8 
nmol/L).  
While possible mechanisms responsible for this association are yet to be elucidated, 
the suggestion that sufficient vitamin D status may be associated with a better 
prognosis for melanoma could have wide ranging implications for public health 
messaging with respect to both melanoma and vitamin D. There will be inherent 
difficulties in devising an appropriate public health message that balances the need 
for sufficient vitamin D status while at the same time avoiding too much sun 
exposure – and the risk of developing melanoma. Until further research can define 
the optimal level of vitamin D necessary for a good melanoma prognosis, it would 
appear sensible for all to ensure that they maintain serum 25(OH)D levels greater 
than 50 nmol/L, particularly those at a greater risk of developing melanoma. 
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Chapter 1: Introduction 
This chapter outlines the problem statement (section 1.1) and the significance of the 
research (section 1.2), and identifies the aim (section 1.3). Section 1.4 defines the 
scope of the research and defines the terms that are used. Finally, section 1.5 
provides an outline for the remaining chapters of the thesis. 
 
1.1 PROBLEM STATEMENT 
Queensland, the “Sunshine State” of Australia, has the highest incidence of 
cutaneous melanoma in the world.1  Melanoma, a cancer originating from the 
melanocytes, or pigment forming cells found in the basal layer of the skin, presents a 
major global public health problem.2 It is the fourth most common cancer diagnosed 
in Australia3, the most common cause of cancer in Australians aged 15–24 years,4 
and in the United States of America it is the most common cancer in the 20–29 year 
old age group.5 Surgery is the most effective form of treatment for melanoma; 
however prognosis is poor with no curative treatment currently available once the 
disease spreads to the regional lymph nodes and other organs.6-8 
The exact cause of melanoma is unknown. Environmental factors, especially sun 
exposure, and genetic factors are strongly linked to the disease, while previous 
history of other skin cancers, increased number of naevi and fair skin phenotype are 
also known risk factors.9,10 Exposure to solar ultraviolet radiation (UVR) is 
considered to be the major risk factor for melanoma in fair-skinned populations,11-13 
yet melanoma can form on parts of the body that are not exposed to the sun14 and is 
diagnosed more often in indoor workers than outdoor workers.15-17  
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Some epidemiological research has suggested that UVR exposure, particularly 
recreational exposure, is associated with increased survival rates from melanoma.18 
Further, it has also been suggested that the possible protective effects of exposure to 
UVR against mortality from melanoma might be due to the positive effects of 
vitamin D on various aspects of cancer biology,19 as approximately 90% of the 
human requirement of vitamin D is obtained through exposure to solar UVR.20  
Cell biology research has shown that cultured melanoma cells proliferate more 
slowly in response to the active form of vitamin D (1,25-dihydroxyvitamin D)21 and 
that 1,25-dihydroxyvitamin D induces apoptosis in human melanoma cell lines in 
vitro.22 Recently, several epidemiological studies conducted in the Northern 
Hemisphere have reported that lower levels of serum 25-hydroxyvitamin D (the 
inactive biomarker of circulating vitamin D) were associated with a poorer outcome 
for patients with invasive melanoma.23-25 
A large Australian study observed that 31% of participants were deficient (< 50 
nmol/L) in vitamin D26 and a small study conducted in Brisbane (the Queensland 
capital) suggested that almost one-third of that population – living in a high ambient 
UVR environment - had low vitamin D status (25 nmol/L–50 nmol/L).27 If low 
vitamin D status at time of melanoma diagnosis does adversely affect prognosis, 
these findings from Queensland – highest melanoma incidence, high prevalence of 
vitamin D deficiency, link between vitamin D status and melanoma prognosis – 
taken together, would have considerable public health significance. 
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1.2 SIGNIFICANCE OF RESEARCH 
No study has been conducted in Australia to investigate if vitamin D status at time of 
diagnosis is associated with melanoma prognosis. This represents a gap in the 
knowledge that may inform why some patients have a better prognostic outcome 
from melanoma than others.  
1.3 AIM 
The aim of this study was to identify, and explore, the nature of any relationship 
between serum 25-hydroxyvitamin D concentration (25(OH)D) of patients with 
newly diagnosed melanoma in Queensland, and the outcome for those patients as 
predicted by histopathological features of the melanoma that are known to be 
associated with prognosis. 
1.4 SCOPE 
Patients aged 18 years or older, who presented with a diagnosis of melanoma to 
either one of two plastic surgeons in Brisbane, Australia over a 12 month period, and 
who satisfied the inclusion and exclusion criteria, were invited to participate in the 
study. The prognostic indicators for melanoma of Breslow thickness, Clark level, 
mitotic rate and ulceration were obtained from the histopathology reports. To obtain 
serum 25(OH)D concentrations that were indicative of the participant’s “usual” 
levels, blood samples were taken at the time of the first appointment with the surgeon 
(prior to the wider-excision surgery); that is before sun exposure behaviour may have 
changed in response to the diagnosis. As a matter of protocol, patients with a 
histologically proven provisional diagnosis of melanoma (following a biopsy usually 
performed by a general practitioner/primary care physician) are seen by either 
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surgeon within four days of their initial diagnosis, and wider-excision surgery 
routinely occurs within seven days of that appointment.  
1.5 OVERVIEW OF THE THESIS 
In Chapter 2, a literature review examines current knowledge on both melanoma and 
vitamin D, before research investigating relationships between melanoma prognosis 
and serum 25(OH)D concentration is found to be limited to three studies conducted 
in Germany and England. These studies are summarised and discussed before the 
need to address certain methodological issues such as timing of blood samples is 
argued and areas that await research are identified.  
Chapter 3 draws on the conclusions of the previous chapter to establish the research 
question and then develop an appropriate method for conducting a study that will 
answer the question and fulfil the study aim. The research instruments and the 
method of their application are then described. Data analysis methods are discussed 
and a risk-factor model is developed and a step-by-step explanation of the model-
building process outlined. 
The study results are delivered in two chapters. Chapter 4 provides descriptive and 
summary statistics relating to the outcomes, main exposure and all covariates 
considered to be potential confounders of the relationship between serum 25(OH)D 
concentration and melanoma prognosis. This chapter sets the scene for the risk factor 
modelling to examine the association between serum 25(OH)D and the histological 
indicators of melanoma prognosis, that is presented in Chapter 5. 
The results from both chapters 4 and 5 are then evaluated and discussed in Chapter 6 
in terms of the contribution they make to existing knowledge on the relationship 
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between 25(OH)D concentration and melanoma prognosis. Recommendations for 
areas where this research could be extended in the future and possible improvements 
to the research design and limitations of the study are suggested, before final 
conclusions are drawn in Chapter 7.
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Chapter 2: Literature Review 
2.1  INTRODUCTION 
To investigate if 25(OH)D concentration is associated with melanoma prognosis, 
electronic databases were searched up to January 2013 using the keywords vitamin 
D, 25(OH)D, 25-hydroxyvitamin D, VDR, vitamin D receptor, melanoma, cutaneous 
melanoma and CMM, in varying combinations and truncations. Only peer reviewed 
journal articles were retrieved and the reference lists from these articles were then 
searched for any hereto, unidentified studies.  Following this initial retrieval, weekly 
alerts were set up on these databases: PubMed, Science Direct, HighWire Press (all 
journals) (aacrjnls-mailer@alerts.stanford.edu) and Web of Science and the same 
system of searching reference lists for further articles was used to locate new 
material. The Queensland University of Technology library retrieved and delivered 
documents that were too old to be available online. Articles were not constrained by 
language and two articles written in German required translation. Books relating to 
both vitamin D and melanoma were also examined.  
This chapter will describe and discuss the findings of that search to identify what is 
currently understood about the relationship between vitamin D and melanoma 
prognosis. Initially skin biology, structure and function will be described, followed 
by a brief introduction to solar ultraviolet radiation and cancers of the skin. 
Epidemiology of cutaneous melanoma will then be explored and the burden of the 
disease in Queensland contextualised in relation to Australia, globally and to other 
cancers and over time. Melanoma aetiology will be discussed and the known risk 
factors identified. After examining clinical and histopathological diagnosis, 
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classification, treatment and management of the disease, the potential role of vitamin 
D will be introduced. Vitamin D nomenclature, production, availability and 
activation are then described in detail before research investigating links between 
vitamin D and melanoma is reviewed. Studies that have specifically examined the 
relationship between vitamin D and prognosis for melanoma are identified and 
discussed. Finally, a summary of findings is presented before the chapter concludes 
by identifying potential areas for further research. 
 
2.2 SKIN BIOLOGY, STRUCTURE AND FUNCTION 
2.2.1 Skin biology and function 
The skin, the largest and most visible human organ, varies in thickness from less than 
0.5 mm on the eyelids to 6 mm between the shoulder blades.28 Covering the entire 
body, the skin has a range of functions that support survival by shielding the internal 
organs and tissues from physical, chemical and microbial attack.29 Physical attack, 
such as punctures, abrasions and absorption, are deterred by the laminar structure of 
the skin, pathogens are repelled by the immune cells of the skin and maintenance of 
body homeostasis is ensured by the ability of the skin to sweat.30 The skin also 
protects the body from the harmful effects of solar UVR and is the site for initialising 
the production of vitamin D.28  
2.2.2 Skin structure 
The skin has two main layers (see Figure 2.1); the epidermis and dermis. Directly 
underneath the dermis is a layer of connective tissue, the subcutaneous layer, which, 
although not technically part of the skin, is often referred to as such.31 
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Figure 2.1. Cross-section of human skin consisting of the epidermis and the dermis, with the 
underlying subcutaneous layer. 
32  
Epidermis 
The epidermis (see Figure 2.2), on average only 0.1 mm thick, protects the deeper 
layers of the skin and is composed of several types of epithelial cells: keratinocytes, 
melanocytes, Langerhans cells and Merkel cells.28 Keratinocytes make up 
approximately 90% of the epidermal cells, produce a tough protein (keratin) and are 
the main structural element of the outer skin.30 Melanocytes produce the polymeric 
pigment, melanin, which contributes to skin colour and plays an important role in 
protecting the keratinocytes from exposure to UVR.30 Langerhans cells play a role in 
immunity and the Merkel cells connect to nerve endings responsible for detection of 
light touch and pressure.31,33,34  
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Figure 2.2. Cross-section of the epidermis showing the four main layers and identifying melanocytes 
and Langerhans cells. 
35 
 
The epidermal cells are found in four distinct layers. From deepest to most 
superficial they are the stratum basale, stratum spinosum, stratum granulosum and 
the stratum corneum. Keratinocytes in the stratum basale undergo mitosis and 
migrate from this layer to be keratinised before being pushed to the surface.30 The 
stratum corneum consists of up to 30 layers of dead keratinocytes arranged in 
overlapping layers to give the skin it’s tough, waterproof characteristics.28 The dead 
cells are continually shed to be replaced by new squamous cell keratinocytes pushing 
up from lower layers.29  
Melanocytes, located in the stratum basale and matrix of the hair bulb, make 
dendritic connections with keratinocytes34,36 and convert the amino acid tyrosine into 
melanin pigments which are released in melanosomes and transferred to the 
keratinocytes to make the brown pigment, melanin.30,34 The amount of melanin 
produced is regulated by UVR exposure, genetic expression of enzymes such as 
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tyrosinase, and hormones (such as the α-melanocyte stimulating hormone)37 and 
determines individual skin colour.38 
Dermis  
The dermis consists of fat, collagen, elastin fibres, salts, water, sebaceous glands, 
sweat glands, hair follicles, nerves and blood vessels.30 This dense, strong skin layer 
is replenished by the rich blood supply that also supplies the multiplying cells in the 
basal layer of the epidermis.28 Collagen comprises the majority of the dermis and 
gives the skin strength and the ability to scatter visible light and the sweat glands are 
responsible for temperature regulation, or homeostasis.31 
Subcutaneous layer  
The innermost layer of the skin connects the dermis above to the underlying organs. 
The subcutaneous layer consists predominately of loose fibrous connective tissue, fat 
and blood vessels.30,31 Fat stored in this layer represents an energy source for the 
body, is an insulation layer against variability in outside temperatures, and also acts 
to cushion the body.28 
 
2.3 SOLAR ULTRAVIOLET RADIATION (UVR) 
Sun exposure from a young age is known to be a significant risk factor for 
melanoma, particularly in fair-skinned people,11,39 yet sunlight is fundamental for life 
on Earth. UVR is the region of the solar radiation spectrum associated with skin 
cancer, in particular the long wavelength UVA (315–400 nm) and the shorter UVB 
(280–315 nm).40 UVC (200–280 nm) does not reach Earth’s surface as it is absorbed 
by oxygen and ozone in the upper atmosphere.41 Approximately 90 to 95% of solar 
UVR energy reaching the Earth’s surface is UVA.42 With a longer wavelength than 
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UVB, UVA can penetrate deeper into skin and it is estimated that 19 to 50% of solar 
UVA reaches the depth of melanocytes, whereas only 9 to 14% of solar UVB reaches 
the melanocytes.43 This long-wavelength property of UVA also allows it to pass 
through most automobile, office and household windows, whereas UVB is blocked 
by window glass.44 Similarly, some research suggests that a substantially greater 
percent transmission of UVA, as compared with UVB, occurs through cotton  
fabrics.45  
2.3.1 UVA versus UVB 
The two UV spectra also have different biological effects. UVB is about 1,000 times 
more effective than UVA in inducing sunburn,43 while UVA, on the other hand, is 
much more potent in inducing immediate pigment darkening (IPD) and persistent 
pigment darkening (PPD).44 Both UVA and UVB cause biologic damage, with the 
formation of single oxygen radicals that subsequently lead to DNA-strand breakage, 
nucleotide damage and mutations.44  
2.3.2 Skin response to UVR 
Humans have adopted mechanisms to moderate the harmful effects of solar UVR, 
including the production of UV absorbing pigments such as melanin.46 While the 
amount of melanin produced by the melanocytes is substantially increased after 
chronic UVB exposure,34 the ratio of the two main types of melanoma pigment: 
eumelanin and pheomelanin, are critical in the determination of an individual’s 
photosensitivity.47-49 Eumelanin acts as a sunscreen to protect the skin from UVR 
induced damage, while in contrast pheomelanin is photosensitising and may promote 
carcinogenesis.33,47 The ratio of epidermal eumelanin to pheomelanin therefore 
affects the susceptibility of the human skin to UVR damage.47 Various studies have 
also documented that the darker the skin is, the lower the percentage of UVR 
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transmitted, thus explaining (albeit very simply), why dark skinned people can live 
free from skin cancer in the equatorial regions.50,51 
 
2.4 CANCERS OF THE SKIN 
The majority of skin cancers are caused by inappropriate exposure (according to skin 
type) to solar UVR.17 The three main skin cancers: Basal cell carcinoma (BCC), 
Squamous cell carcinoma (SCC) and cutaneous melanoma, originate in the epidermis 
and take their names from corresponding cell types: basal cells, squamous cells and 
melanocytes.52 BCCs and SCCs are combined as a group known as non-melanoma 
skin cancers (NMSC) and are the most commonly reported cancers in Australia.53  
Melanoma accounts for less than five percent of all detected skin cancers.54 
Nevertheless, as they are rapidly growing, appear at any age, and on any part of the 
body, they are the most aggressive of all skin cancers due to their high likelihood of 
metastasis.55 The melanoma usually presents as a freckle or mole that has changed 
size, shape, colour or texture, or a new spot that is very dark in colour.56 Melanomas 
are often brown or black; yet this is not always the case as they can also be devoid of 
colour (amelanotic melanoma).57  
2.4.1 Melanoma cell of origin theory 
In response to solar UVR, epidermal keratinocytes regulate the survival, 
differentiation, motility and proliferation of melanocytes, stimulating them to 
produce melanin when the skin is exposed to the sun.37 Melanin is responsible for 
making the skin tan (or brown) and for protecting the deeper layers of the skin from 
the harmful effects of the sun.58 Melanocytes, derived from the neural crest during 
embryonic development,59 are found in the epidermis, the eye, and in the epithelia of 
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the nose, oropharynx, urinary tract, anus and vagina.60 The traditional model of 
melanoma development is that mature epidermal melanocytes are the cells of origin 
responsible for tumour development. This view is based on pathological features that 
suggest melanomas develop in the epidermis and then invade the dermis.61  
This traditional view is now being challenged by research showing that 
subpopulations of tumour stem cells (TSCs) are present in solid cancers.62,63 TSCs 
are capable of self-renewing, and although they comprise only a small part of a 
tumour, they have been shown to have the ability to generate new tumour nodules. 
Melanomas, like other solid tumours, have a subpopulation of TSCs, and with 
research identifying that tumour cells require an accumulation of genetic and 
phenotypic changes over extended periods of time, there is support for the theory that 
melanoma may develop from such a precursor cell that has acquired malignant 
mutations over time.62  
 
2.5 EPIDEMIOLOGY OF MELANOMA 
2.5.1 Current incidence trends 
The first reported mention of melanoma was by Hippocrates in the fifth century,  
B.C.64 Melanoma now contributes significantly to the public health burden of many 
countries with the incidence rising globally since the 1950s.65-67 The most recent 
global estimates are that there were approximately 200,000 new cases of invasive 
cutaneous melanoma diagnosed in 2008, with the disease reportedly the sixth most 
frequent cancer diagnosed in westernised countries of mainly Caucasian 
populations.65  
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Australia 
In 2008, Australia had the highest age-standardised incidence rate for cutaneous 
melanoma (37 cases per 100,000 people) of any country in the world.68 This rate was 
more than 12 times higher than the average world rate of three cases per 100,000 
people.68 With the exception of a levelling off period in the early to mid 1990s, 
Australian incidence rates, for both males and females (see Figure 2.3), have been 
steadily increasing over the past three decades68 and show similar temporal patterns 
to data from countries in Europe and the United Kingdom.6,69  
 
 
 
Note: Age-standardised to the Australian Population.  
# ASI: Age-standardised incidence rate 
Figure 2.3. Incidence rate trends for melanoma in Australia for 1982–2008. 
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The incidence rates for Australian males doubled from 27 cases per 100,000 males in 
1982, to 57 cases per 100,000 males in 2007, while in the same time period the rate 
for females increased by 47% from 26 cases per 100,000 females to 38 cases per 
100,000 females.68  
Recent data indicate that Australian incidence rates may be stabilising due in part to 
a slight decline in incidence among young females (aged 25–44 years), and males in 
general.65 In males, the risk of being diagnosed by age 75 is 1 in 24 or 1 in 15 by age 
85, and in females the risks are 1 in 35 by age 75 and 1 in 24 by age 85.68 In the ten-
year period from 1998–2008, the annual average increase in incidence rates for 
melanoma was 1% per person, while in the period 2006–2008 the increase was 
0.6%.54 
United States of America 
By comparison, in the United States in 2004, the equivalent lifetime risk was 1 in 55 
for men and 1 in 82 for women.70 The latest National Cancer Institute’s Surveillance, 
Epidemiology and End Results (SEER) data for 2005–2009 reports age-adjusted 
incidence rates of 27.2 per 100,000 males and 16.7 per 100,000 females.5  
Queensland 
Queensland, Australia’s most north-eastern state, has the highest age-standardised 
incidence rates for melanoma in the world, with 83.2 cases per 100,000 for males and 
53 cases per 100,000 for females reported in 2008.1,3  For Queensland males,3 the 
approximate risk of being diagnosed with melanoma by age 75 is 1 in 18 increasing 
to 1 in 11 by age 85. In females,1 the risks of being diagnosed with melanoma are 
lower at 1 in 26 by the age of 75 years and 1 in 19 by the age of 85 years.  
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Queensland incidence in comparison to other states and countries   
Data (see Table 2.1) from the most recent Cancer Incidence in Five Continents 
publication from the International Agency for Research on Cancer (IARC), shows 
that for the period 1998 to 2002, the reported melanoma incidence for Queensland 
was more than three times that of any country in Europe.71 
Table 2.1 
Selected IARC figures for comparative melanoma incidence 1998–2002 
Country Age-standardised (world) incidence (per 100,000) 
 
  
Male 
 
Female 
Queensland, Australia 55.8 41.1 
New South Wales, Australia 38.5 26.5 
Victoria, Australia 27.3 23.4 
New Zealand 34.8 31.4 
US SEER 14 registries 
    non-Hispanic whites 
19.4 14.4 
Vaud, Switzerland 16.6 19.6 
Norway 14.2 14.6 
Sweden 11.9 12.1 
Denmark 11.9 14.1 
Saarland, Germany 8.1 7.8 
Yorkshire, England 6.9 8.9 
Serbia 3.8 4.8 
Latvia 3.2 4.2 
Belarus 2.7 3.5 
 
71 
 
2.5.2 Burden of disease 
Melanoma is the fourth most common cancer diagnosed in Australia,3 representing 
9.6% of all cancers diagnosed (see Figure 2.4). It is also the most common cause of 
cancer in the 15-24 year age group.4,54   
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Figure 2.4. The 10 most commonly diagnosed cancers in Australia, 2007.  
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In 2007, melanoma was ranked eighth in Australia’s causes of cancer burden of 
disease and was estimated by the Australian Institute of Health and Welfare (AIHW) 
to have accounted for 22,300 disability adjusted life years (DALYS) in 2010.68 
16,800 of the DALYS were lost due to premature death ,while the remainder were 
healthy life years lost due to disability or disease.68 Males reportedly suffered the 
greater burden of disease from melanoma, with more than twice the number of 
DALYs (15,300) of females (7,000).68  
2.5.3 Mortality from melanoma 
Absolute mortality rate 
IARC72 reported an estimated 46,000 deaths from melanoma globally in 2008. The 
Australian Cancer Incidence and Mortality books reveal that in 2007 there were 
1,279 deaths from melanoma, which represented 3.2% of all cancer deaths in 
Australia.54 
Temporal trends in mortality rate 
While the incidence of melanoma worldwide is steadily increasing, mortality data 
from Australia, the United Kingdom, Scotland, France and Sweden, indicate that 
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death rates from melanoma are increasing more slowly.54,69,73 In Australia,74 the age-
standardised mortality rate (ASM) for melanoma increased from 3.3 deaths per 
100,000 in 1968 to 5.7 deaths per 100,000 in 2007. This increase was driven largely 
by the increasing mortality rates in males. Thus, while ASM rates for females have 
remained quite steady over the past four decades (from 2.8 deaths per 100,000 
females in 1968), rates for males have slowly increased from 3.9 per 100,000 males 
(see Figure 2.5).54 In 2007, the ASM rates for melanoma were higher for males (8.5 
deaths per 100,000 males) than for females (3.4 deaths per 100,000 females).54  
 
 
Note: Age-standardised to the Australian Standard Population 2001  
# ASM: Age-standardised mortality rate 
 
Figure 2.5 Australian trends in mortality rates for cutaneous melanoma (1968-2007).  
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rates for Scottish females remained relatively unchanged at 1.5 deaths per 100,000 
females.69 This has led to the suggestion that a 1980s melanoma awareness campaign 
may be responsible for the relatively slow rise in Scotland’s melanoma mortality rate 
compared to the incidence rate, due to earlier detection and excisions of thinner 
lesions.69 However, this does not explain the lack of change in the female mortality 
rate. 
Further, in Australia melanoma mortality rates increase with increasing age, more so 
for males than for females (see Figure 2.6).54 
 
 
Note: Age-standardised to the Australian Standard Population 2001  
Figure 2.6. Death rates for cutaneous melanoma by age and sex (2007). 
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55–79 years age group and a three to four percent increase per annum in persons over 
the age of 80 years.75 
2.5.4 Survival from melanoma 
Approximately one quarter of all melanomas diagnosed in Australia in the period 
1982–2002 were classified as Clark level 1 (in situ) tumours.76 The detection of 
proportionally more in situ and thin melanomas (less than one millimetre) has 
positively impacted on survival from melanoma in Australia.76 The 20 year survival 
rate77 for thin melanomas is 96%. Localised (in situ) melanomas are reported to have 
a 99% survival rate five years after diagnosis,74  while in comparison, thicker 
melanomas (greater than four millimetres) are reported to have a five-year survival 
rate of 55%.74,78 This is similar to data from Scotland where five-year survival rates 
for thicker melanomas (greater than four millimetres) are reported to be 52.4% for 
males and 48.3% for females.69  
In Australia in the five-year period from 2006–2010, females (94%) had a higher 
survival compared to males (89%) with no difference noted according to remoteness 
or socioeconomic status.74 Nevertheless, overall five-year survival rates improved 
only marginally, from 88% in 1980 to 90% in 2004.79 With incidence rates 
increasing in the same period, these trends are most likely related to earlier detection 
of proportionally more in situ and thinner lesions,76 or possibly, some benefits of the 
primary prevention programs that have been in place nationally in Australia since the 
early 1980s. 
2.5.5 Melanoma risk factors  
In the 1950s sunlight was first suggested as the main environmental agent for 
melanoma due to the higher incidence of the disease in fair-skinned peoples.12,13 
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Considerable evidence has always supported the shorter wave UVB radiation (280–
315 nm) as the responsible risk factor for melanoma, however more recently the 
longer wave, UVA radiation (315–400 nm) has also been implicated.43,80 In 2006, a 
systematic review conducted by IARC determined that UVR emitted by tanning beds 
was associated with melanoma risk.81 Subsequent to that report, in 2010 Lazovich et 
al82 observed statistically significant increases in risk (OR = 4.44, 95% CI: 2.45, 
8.02) in tanning beds emitting predominantly UVA radiation.  
The highest level of evidence describing major risk factors for melanoma is provided 
by three systematic meta-analyses reported by Gandini et al9,10,83  in 2005. After 
conducting a systematic literature review of all observational studies on melanoma 
and risk factors published prior to September 2002, Gandini et al obtained studies 
that were independent, comparable, from populations that were homogenous for the 
risk factor under review, and which provided sufficient information to estimate 
relative risks.9,10,83 Relative risks (RR) were extracted from 46 studies for common 
and atypical naevi, RR for sun exposure from 57 studies, and RR for family history, 
actinic damage and phenotypic factors from 60 studies.9,10,83 Pooled estimates for the 
risk factors of interest were obtained using fixed and random effects models, between 
study variation and bias was explored by sub-group analysis and meta-regression, 
and publication bias and reliability of results was investigated by sensitivity analysis. 
Studies included in the meta-analyses were conducted in various regions of the world 
including North and South America, Europe, Israel and Australasia. 
The meta-analyses9,10,83 identified the following factors as the strongest predictors of 
cutaneous melanoma risk: 
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• skin phenotype (fair versus dark: RR = 2.06, 95% CI: 1.68, 2.52) 
• skin type (I versus IV: RR = 2.09, 95% CI: 1.67, 2.58) 
• number of common naevi: (greater than 100 naevi versus less than 15 
naevi: RR = 6.89, 95% CI: 4.63, 10.25) 
• number of atypical naevi (5 versus 0: RR = 6.36, 95% CI: 3.80, 10.33)                                                                      
• presence of actinic damage, including solar lentigos and elastosis (RR = 
2.02, 95% CI: 1.24, 3.29) 
• presence of pre-malignant and skin cancer lesions (RR = 4.28, 95% CI: 
2.80, 6.55) 
• positive family history of melanoma (RR = 1.74, 95% CI: 1.41, 2.14). 
 
Higher levels of sun exposure were also identified by Gandini et al,10 as a strong risk 
factor for melanoma, with varying relative risks dependent on latitude, skin 
phenotype and phototype, and sunburn history. Gandini et al10 acknowledge that 
while the measurement of sun exposure is inconsistent across studies and may be 
subject to recall bias from both cases and controls, intermittent sun exposure is 
positively associated with melanoma risk whereas high continuous UVR exposure is 
inversely associated. The researcher’s caveat for supporting intermittent sun 
exposure as a risk factor for melanoma, is that this was suggested by “well 
conducted” studies.10 Sunburn history was also noted to be a risk factor, however 
Gandini et al report that histological type, particularly lentigo maligna melanoma 
(commonly associated with chronic UVR exposure), influenced the estimated RR.10 
Although Gandini et al83 investigated skin phototype as a possible risk factor for 
melanoma, none of the studies included in their meta-analysis reported results from 
studies that used objective measurement tools. Instead, studies reported skin type 
 Chapter 2: Literature Review 24 
using the Fitzpatrick classification, or definitions used for “skin type” were based on 
the skin’s reaction to sunlight. An Italian study84 examined objective measures of 
constitutive skin colour in relation to melanoma risk and found that skin brightness 
(L*) of an unexposed body site is associated with an increased melanoma risk (OR = 
1.20, 95% CI: 1.12, 1.30). In 2002, a case-control study conducted by Brenner et al84 
used a reflectance spectrophotometer to assess constitutive skin colour of 183 
diagnosed melanoma cases and 179 controls. Measurements were taken on the 
buttock (as an “unexposed” site), and although the study population included 
participants of Italian heritage, all recorded measurements met the criteria for low 
pigmentation (L* > 60).84 The association between increased melanoma risk and L* 
persisted after the authors adjusted for other potential confounders. Others have also 
used reflectance spectrophotometry to show that cutaneous melanin density of 
another unexposed body site - the upper, inner arm, is a strong predictor of 
melanoma risk, particularly for males.85 
Demographic risk factors 
As with most cancers, age is one of the strongest risk factors for melanoma.86 In 
Australia for example, the risk of developing melanoma in 2008 was 1 in 909 for 30–
34 year olds, 1 in 485 for 40–44 year olds and 1 in 129 for 70–74 year olds.54 While 
the incidence of melanoma increases dramatically with age (see Figure 2.7), this is 
particularly noticeable in males.54,68 
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Note: Age-standardised to the Australian Standard Population 2001 
Figure 2.7. Australian age-sex specific incidence rates for melanoma (2008). 
54 
It should be noted that while melanoma is predominantly found in white skinned 
populations, a recent large cohort study87 identified that age, male sex and sunburn 
phenotypes may also be risk factors for melanoma in non-white populations 
(excluding African Americans). 
Latitude 
Whiteman and Green (2005) have suggested country of residence is another 
important determinant of the absolute risk of a melanoma occurring in a fair-skinned 
person.86 The role of solar UVR in the development of melanoma is, in general, 
supported by examination of global melanoma incidence figures that show a clear 
latitude gradient of increasing incidence with decreasing latitude.71,88-90 Within 
Australia (see Table 2.1, page 17), the potential influence of latitude is clearly 
demonstrated in the decreasing incidence rates from north to south.3,71 This is not the 
case in Western Europe however, where the European national cancer registries 
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report that the highest incidence rates are found in the Scandinavian countries.6,71 
This is possibly related to the higher use of sun beds and sunny holidays in these 
populations living in low ambient UVR locations.    
Patterns of sun exposure 
Studies have reported that the incidence of melanoma is higher in those exposed to 
UVR intermittently, rather than those exposed to a smaller quantity of UVR every 
day.52,91-93 As previously reported, a meta-analyses of 57 studies by Gandini et al10 
showed a positive association with intermittent sun exposure (RR = 1.61, 95% CI: 
1.31, 1.99), and an inverse association for high continuous sun exposure patterns (RR 
= 0.95, 95% CI: 0.87, 1.04); although the latter was not statistically significant. This 
may explain the higher melanoma incidence in indoor workers15,16,94 compared to 
outdoor workers (with high cumulative UVR exposure) and the small proportion of 
melanomas that arise in areas of the body rarely exposed to the sun, such as the 
buttocks.95 Gandini et al10 have suggested that the development of melanomas on 
intermittently exposed body sites (rather than continuously exposed), especially in 
younger people, may be due to the relatively unprotected skin allowing high 
transmission of UVR to the melanocytes. 
Divergent pathways theory 
The occurrence of melanomas on skin sites not commonly exposed to the sun, 
particularly in younger people and indoor workers, but with a predilection to sun 
exposed sites in older populations, has led to a “divergent pathways” theory to 
explain melanoma development on different body sites.96-98 Queensland researchers 
have found that the prevalence of naevi and solar keratosis differs significantly 
between patients with truncal melanomas and those with melanomas of the head and 
neck.98 Melanomas of the head and neck, rather than the trunk, were more likely to 
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be detected in people with fewer naevi (OR = 0.34, 95% CI: 0.15, 0.79), more than 
20 solar keratoses (OR = 3.61, 95% CI: 1.42, 9.17), and with a tendency to have a 
prior history of surgical excisions to remove solar-induced skin lesions (OR = 1.87, 
95% CI: 0.89, 3.92).98 People with melanomas of the head or neck were also 
statistically significantly more likely to have medium (OR = 2.27, 95% CI: 1.04, 
4.99) or higher (OR = 3.70, 95% CI: 1.52, 8.98) levels of occupational sun exposure 
than those of people with melanoma of the trunk.98  
These findings suggest that there are two pathways to melanoma development. 
Melanomas of the head and neck are related to cumulative sun damage (consistent 
with their occurrence in older age groups), whereas melanomas of the trunk are 
associated with melanocyte proliferation due to skin phenotype, specific genetic 
mutations, and intermittent sun exposure.98  
Genetic susceptibility  
Recently, researchers investigating the role of genetics in melanoma development 
have identified certain gene mutations associated with primary melanomas 
particularly with respect to the melanocortin receptor 1 gene (MC1R), proto-
oncogene B-Raf (BRAF), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog (KIT) and NRAS genes.99-102 Inherited mutations in genes encoded by the 
CDKN2A locus have also been associated with high melanoma risk (particularly in 
the context of familial melanoma), yet the reported prevalence is very low.103,104 
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2.6 CLINICAL AND HISTOPATHOLOGICAL DIAGNOSIS OF 
MELANOMA 
 
2.6.1 Clinical diagnosis 
Melanomas are more likely to be detected by the patient (44%), than by doctors 
(25.3%) or partners (18.6%).105 Signs and symptoms of melanoma can include 
itching, changes in size, shape or colour of an existing skin lesion, or in more 
advanced cases, bleeding and crusting. Trained medical practitioners will apply the 
ABCD(E) rule (Asymmetry, Border irregularity, Colour variation, large Diameter 
[and Evolution]) to initially identify suspicious lesions.106 Identification is aided by 
dermoscopy, a technique that allows clear and magnified vision of features of skin 
lesions unable to be seen with the naked eye.107 Complete surgical excision of the 
suspected lesion, with a clear two millimetre margin confirmed by histological 
examination, is the recognised gold standard in the clinical diagnosis of a 
melanoma.108,109 
2.6.2 Histopathological reporting of melanoma  
The aim of the histopathology report is to provide the information needed for the 
clinician to optimally manage the patient. Macroscopic and microscopic examination 
of the excised specimen by a pathologist gives dimensions and visual descriptions of 
the specimen, identifies the correct diagnosis of primary melanoma, and verifies 
complete excision of the tumour.8 In addition, histopathology describes the 
melanoma type, the tumour thickness (Breslow), the anatomical level (Clark level) of 
the tumour, and the presence of ulceration or mitosis. Other features often included 
in the histological report (cell type, solar elastosis, vascular invasion, regression) are 
relevant for studying the epidemiology and pathogenesis of the tumour.8  
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Immunohistochemistry is often performed during pathological examination of the 
specimen.110 As S100 protein, a neuronal protein found in glial and Schwann cells 
and also in malignant melanocytes, is expressed by most melanoma cells, S100 
staining of the entire excised specimen offers a more accurate means of assessing 
dermal and neural invasion, tumour thickness, and peripheral margins.110,111  
2.6.3 Histopathological features of melanoma 
In 1969, Clark et al56 reported that most melanomas arose in epidermal melanocytes, 
as opposed to originating in existing naevi, and that the macroscopic appearance, 
defined microscopic characteristics, location and age, were determinants in 
identifying the various types of melanoma. The three main subtypes reported are 
superficial spreading melanoma (SSM), nodular melanoma (NM) and lentigo 
maligna melanoma (LM) or Hutchinson’s melanotic freckle.56 SSM, characterised by 
a relatively long initial flat phase, is the most common melanoma type and has been 
associated with intermittent small bouts of UVR exposure.8,56 NM, on the other hand, 
presents as a fast growing nodular lesion that is more common in older people and is 
more likely to be found on the head and neck than on other areas of the body.56,112 
Like SSM, lentigo maligna melanomas also have a long initial flat phase, but these 
are more likely to present in outdoor workers, on chronically sun-damaged skin, and 
on the faces of older patients.8,56,113  
Clark et al56 also reported that based on the depth of invasion, each melanoma had a 
predicable biological behaviour pattern. They identified five anatomic levels of 
invasion that were considered to provide an accurate prognosis56: 
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• Clark level I: the melanoma occupies only the epidermis.  
• Clark level II: the melanoma penetrates to the papillary dermis (the layer 
under the epidermis) 
• Clark level III: the melanoma fills the papillary dermis and impinges on 
the reticular dermis, the next layer down.  
• Clark level IV: the melanoma penetrates into the reticular or deep dermis 
• Clark level V: the melanoma invades the subcutaneous fat.  
 
Melanoma are still classified according to the Clark levels, however due in part to the 
fact that levels III and IV vary greatly in thickness114 and that interpretation of levels 
is subjective and prone to inter-reporter variation,115 Breslow thickness, the 
microscopic measurement of the distance in millimetres between the upper layer of 
the epidermis and the deepest point of tumour spread, is now regarded as the most 
important prognostic factor for melanoma, followed by identification of the tumour 
as a primary melanoma and confirmation that it is completely excised.116 
2.6.4 Classification and staging 
Melanomas are often classified into stages according to the thickness of the tumour, 
whether it has ulcerated, has lymph node involvement or whether there are 
metastases.116 Lymph node involvement and metastases are confirmed by clinical 
staging techniques. The system of melanoma classification used today is based on the 
2002 publication of the American Joint Committee on Cancer (AJCC) and the 
International Union against Cancer (UICC).8 Early melanomas (Stages I and II) are 
localised, while more advanced melanomas (Stages III and IV) indicate metastatic 
spread to other parts of the body.117  
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2.6.5 Treatment and management of melanoma 
Treatment for primary melanoma is a wide local excision of the melanoma including 
the surrounding skin and subcutaneous tissues.8 The size of the wider excision is 
based on the size and depth of the visible lesion, with the aim to completely excise 
all in situ and invasive melanoma cells.8 As previously mentioned, histopathology, 
the only clinically reliable tool for a definitive diagnosis of melanoma,108 should 
confirm that the wider excision is complete. If lymph and systemic metastases are 
present on clinical staging, the life expectancy of the patient declines 
dramatically.58,118 Any investigations performed after diagnosis are therefore aimed 
at the detection of regional or systemic disease.8  
Nevertheless, a growing body of evidence now suggests that such investigations, 
which include chest x-rays, Computerised tomography (CT), Magnetic resonance 
imaging (MRI) and Positive Emission Tomography (PET) scans, cannot be 
recommended due to lack of any data indicating that they alter outcomes or are cost-
effective. 119-122 Management of melanoma, and in particular the detection of lymph 
node metastases, is therefore limited to clinical examination of the lymph nodes at 
regular surveillance visits. 
Tumour biomarkers 
The use of tumour biomarkers in predicting metastatic spread of melanoma at an 
early stage of the disease has previously been considered questionable, yet they have 
recently been attracting attention as a possible adjunct to clinical examination in the 
follow up stage of melanoma surveillance.123,124 S100 proteins, are found in the 
cytoplasm and nucleus of many cells, and are involved in the regulation of cellular 
processes such as cell cycle progression and differentiation.125 Several studies have 
reported a correlation between serum levels of S100β 123,125,126 or S100ββ124, and 
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relapse and survival from melanoma, with serum concentrations of S100β thought to 
reflect proliferation of melanoma cells and tumour mass. 
2.6.6 Melanoma prognosis 
Studies over the last 30 years have determined that the prognosis for patients with a 
primary melanoma (as opposed to a secondary metastasis) depends on a number of 
variables.116,117,127-130 A study of 17,600 melanoma patients by Balch et al in 2001 
demonstrated that survival was most powerfully predicted by Breslow thickness and 
ulceration.116 Level of invasion (Clark level) was also found to be significant within 
the category of thin melanomas (≤ 1 mm).116 Conversely, two later studies found that 
mitotic rate was second only to Breslow thickness as an important prognostic 
variable.130,131 The 2003 study by Azzola et al130 examined records of 3661 patients 
in the Sydney (Australia) Melanoma Unit database, while the study by Thompson et 
al131 in 2011 analysed records of 13,296 patients in the AJCC melanoma staging 
database. 
UVR exposure and melanoma prognosis 
Few studies have explored the association between sun exposure and melanoma 
prognosis. While considering that UVR exposure is the main environmental risk 
factor for melanoma, it is rather paradoxical that researchers have suggested that 
melanoma may in fact be more benign (have a better prognosis) if associated with 
high ambient UVR exposure.18 One of the first studies to suggest a link between 
higher sun exposure and improved melanoma prognosis found that patients with a 
history of high sun exposure, independent of the melanoma body site, mitotic rate, 
thickness and early detection, had a 40–60% lower mortality rate over 5 years than 
those reporting a history of low sun exposure.18 Berwick et al18 also reported that the 
presence of solar elastosis (a histological marker of chronic sun damage) was 
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statistically significantly inversely associated with fatality from melanoma (HR = 
0.5; 95% CI: 0.3, 0.9). While this association was not found in three other studies,132-
134 earlier studies had found similar results.129,135,136 One explanation for these 
findings could be that chronic sun exposure and sun damage are in fact in some way 
protective for aggressive melanoma.  
Another study137 found that a summer diagnosis was associated with a significant 
protective effect on survival from melanoma (Relative fatality = 0.72; 95% CI: 0.65, 
0.81). This effect was independent of histologic indicators of prognosis, including 
Breslow thickness.137 Boniol et al137 reported that melanomas diagnosed in winter 
were thicker than those diagnosed in summer, and in an Italian study of 260 
melanoma patients, Rosso et al138 found that patients who had taken more sunny 
holidays prior to their diagnosis had a better survival. Another European study139 
estimated the average number of sunlight hours in 36 European cities, and found that 
lower melanoma mortality rates occurred in countries with the sunniest climates. It 
has been suggested that the mechanism responsible for these results could be that 
recent UVR exposure prior to melanoma diagnosis is indirectly protective for 
survival as a result of the anti-neoplastic effects of vitamin D on the tumour.19,88,140 
  
2.7 VITAMIN D 
Vitamin D is a fat-soluble steroid hormone precursor, named in the early 20th century 
after the discovery that cod-liver oil prevented the formation of rickets in  
children.141-143 The term vitamin D refers to two molecules: vitamin D2 
(ergocalciferol) and vitamin D3 (cholecalciferol).144 The majority of vitamin D (90% 
or more) in many populations is obtained by exposure to sunlight (vitamin D3), 
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leaving only a small amount of the vitamin to be obtained through diet or 
supplementation (vitamin D3 or vitamin D2).145,146 Vitamin D is important in bone 
metabolism and is now thought to be important for a range of other physiological 
functions. 
2.7.1 Cutaneous production of vitamin D 
The stratum basale is the site for the UVR-mediated photosynthesis of vitamin D3 
when 7-dehydrocholesterol (7-DHC) in the cell membrane of keratinocytes is 
exposed to UVR in the UVB spectrum (280 – 315 nm).31,147 7-DHC, a sterol in the 
cholesterol biosynthetic pathway: lanosterol  lathosterol 7-dehydrocholesterol 
cholesterol,148,149 differs from cholesterol by one additional double bond located in 
the steroid structure.150 7-DHC absorbs UVB, causing the B-ring to open with the 
formation of previtamin D3.151 After approximately 2 hours, previtamin D3 undergoes 
a thermal isomerisation reaction at skin temperature to form vitamin D3, which is 
stored in the fat cells in the dermis before entering the blood stream where it is bound 
to the vitamin D binding protein.152  
7-DHC is found throughout the entire epidermis and dermis, however the highest 
concentrations of 7-DHC per milligram of lipid are located in the stratum 
basale.148,151 Two studies153,154 have reported vitamin D3 production per unit area of 
epidermis irradiated. In 1958 Wheatley et al153 found that 400 IU was produced from 
irradiation of three square inches of epidermis, while in the same year Bekemeier154 
reported that 4 to18 IU of vitamin D3  were synthesised within three hours from the 
irradiation of one square centimetre of white human skin. Factors influencing the 
cutaneous production of vitamin D3 from UVR exposure include factors that affect 
ambient UVB levels; time of day, season, cloud cover, latitude, altitude; and 
individual-level factors, such as orientation to the sun, body surface area exposed, 
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skin pigmentation (melanin density) and use of sunscreen (at recommended 
levels).152 It has also been suggested that levels of 7-DHC decline with age,155 thus 
decreasing the capacity of human skin to produce vitamin D3.  
2.7.2 Vitamin D in the diet 
A small amount of vitamin D in the form of either vitamin D3 (animal sources) or 
vitamin D2 (plant sources) is obtained through the diet. Oily fish such as salmon, 
mackerel and tuna are good sources of vitamin D, as are cod liver oil and irradiated 
mushrooms.147,152 Very small amounts of vitamin D can be obtained through eggs, 
meat and dairy products, and for some populations in the United States and Europe, 
supplemented foods are the major dietary source.156 In 1997 an “adequate intake” 
(AI) was suggested for vitamin D157, but there were no Recommended Daily 
Allowances (RDI) until these were set by the United States Food and Nutrition Board 
in 2010.158 These recommendations are based on low exposure to sunlight and 
suggest an adequate intake of 400 IU for babies, 600 IU for ages 1 to 70 and 800 IU 
for those aged over 70.158 
2.7.3 Vitamin D activation 
25-hydroxyvitamin D (25(OH)D) 
Both ergocalciferol and cholecalciferol are transported via the bloodstream to the 
liver, where they are hydroxylated to form 25-hydroxyvitamin D (25(OH)D), also 
commonly referred to as calcidiol.159  25(OH)D circulates in serum and is a good 
biomarker of the status of both skin synthesis and dietary intake of vitamin D due to 
its ease of measurement and its long half-life in circulation (estimated between three 
and five weeks).147,160,161 For these reasons it is the universally accepted indicator of 
vitamin D status.162,163 This biologically inactive form of vitamin D is subsequently 
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hydroxylated in the kidneys, with some additional production in other tissues, to 
form calcitriol, or 1,25-dihydroxyvitamin D (1,25(OH)2D).20 
1,25-dihydroxyvitamin D (1,25(OH)2D) 
1,25(OH)2D serum concentration is very tightly regulated and maintained at low 
circulating levels despite large changes in 25(OH)D concentration.164  The main 
physiological function of 1,25(OH)2D, under the control of the parathyroid hormone  
(PTH), is to maintain adequate levels of calcium in the circulation.165 1,25(OH)2D 
also regulates phosphorus absorption in the small intestine and is essential for bone 
development.145 Vitamin D metabolic enzymes have now been found in a range of 
other cell types, so that active 1,25(OH)2D can be synthesised and act at the local cell 
level to have local effects, for example, on immune function.165 
 
2.8 THE VITAMIN D RECEPTOR (VDR)  
Intracellularly, 1,25(OH)2D binds to a nuclear vitamin D receptor (VDR).161 Present 
on nearly every cell in the human body, the VDR is an intracellular hormone receptor 
specifically for vitamin D.166 The VDR gene is located on chromosome  
12q12-q14.166 VDRs have been found in many cancer cells including those from 
tumours of the prostate, breast, colon, cervix, bladder, pancreas, pituitary and thyroid 
glands.167,168 VDRs have also been found in normal melanocytes and in cultured 
melanoma cells.169 
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2.9 OPTIMAL VITAMIN D CONCENTRATION 
Historical 
Rickets is probably the most commonly known effect of vitamin D deficiency and 
was first described141 by the Greek historian Herodotus (485–426 BC). In 1822, the 
Polish researcher, Sniadecki, observed that children living in the city of Warsaw had 
a much higher rate of rickets than children from the rural areas in Poland, and 
suggested that disease may be caused by lack of exposure to sunshine.170 Later that 
century, Palm recommended that children should sunbathe to prevent rickets,141 and 
then in the early 20th century it was shown that cod-liver oil also contained 
something that could cure rickets.171 
Current recommendations  
Vitamin D status is often classified as “deficient”, “insufficient”, “sufficient” or 
“optimal”. There remains considerable controversy around the optimal level of 
25(OH)D necessary for good health. While some suggest the optimal serum level of 
25(OH)D should reflect the concentration necessary to suppress the parathyroid 
hormone, this level has been reported to vary widely from 20 nanomoles per litre 
(nmol/L) to 110 nmol/L.172-174 Others have suggested optimal levels of                 
37.5 nmol/L175, 75 nmol/L176 and 80 nmol/L.177 Based on a review of associations 
with a wide range of disease outcomes, and requirements for bone health, the United 
States Institute of Medicine (IOM) recommended in 2011 that a serum 25(OH)D 
level of 50 nmol/L should be considered sufficient.178 Further, while there appeared 
to be a general consensus that a serum concentration of 25(OH)D of less than 25 
nmol/L was classed as deficiency,144,179 the IOM concluded that less than 30 nmol/L 
constituted risk of deficiency.178 Blurring this disagreement is the wide variability in 
measurement results dependent on the assays and laboratory techniques used.180-182  
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Sub-optimal vitamin D and health  
Vitamin D deficiency and insufficiency have been associated with a wide variety of 
chronic health problems. A review of ecological, case-control and cohort studies 
found evidence that higher concentrations were beneficial for autoimmune, 
cardiovascular and cerebrovascular diseases, bone health, muscle strength and type 2 
diabetes.183 Results from the Third National Health and Nutrition Examination 
Survey (NHANES) prospective cohort study suggest that both low and high levels of 
serum 25(OH)D may be associated with an increase in all-cause mortality.184 
  
2.10 VITAMIN D AND CANCER 
Vitamin D is considered to be a vital component of cellular networks that inhibit the 
proliferation of cells and encourage apoptosis.140 Recent research in rodents suggests 
that optimal levels of 25(OH)D may actually decrease the risk of contracting some 
cancers, as well as limiting their invasive capacity and ability to metastasise.167  
Many observational studies185-187 have been published on the association between 
vitamin D status and risk for various cancers, but in particular breast, prostate and 
colorectal cancer. Meta-analyses of these studies have confirmed a link between low 
vitamin D status and increased risk of colorectal cancer, with the findings in relation 
to breast cancer equivocal.188,189 Nevertheless, the World Health Organisation’s 
(WHO) 2008 report on vitamin D and cancer160 concluded that results at that time 
from observational studies were mixed for breast cancer, showed no link to prostate 
cancer risk, but did support a link to colorectal cancer. The WHO suggested that 
further cohort studies were warranted.  
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In relation to skin cancers, one case-control study in American males found an 
association between high levels of 25(OH)D and a reduced risk of NMSC.190 
Conversely, in a case-control study of American women, those in the highest quartile 
serum of 25(OH)D were more likely to have an increased risk of BCC (OR = 2.07, 
95% CI = 1.52–2.80, P for trend < 0.0001) and SCC (OR = 3.77, 95% CI = 1.70–
8.36, P for trend < 0.0002), than those in the lowest quartile.186  
 
2.11 VITAMIN D AND MELANOMA 
2.11.1 Cell biology research 
In the early 1980s, intracellular receptors (VDR) for vitamin D (1,25(OH)2D) were 
identified in both melanoma cell lines and in melanoma tissue in rodents.21 Colston 
et al (1981) also demonstrated that 1,25(OH)2D inhibited proliferation of melanoma 
cells both in vitro and in vivo.21 Later in the 20th century, 1,25(OH)2D was identified 
as inhibiting invasiveness191 and inducing differentiation in melanoma cell lines.192 
In other laboratory-based trials, cultured melanoma cells synthesized 1,25(OH)2D 
from 25(OH)D169 and the 1,25(OH)2D molecule was shown to induce apoptosis in 
human melanoma cell lines in vitro.22 Similarly, in vivo trials have found that vitamin 
D (1,25(OH)2D) can suppress melanoma growth and inhibit metastasis in 
immunosuppressed rodents.191,193 
2.11.2 Genetic research 
Several researchers have hypothesised that polymorphisms in the VDR gene may 
affect the risk of developing melanoma.194,195 However a meta-analysis of six studies 
that investigated the association between VDR polymorphisms and melanoma risk 
found conflicting results and the authors suggested that further population based 
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studies were needed to fully address this area.19 More recently (in 2009), Randerson-
Moor et al196 provided additional evidence to suggest that both the VDR and vitamin 
D may have a small role to play in melanoma risk and could possibly contribute to 
poorer outcomes after disease diagnosis. Research to analyse the expression pattern 
of the VDR in melanoma is limited to one retrospective study that also examined 
tissue from other skin lesions and normal skin.197 All participants in the study were 
white, and although age and sex were reported, questionnaire data were not recorded. 
In addition to examining VDR expression, the study used histological staining to 
quantify solar elastosis. The VDR expression in melanoma cells was correlated with 
type, level, thickness and mitotic rate, with data in relation to ulceration not 
reported.197 Findings from this study showed that VDR expression in melanoma 
tissue and the surrounding skin was significantly reduced when compared to normal 
skin. The main limitation of this study was that the technique used a brown/ black 
stain, Diaminobenzidine, rather than a red stain, which could have resulted in 
melanin being confused with the VDR.  
2.11.3 Epidemiological research 
Results from epidemiological studies investigating relationships between sun 
exposure and melanoma generally support a beneficial role for vitamin D in both 
melanoma incidence and melanoma prognosis.  
Vitamin D and melanoma risk 
Few studies have evaluated the association between vitamin D intake and melanoma 
risk and results have been conflicting. An early case-control study by Weinstock et 
al198 found no association between vitamin D intake and melanoma risk. In 2009, a 
large cohort study (n > 65,000, including 455 participants who had developed 
melanoma) investigated the association between dietary and supplemental vitamin D 
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intake and melanoma risk.199 This study found there was no evidence of reduced 
melanoma risk in association with either the highest quartile of dietary vitamin D 
intake (RR = 1.31; 95% CI: 0.94, 1.82), 10-year average supplemental vitamin D 
intake (RR = 1.13; 95% CI: 0.89, 1.43), or a combination of dietary and 
supplemental intake (RR = 1.05; 95% CI: 0.79,1.40).199 Similarly, a study including 
176 women with melanoma in the Women’s Health Initiative cohort (n = 36,282) 
also found no association with vitamin D intake.200 Conversely, in case-control 
studies using food frequency questionnaires, Millen et al and Vinceti et al both 
observed an inverse relationship between vitamin D intake from diet and melanoma 
risk.201,202 Millen et al201 recruited 497 patients newly diagnosed with melanoma and 
561 controls and concluded that persons with higher intake of vitamin D had reduced 
risk of melanoma (OR = 0.66, 95% CI = 0.42, 1.02). Vinceti et al202 studied 380 
cases and 719 controls and found that an increase in vitamin D intake of 1ug (1 ug = 
40 IU) per day was associated with an odds ratio for melanoma risk of 0.85 (95% CI 
0.74, 0.97). 
Studies examining the association between serum 25(OH)D levels and melanoma 
risk are scarce. In a small sample (n = 14) of melanoma patients, Reichrath and 
Querings203 found that all patients had “sufficient’ 25(OH)D levels (range: 50–125 
nmol/L). A larger case-control study of Finnish male smokers204 also found a lack of 
association between serum 25(OH)D levels and melanoma risk, as did a case-control 
study (cases: n = 92, controls: n = 276) in Northern England.196 
Vitamin D and melanoma prognosis 
In accordance with the work of Berwick et al,18 where it was suggested that higher 
vitamin D status may be associated with decreased mortality after melanoma 
diagnosis, a number of both experimental and observational studies have now been 
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conducted to investigate this possible relationship. A retrospective cohort study (n = 
217) conducted in the United Kingdom concluded that vitamin D supplements may 
be protective for melanoma prognosis (OR = 0.6; 95% CI: 0.4, 1.1).24 While the 
results were only marginally non-significant, these results did not include dietary 
vitamin D intake. The findings of that study were tested in a survival analysis of 872 
melanoma patients with lesions of Breslow thickness greater than 0.75 mm who were 
recruited in northern England over a six year period and followed-up for, on average, 
4.7 years.24 Clinical and histopathological data, a questionnaire and serum samples 
collected three to six months after surgery, enabled Newton-Bishop et al (2009) to 
also examine associations between 25(OH)D levels and Breslow thickness, relapse-
free survival (RFS) and overall survival (OS).24 
The authors concluded that higher serum 25(OH)D levels at sampling were 
associated with thinner tumours (P = 0.002) and were protective for relapse and 
death from melanoma24. A 20 nmol/L increase in serum 25(OH)D was associated 
with decreased risk of relapse (HR = 0.79; 95% CI: 0.64, 0.96; P =0.01) or death 
(HR = 0.83; 95% CI: 0.68, 1.02), i.e. improved RFS and OS. The authors stated that 
although adjusted for age, sex, site, thickness and body mass index (BMI) this 
inverse relationship may have been due to unmeasured confounders.24 As sun 
avoidance behaviour after melanoma diagnosis is relatively common205,206 and the 
half-life of 25(OH)D is approximately three to five weeks,147,160,161 it is possible (or 
even likely) that the 25(OH)D levels recorded in this study may be reflective of early 
changes in sun behaviour, and might not accurately represent the 25(OH)D levels at 
the time of diagnosis. 
Another prospective study looked at the association between direct and indirect 
measures of vitamin D status, namely serum 25(OH)D levels and UVR exposure, on 
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the incidence and prognosis for melanoma.25 Using similar methodology to Newton-
Bishop et al, the German study25 of 205 patients diagnosed with invasive melanoma 
collected clinical, histopathological and questionnaire data. Serum samples were 
obtained between October and April, only (despite recruitment at diagnosis 
throughout the year). The authors found that serum 25(OH)D levels were reduced in 
Stage IV melanoma patients as compared to those with Stage 1a or 1b disease (P = 
0.006), but they were unable to comment on the role of 25(OH)D in melanoma 
pathogenesis and prognosis due to retrospectivity and sample size.25  
A more recent study, also from Germany, recruited melanoma patients 
approximately six months after diagnosis and determined their serum 25(OH)D at 
that time, and after a further six months.23 The investigators23 concluded that lower 
25(OH)D levels were associated with increased tumour thickness (< 1mm; ≥ 1–4 
mm; > 4 mm: coefficient -1.45, P = 0.028) and higher AJCC stage (coefficient: -.79, 
P = 0.036). 
 
2.12 SUMMARY 
The highest global incidence rate for melanoma is found in Queensland, Australia.54 
Melanoma is the most aggressive skin cancer given its ability to grow rapidly in a 
vertical manner and then metastasise to other organs.55 Exposure to solar UVR is 
considered one of the major risk factors for melanoma, along with fair skin 
phenotype, family history of melanoma, older age, increased numbers of common 
and atypical naevi, and country of residence.9,10,83,98 Prognosis for melanoma is best 
predicted by Breslow thickness, mitotic rate, presence of ulceration, and Clark 
level.116,131 
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Studies looking at the relationship between sun exposure and melanoma have found 
that higher sun exposure and evidence of solar dermal damage were inversely 
associated with fatality from melanoma18 and that melanomas diagnosed in summer 
had a better prognosis than those diagnosed in winter.137 The results from these 
studies, and others, have prompted suggestions that sun exposure may have a 
beneficial effect on melanoma prognosis and has led to the hypothesis that the 
positive effect of sun exposure on melanoma prognosis could be mediated by 
improved vitamin D status.19,140 
In vitro and in vivo studies have shown that vitamin D can suppress melanoma 
growth in melanoma cell lines22 and in mice.191,193 Vitamin D, a fat-soluble hormone 
derived predominantly from exposure of the skin to UVR in the UVB spectrum, is 
required to maintain calcium and phosphorous homeostasis. Vitamin D status is 
universally measured by serum 25-hydroxyvitamin D (25(OH)D) levels. Serum 
25(OH)D has a long half-life in the circulation (estimated between three and five 
weeks)147,160,161 and these levels are regarded as a biomarker of the status of both 
cutaneous synthesis and dietary intake of vitamin D. Although there is wide 
disagreement on optimal levels and wide variability in measurement techniques, low 
levels of serum 25(OH)D have previously been associated with the incidence of 
some cancers.188,207,208 
Vitamin D intake was not found to have any association with melanoma risk in one 
study,199 while another study24 found that vitamin D supplementation had a 
beneficial effect on melanoma prognosis. While few epidemiological studies have 
investigated the potential link between vitamin D and melanoma prognosis, the 
authors of the latter study subsequently conducted a prospective cohort study and 
concluded that higher serum 25(OH)D levels at sampling were associated with lower 
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Breslow thickness and a lower rate of metastases.24 This research, in conjunction 
with results from a study published in the same year25 and a more recent study 
published in 2012,23 both showing reduced levels of serum 25(OH)D in patients with 
advanced melanoma, adds some weight to the hypothesis mentioned above. That is: 
that vitamin D, or its proxy, recent sun exposure has a positive effect on melanoma 
prognosis.  
The three studies that have investigated this possibility have paved the way for 
further research to build on their knowledge base. There are some missing links in 
the puzzle. First, thin melanomas (< 0.75 mm) and in situ melanomas have not been 
adequately studied to date. These form a large proportion of all melanomas 
diagnosed, and to accurately understand the real relationship between vitamin D and 
melanoma prognosis, serum 25(OH)D levels in patients with both thin and thicker 
tumours need to be investigated. Secondly, serum 25(OH)D levels at “diagnosis” 
with melanoma have not as yet been ascertained. To achieve that, and to minimise 
potential bias, serum would need to be obtained prior to wider excision surgery 
(before the patient’s sun behaviour could potentially change in response to the 
melanoma diagnosis). To avoid the problems previously mentioned with respect to 
measurement variability, all serum samples should be analysed in one batch. 
Additionally, a number of factors that could potentially confound or mediate the 
association between serum 25(OH)D and melanoma prognosis, including skin 
pigmentation and phenotypic characteristics, and use of sunscreen do not appear to 
have not been measured in the studies conducted to date. Future studies could 
consider implementing methods to measure such factors.  
Finally, all studies identified to date were conducted in the higher latitudes of the 
Northern Hemisphere. Latitude is both a potential risk factor for melanoma71,88 and 
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also one of the factors that can influence cutaneous production of vitamin D3 from 
UVR exposure.152 To further enhance our understanding of the relationship between 
25(OH)D levels and melanoma prognosis, it is appropriate to investigate whether 
these results: 
1. from Northern Hemisphere research are comparable to those from research 
conducted in the lower latitudes of the Southern Hemisphere, in a region 
already identified to have high prevalence of vitamin D insufficiency 
2. are similar when 25(OH)D levels at time of diagnosis are considered, and 
3. are true for in-situ and thin (< 0.75 mm) melanomas, as well as for thicker 
melanomas. 
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Chapter 3: Research Design and Analytic 
Approach 
3.1 INTRODUCTION 
In Chapter 2, a review of the literature found that three studies had investigated the 
relationship between serum 25(OH)D level and melanoma prognosis. These studies 
provide evidence to suggest that a relationship does potentially exist and in doing so 
have built a solid foundation for further research in this area. An opportunity to 
increase the existing body of knowledge was identified. The review also found that 
both season at the time of diagnosis, and serum levels of S-100β, have been 
previously associated with melanoma prognosis. 
This chapter commences by reviewing and considering the methods and research 
instruments used in previous studies into relationships between serum 25(OH)D level 
and melanoma prognosis, before outlining the criteria considered pivotal in 
conducting a study that would address the study aim, while overcoming some of the 
limitations of previous research. The criteria will also allow associations between 
melanoma prognosis and season at time of diagnosis, and serum levels of S-100β, to 
be investigated.   
An observational, cross-sectional study is selected as the desired study design and the 
study sample and study procedure identified. The data collection instruments and the 
methods used for their implementation are then described in detail. It will be noted 
that in some areas of interest (such as life time sun exposure) more than one 
instrument is used with the aim of counteracting any potential bias that may occur 
with, for example, recall of past events. Management of data, including the use of 
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any coding practices is then described. Methods of data analysis are discussed and 
the model selection is explained. A step-by-step explanation of the model building 
process is subsequently provided. 
 
3.2 REVIEW OF METHODS USED IN PREVIOUS STUDIES 
The three studies previously described (pages 42-43) all used a prospective cohort 
study design and recruited patients with histologically proven cutaneous melanomas 
of various stage and type. One of the research groups25 also incorporated a small 
case-control study into their study design. Measures of exposure varied between the 
studies. Newton-Bishop et al24 administered a self-report questionnaire 3 to 6 months 
after diagnosis. The questionnaire included items on drug intake, dietary 
supplementation, age, height and weight, but it is unclear if information such as skin 
type, number of naevi, history of NMSC, sunburn history, family history of 
melanoma and lifetime sun exposure was collected.24  Blood samples for serum 
25(OH)D analysis were taken between 3 and 6 months after surgery, and 
histopathology reports and clinical notes were accessed to obtain details of the 
primary tumour and relapse data for 872 melanoma patients with melanomas of 
Breslow thickness greater than 0.75 mm.24  
Nurnberg et al25 recruited 205 melanoma patients and 141 healthy volunteer controls 
for their study. Data from the volunteer controls were included in some analyses to 
determine if results relating to serum 25(OH)D levels and questionnaire items 
differed between the two groups.  The self-administered questionnaire, completed by 
approximately 25% of both groups (melanoma group: n = 58 and volunteer group: n 
= 42), provided information on skin type, height, weight, history of sun exposure, 
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sunscreen use and painful sunburns. An objective measure of lifetime sun exposure 
or skin type does not appear to have been used. Nurnberg et al25 report that all 
participant’s blood samples were taken between October and April to minimise 
seasonal variation in 25(OH)D levels (although participants were recruited following 
melanoma diagnosis throughout the year). The clinical and histopathological data 
obtained for this study were used to allocate patients to a melanoma “stage”. 
Melanomas classified as Clark Level 1 (in situ) were not represented in this study.  
It is not clear how Gambichler et al23 obtained data for their study, however age, sex, 
body mass index (BMI), season and skin type were ascertained and serum was 
collected for 25(OH)D analysis up to six months after diagnosis. 
 
3.3 AIM, OBJECTIVES AND RESEARCH QUESTION 
Based on the review of the literature, the aim, objectives and the research question 
for the QUT Melanoma Study were: 
3.3.1 Aim  
To identify, and explore the nature of any relationship between the serum 25(OH)D 
level at diagnosis of patients newly diagnosed with melanoma in Queensland, and the 
outcome for those patients as predicted by histopathological features of the 
melanoma that are known to be associated with prognosis.  
3.3.2 Objectives 
The primary objectives of this research were to: 
1. Recruit a cohort of patients newly diagnosed with melanoma from an area 
with high melanoma incidence, including those with in situ (Clark Level 1) 
tumours 
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2. Examine vitamin D status (serum 25(OH)D concentration) at time of 
melanoma diagnosis in relation to histopathological features (Breslow 
thickness, Clark level, presence of ulceration and mitotic rate) previously 
shown to be predictive of prognosis, after adjustment for possible 
confounding factors.  
Secondary objectives were to: 
3. Describe seasonal variation in vitamin D status within the sample 
4. Identify any relationship between S-100β level and the histopathological 
features of the tumours. 
 
3.3.3 Research question 
The research question to answer was: 
What is the relationship between serum 25(OH)D concentration at time of diagnosis 
with melanoma and histopathological features of melanoma that are associated with 
prognosis in an “at risk” population. 
3.3.4 Conceptual design 
To add to the existing knowledge in the area and to answer the research question, the 
following criteria were considered pivotal in the study’s conceptual design: 
1. Accessibility to melanoma patients that was feasible and reliable 
2. Patients with both non-invasive and invasive melanoma to be recruited 
3. Recruitment to take place over a 12 month period to allow the effect of 
season on the relationship between serum 25(OH)D and melanoma prognosis 
to be investigated 
4. Primary outcome data (histopathological features of the melanoma related to 
prognosis) to be obtained from histopathology reports of both biopsy and 
wider excision specimens 
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5. To minimise disease-related bias: 
a. Patients with melanoma to be recruited prior to the wider-excision of 
their melanoma, before sun exposure behaviour potentially changes in 
response to melanoma diagnosis 
b. Blood samples for serum 25(OH)D analysis to be obtained from 
melanoma patients as soon as possible after diagnosis, and prior to 
surgery for the wider-excision of the melanoma  
c. Data on demographics and risk factors for melanoma such as sun 
exposure history, latitudes of residence during life, family history of 
melanoma, history of NMSC, history of sunburns in childhood and 
sun protection habits to be obtained via a questionnaire administered 
prior to wider excision surgery  
6. To minimise bias due to assay variability, serum samples to be analysed in a 
single batch for 25(OH)D and S-100β 
7. To minimise recall bias, other known risk factors for melanoma to be 
measured objectively where feasible (spectrophotometric skin type, 
researcher-assessed eye and hair colour and naevi count, histological solar 
elastosis for cumulative sun damage), and by validated questionnaire where 
this is more appropriate (e.g. hair colour as a teenager, tanning and burning 
tendencies, lifetime sun exposure). 
  
3.4 STUDY DESIGN  
An observational, cross-sectional study design was chosen to ensure that all criteria 
for fulfilling the objectives of the research were satisfied.  
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3.4.1 Study sample (Objective 1) 
All melanoma patients presenting to two Brisbane medical clinics over a twelve 
month period and who met the inclusion and exclusion criteria were invited to 
participate in the study. The small number of patients diagnosed with melanoma 
precluded random sampling, so convenience (purposeful) sampling was used. An 
estimated sample size of 100 participants was determined to be feasible based on:  
• historical data from the two clinics regarding the number of patients 
presenting annually with melanoma  
• the time frame available for the study 
• financial limitations 
• resource limitations (manpower). 
 
Plastic surgeons  
Although cutaneous melanoma is commonly diagnosed from excision or shave 
biopsies performed by primary care physicians or dermatologists, good clinical 
practice recommends that further wider excision of the lesion is then indicated down 
to, but not including the deep fascia (unless it is involved).8 For patient comfort and 
to contain bleeding, this surgery is normally performed as day surgery and often by 
plastic surgeons. Therefore, two plastic surgeons in Brisbane, Australia were 
approached, agreed to assist with the research and consented for their patients to be 
recruited to the study (the researcher is a registered nurse and has worked for one of 
the surgeons for 14 years). Patients with a positive biopsy report, and who met the 
exclusion and inclusion criteria (below), were invited to participate in this study. 
Inclusion criteria: 
• patients with a histologically proven cutaneous melanoma (non-invasive 
and invasive)  
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• aged 18 years or older 
• able to read and understand English. 
 
Exclusion criteria: 
• diagnosis made from metastatic melanoma or lymph node tissue 
• reporting of pre-existing conditions that could alter the vitamin D pathway 
such as: history of cirrhosis of the liver, chronic liver disease or history of 
kidney disease 
• transplant recipients 
• patients on high dose calcium therapy (which could impact the metabolism 
of vitamin D).209 
 
3.4.2 Study procedure 
The study protocol (see Appendix A) stated that the surgeon, having determined that 
the patient satisfied the criteria above, would advise the patient of their eligibility to 
take part in the QUT Melanoma Study. I did not speak to patients in advance of their 
appointment with the surgeon and the patient was treated and regarded first and 
foremost as a patient of the surgeon, and secondly as a study participant. Similarly, it 
was a privilege to have access to the intimate workings of such busy surgeries and I 
ensured that I was as unobtrusive as possible at all times. 102 melanoma patients 
presented to the surgeons during the 12-month period from July 2010 to July 2011. 
All were informed of the study and 100 consented to participate. 
3.4.3 Recruitment 
Initially, each patient was given a letter to read by the surgeon (see Appendix B), but 
time constraints in these busy practices meant that this was not feasible and both 
surgeons independently asked if this protocol could be deleted, preferring to verbally 
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introduce the study.  To ensure that I was on hand to speak to any prospective 
participants, the practice managers of each practice contacted me in advance of all 
appointments made for melanoma patients. Both surgeries have a policy of seeing 
probable melanoma patients as a matter of urgency (within 1-3 days) following the 
initial phone call to arrange an appointment; therefore most appointments are made 
before-hours, after-hours or squeezed in whenever possible around previously 
scheduled patients. At the initial appointment, the patient is often confused, upset and 
shocked by their diagnosis and by their rapid escalation through the medical system. 
The methods used in this study, and their application, were therefore designed with 
the patient foremost in mind to minimise any further time or emotional burden on the 
patient. An overview of how this was implemented is illustrated in Figure 3.1. 
 
 
Figure 3.1. Overview of study procedure. 
• Surgeon assesses patient for eligibility 
• Patient introduced to researcher 
• Participant Information Sheet explained 
• Consent signed 
• Appointment made for follow up visit 
• Blood sample taken 
• Patient takes questionnaire home  
 
T1 Pre-operative visit  
• Questionnaire returned to researcher 
• Patient attends doctor's consultation 
• Researcher checks questionnaire 
• Clinical examination conducted 
T2 Post-operative visit (6-10 days after T1) 
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T1: Pre-operative visit 
After consenting verbally to the surgeon to release a copy of their pathology report, 
patients were introduced to me at the end of their initial consultation with the 
surgeon.  Prior to signing a consent form (see Appendix C), the patients and any 
family or friends present, were taken to a quiet area in the surgery and I re-
introduced myself before describing the study, the patient’s potential involvement 
and the options for consent to all or various parts of the study. This time was useful 
for the patient to ask questions, not only about the study but also about the 
forthcoming chain of events: surgery, post-operative care, return visits etc.  
The patient was then given a detailed participant information sheet (see Appendix D) 
that reiterated the contents of the previous discussion and included background 
information on the study, on vitamin D, and on melanoma. The participant 
information sheet also clearly set out the protocol and timeframe for the collection of 
data to ensure that prior to consenting to take part in the study patients were well 
informed of any extra burden this may impose on them. Patients were reassured 
about confidentiality, assigned an identifying (ID) number from M001 to M100 and 
all documentation was then coded with this number.  
The patient signed the consent form and was then given a copy of that, the 
participant information sheet and a coded QUT Melanoma Study Questionnaire (see 
Appendix E) in a clear plastic folder clearly labelled with their ID number and with 
my business card attached. It is normal practice for patients to return to the surgeon’s 
rooms six to ten days post-operatively for removal of sutures (it should be noted that 
both plastic surgeons who recruited participants to the study adhere to these same 
time protocols). Participants were asked if this post-operative appointment would be 
a suitable time for them to return their questionnaire and to undergo the QUT 
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Melanoma Study Clinical Examination (see Appendix F), thus ensuring that all study 
protocols could be completed during routine appointment times. Participants were 
then accompanied to a commercial pathology company’s collection room (located in 
the same building) for the study’s pre-operative blood test. In many cases (71%), pre-
operative blood tests had already been ordered by the surgeon and the QUT 
Melanoma Study sample was drawn without requiring any further venepuncture.  
T2: Post-operative visit 
At the first post-operative visit the QUT Melanoma Study Questionnaire was 
checked for any missing or unclear data and the patient had any queries clarified 
before the QUT Melanoma Study Clinical Examination was conducted. In the event 
that participants had forgotten to bring the questionnaire to the appointment (6%), a 
stamped self-addressed envelope was provided to allow quick and easy return of the 
form.  
3.4.4  Recruitment risk management strategies 
Recruitment commenced in July 2010 with one surgeon, however in November 2010 
with the regime established and streamlined, recruitment began from both surgeons 
simultaneously. During the recruitment period, constant communication within the 
study team, including reviews every two weeks, ensured that cohort recruitment 
remained on track. In the event that the established regime was not achieving 
adequate study numbers, two further surgeons had also been approached prior to the 
commencement of the study with a request to be on “stand by”.  Although 
recruitment was on target, consideration was given to increasing the estimated 
sample size by also recruiting patients from those surgeons. We (the study team) 
decided this would not be feasible given that the time already involved in one person 
recruiting patients and collecting data was substantial.  
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There was no loss to follow up between T1 and T2 as these visits were undertaken as 
part of usual care. Melanoma patients are very aware of the need to adhere to the 
strict melanoma surveillance procedures that are in place and rarely miss a scheduled 
appointment. The same risk management strategies that work so efficiently in the 
surgeon’s clinics to avoid failure to return for a post-operative appointment were 
incorporated in the QUT Melanoma Study. These included: 
• making the participant aware that the researcher was available at any time 
to discuss the study 
• ensuring that at T1 they received a business card with all contact details 
attached to the front of a personalised study pack 
• ringing them on the day if they missed the appointment 
• reducing participant burden by scheduling T2 to coincide with the normal 
scheduled melanoma post-operative visit  
• accompanying all participants to any additional tests (e.g. scans) that had 
been ordered at T1. 
 
3.5 DATA COLLECTION INSTRUMENTS 
A copy of all instruments is provided in the Appendices to this document. 
3.5.1 Questionnaire 
The QUT Melanoma Study Questionnaire, comprising 58 questions, was developed 
and used by the Queensland Institute of Medical Research (QIMR) in over 700 
participants in their ‘Causes of Melanoma Study’. Professor David Whiteman very 
kindly consented for the questionnaire to be used, thus ensuring that by maintaining 
the consistency of study questions, valid comparisons between the two studies could 
be made if desired.210  
The self-report questionnaire included questions on: 
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• demographics – date and place of birth, sex, education, marital status 
• city of birth and all cities and towns lived in, from primary school to 
present day 
• the anatomic location of melanoma  
• history of the study melanoma 
• frequency of skin examinations 
• skin phenotype – hair and eye colour as a teenager, tanning and burning 
propensity  
• time spent in the sun as a school child 
• hair style (covering ears) during school years 
• naevus and freckle burden as a teenager 
• sunburns during primary and secondary school years, and since leaving 
school 
• occupational history  
• adult occupational and recreational sun exposure behaviour 
• sun protection as an adult 
• skin cancer history and skin cancer screening  
• smoking history 
• family history of melanoma. 
 
Melanomas were reported by the participant in the questionnaire as occurring in 
seven general sites (including back, chest, head) and also in fourteen more specific 
sites (for example: “side of neck” and “back of neck” were more specific to the neck 
region). Propensity to sunburn was determined by the response of the skin to being in 
the strong sun for 30 minutes in the middle of the day for the first time in summer 
according to a five point scale ranging from never burning to always burning. To 
elicit tanning propensity, the participant was asked to indicate their level of tan after 
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spending several weeks at the beach in the strong sun: no tan, light tan, moderate tan 
or deeply tanned. Naevus burden as a teenager was recorded by ticking one of four 
pictures depicting a person with varying numbers of naevi: none, few, some, or 
many. Four faces depicting no freckles to many freckles were used as a visual guide 
to answer the question “When you were a teenager, how many freckles (for face and 
arms) did you have at the end of summer?”  
The questionnaire measured the time spent in the sun as a school child by asking 
identical questions for primary school and secondary school. Using a five point scale 
of never, rarely, sometimes, usually and always or almost always, the questions 
asked how often they were outdoors in the sun in summer after school, and on 
weekends and holidays. Adult sun behaviour data were obtained by participants 
reporting the following information for each year of life from the time they left high 
school to diagnosis (questionnaire page 12): type of job, place of work (city/town), 
age of starting and stopping work in that place, number of days worked in the job and 
amount of time spent in the sun in summer on work days and non-work days at each 
job (mostly indoors, outdoors for 1–4 hours, mostly outdoors).  
Adult sunscreen use at two time points, five years ago and ten years ago, was 
assessed for three body areas: 1) face, head and neck, 2) hands or forearms, and 3) 
other parts of the body; and according to the number of days per week sunscreen was 
applied. Six response options of none, occasional, 1–2 days, 3–4 days, 5–6 days, and 
every day, were provided. Sunburn (during primary school, high school and since 
leaving school), described as blistering, soreness for two days or more, or peeling, 
had six levels of response from never, 1 to 5, 6 to 10, 11 to 20, 21 to 50, and more 
than 50 sunburns.  
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Previous history of NMSC was ascertained by asking how many skin cancers had 
been either cut out, frozen or burnt off, treated with radium or in other ways. History 
of sunspots was determined in the same manner. 
Any areas of uncertainty that may have arisen in relation to the questionnaire were 
resolved at the clinical examination visit. The clinical examination also allowed an 
opportunity to revisit some items included in the questionnaire to check any items 
that may have caused recall problems: in particular family history of melanoma, 
numbers of lesions previously removed and outdoor activities since completing high 
school. Visual aids (see Appendices G and H) were used to confirm teenage hair and 
eye colour.  
3.5.2 Clinical examination 
The QUT Melanoma Study Clinical Examination followed a protocol developed and 
tested by Professor David Whiteman and others at QIMR. I conducted all 
examinations at T2, after first undertaking training to update skills and gain 
confidence in conducting accurate and effective skin examination (with thanks to Dr 
Marcia Davis, a dermatologist who has conducted in excess of 600 clinical 
examinations at QIMR). 
Clinical examination data were collected on: 
• the anatomic location of melanoma  
• number of current naevi  
• naevi previously removed 
• current freckle, solar lentigo and solar keratosis burden 
• determination of skin type by spectrophotometry  
• height and weight 
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• current eye colour. 
Further data were collected at the clinical examination on: 
 
• family history of melanoma 
• supplement use. 
The location of the study melanoma was identified to confirm that this was in 
agreement with the histopathology report. The number of naevi was quantified by 
examination of the head, neck, trunk and upper limbs (from the hipline up) to 
identify any naevi 2 mm or greater in diameter. Freckle and solar lentigo density was 
identified for three regions: the forearms, the face and the shoulders, according to a 
four-point scale of none, minimal, moderate and heavy. Solar keratoses were 
quantified for the dorsum of hand, dorsum of forearm, forehead, cheek, nose and 
chin for both sides of the body. If more than 50 keratoses were present at any one 
sub-site, this was recorded as 50+.  Weight was measured using electronic scales and 
height was obtained from patient’s driver’s licences. Eye colour was compared to a 
standard eye colour chart (see Appendix H), while answers to questions regarding 
family history of melanoma and use of vitamin D or calcium supplements were 
recorded as yes or no. If vitamin D supplementation was obtained from a 
multivitamin formula, this was only recorded as “yes” if the formula contained 
greater than 200 IU of vitamin D. Spectrophotometry was used to gain an objective 
measure of skin type and is described below. 
Spectrophotometry 
Reflectance spectrophotometry measures reflected light in the range of 360–740nm 
(visual spectrum) and uses colorimetry to assess skin colour. Measurements of skin 
reflectance, obtained from parts of the body that are both exposed (dorsal forearm 
and forehead) and not usually exposed to the sun (upper inner arm), were recorded 
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using a portable hand-held spectrophotometer: Konica Minolta CM-2500d (Minolta 
Camera Company, Ltd., Osaka, Japan). Measurements were recorded in the three 
dimensional colour space known as the CIELAB (Commission Internationale 
d’Eclairge 1976) L*a*b* colour space.211 The value of L (“lightness”) is measured 
using a scale from 0 (black) to 100 (perfect white), a* relates to colour ranging from 
red to green and b* relates to colour from blue to yellow.211 The protocol for the 
spectrophotometer use is included in Appendix I.  
3.5.3 Serum for 25(OH)D and S-100β (Objectives 2, 3 and 4) 
To fulfil the second, third and fourth objectives of the study, prior to wider excision 
surgery a blood sample for measurement of serum concentrations of 25(OH)D and S-
100β was obtained from all participants by a trained phlebotomist in the rooms of a 
commercial pathology company. The blood was drawn, centrifuged, the serum 
aliquoted and identified by ID number only, and then transported to QUT’s Kelvin 
Grove Campus in a cold box and stored at -80°C in the AusSun laboratory (Room 
E210, Kelvin Grove Campus).  
All serum analyses were performed at the AusSun laboratory at QUT in Brisbane, 
Australia. Concentration of 25(OH)D was measured as a single batch using a 
commercial chemiluminescent immunoassay (LIAISON® 25_OH Vitamin D 
TOTAL assay: DiaSorin, Inc., Stillwater, MN). This assay measures total 25(OH)D 
including 25(OH)D2 (ergocalciferol) and 25(OH)D3 (cholecalciferol). Intra-assay 
variability was 3–6%. Corresponding values for inter-assay variability were 6–9%. 
The laboratory that performed the testing is a participant in the Vitamin D External 
Quality Assessment Scheme (DEQAS). Serum S-100β levels were analysed using 
LIAISON® Sangtec®100 (DiaSorin, Saluggia, Italy), a frequently used assay that 
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has been shown to have good reproducibility and is reported to have the highest 
sensitivity and accuracy when compared to other assays.125,212,213 
3.5.4 Histopathology (Objective 2) 
Data regarding the histopathological features of the cutaneous melanoma were 
obtained from the participant’s biopsy and wider excision histopathology reports. All 
definitive (wider) excisions were reported by dermatopathologists from Sullivan 
Nicolaides Pathology, one of Australia’s largest pathology practices. All 
dermatopathologists, led by Dr David Weedon, are Fellows of the Royal College of 
Pathologists Australia (FRCPA). Sullivan Nicolaides Pathology is quality certified to 
ISO standards. 
Outcome data obtained were: 
• Breslow thickness (millimetres) 
• Clark level (levels 1–5) 
• mitotic rate (per square millimetre) 
• ulceration (presence or absence). 
Additional data also obtained from the histopathology reports included: 
• melanoma type  
• melanoma site  
• extent, or presence of, solar elastosis. 
Solar elastosis is not always routinely included in melanoma histopathology reports; 
therefore a comment was added to all wider-excision pathology request forms 
requesting that the pathologist describe the extent of solar elastosis observed in the 
specimen. 
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3.6 DATA MANAGEMENT 
Data from the questionnaire and clinical examination, blood samples and 
histopathology reports, were initially recorded in Excel (Microsoft Office 2007) in 
pre-coded numeric format with some exceptions: 
• place names, which were subsequently allocated a latitude using World 
Atlas214 
• certain data from the histopathology reports, including melanoma type, 
anatomic site of melanoma and degree of solar elastosis were entered 
verbatim as string variables, and then subsequently recoded into numeric 
variables.  
Routinely, all data collected during one week was recorded in Excel that week to 
minimise data entry error caused by repetitious entry of large quantities of data. The 
data entry process was audited by re-entering data from all IDs ending in 6 (i.e. 
M006, M016, M026 etc.) after 10 questionnaire or clinical examination data had 
been entered.   
At the completion of the twelve month recruitment period, the Excel data files were 
copied to the statistical analysis program, Stata IC Version 11.2.215 Data cleaning and 
consistency checking was then undertaken before analysis commenced. Frequency 
distributions of all variables were run to check for missing, invalid and incongruous 
values. Continuous variable values (age, serum 25(OH)D, S-100β, Breslow, 
spectrophotometry readings, height, weight, BMI, number of naevi) were checked to 
ensure they were within a plausible range. I personally undertook all data collection, 
management, entry and cleaning.  
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3.7 DATA ANALYSIS PREPARATION 
Before commencing analysis many variables required recoding and, or, regrouping.  
3.7.1 Questionnaire data  
Age was used as a continuous variable and also regrouped as a two-level categorical 
variable with a cut-point of 60 years to best represent the sample distribution (median 
age = 62.5 years, mean age = 61.4 years). Information generated from the questions 
relating to sun exposure after school and on the weekends during primary and high 
school was aggregated to form two groups of “low” and “high” exposure.  Sunscreen 
use was regrouped from six to three categories by combining: a) never and 
occasional, b) 1–2 and 3–4 days per week, and c) 5–6 and 7 days per week. 
Combined with scores from the three anatomic areas for sunscreen use: 
• face or head or neck 
• hands or forearms, and 
• other parts of the body, 
two variables were created for sunscreen use. 
1. sunscreen use five years ago,  and  
2. sunscreen use ten years ago. 
Sunburn has been previously considered as both a dichotomous and an ordinal 
categorical variable.216,217 Whiteman and Green216 also report that wide variation 
exists in the reporting of sunburns particularly with respect to life-periods and 
quantification of exposure. Sunburns were reported as a categorical variable in the 
three life-periods explored in the questionnaire: primary school, secondary school 
and after school (adult), quantified according to the range in number of burns 
reported (see Table 3.1). 
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While decisions regarding most recoding were based on the logical grouping of the 
different levels of response, other responses, such as eye colour (personal 
communication with Dr Guy D’Mellow, FRACS, Ophthalmologist), were regrouped 
based on professional advice (see Table 3.1). Some categories were also collapsed 
due to small numbers in specific levels. 
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Table 3.1 
Regrouping of categorical covariates  
Covariate Likert scale used in 
questionnaire 
 
Recoding 
“How long ago did someone notice a 
problem with the spot?”   
< 3months 
3–6 months 
6–12 months 
1–5 years 
> 5years 
Don’t remember 
< 3 months 
3–12 months 
1–5 years 
 
 
Don’t remember = missing 
Freckle burden as teenager, and 
Naevi burden as teenager 
none 
few 
some 
many 
none 
few/some 
many 
Burning tendency never 
rarely 
sometimes 
mostly 
always 
never/rarely burn 
sometimes burn 
always burn 
Tanning tendency tans deeply 
tans moderately 
tans slightly 
does not tan 
tans deeply/moderately 
tans lightly/ does not tan 
“How often were you outdoors in the 
sun after school / on weekends and 
holidays in summer?” and 
“How often did you wear a hat at those 
times” 
never 
rarely 
sometimes 
usually 
always 
never, rarely or sometimes 
usually & always 
 
Primary school sunburns, 
Secondary school sunburns, and 
Adult sunburns  
never 
0–5 
6–10 
11–20 
21–50 
> 50 
 
0–5 burns 
6–20 burns 
21–50+ 
Sunscreen use as adult 
1) 5 years ago 
2) 10 years ago 
never 
occasional 
1–2 days a week 
3–4 days a week 
5–6 days a week 
every day  
never/occasional 
1–4 days a week 
5–7 days a week 
 
Hair colour as young teenager black 
dark brown 
auburn/strawberry blonde 
blond 
red 
light brown 
other 
black/dark brown 
light brown 
auburn/strawberry blonde/blond/red 
 
Eye colour blue 
grey 
hazel 
green 
brown 
blue/grey 
hazel/green 
brown 
Education primary school 
secondary school 
trade certificate 
technical/college diploma 
university degree 
other 
primary/secondary school 
trade/technical/college diploma 
university degree 
 Chapter 3: Research Design and Analytic Approach 68 
Sun exposure variable 
A new variable for Reported Adult Sun Exposure was generated from the 
questionnaire. Participants reported the following information for each year of life 
from the time they left high school (see page 12 of Appendix E): 
• place of work (city/town) 
• age of starting and stopping work in that place 
• number of days worked in the job 
• amount of time spent in the sun in summer on work days and non-work 
days at each job (1 = mostly indoors, 2 = outdoors for 1–4 hours, 3 = 
mostly outdoors). 
Eighteen years of age was classed as “adult” and any work reported prior to that age 
was omitted from any calculation. Locations or cities were recoded with their 
relevant absolute latitude.  
Sun exposure work was calculated for workdays at each job as follows: 
Sun exposure time in years [Age finished job minus age commenced job] 
   X 
Latitude effect (90 – latitude)/90) 
X 
Workdays sun exposure time (number of days worked x amount of time 
outdoors in sun) 
 
Sun exposure non-work was calculated for non-work days at each job as follows: 
Sun exposure time in years (Age finished job – age commenced job) 
X 
Latitude effect (90 – latitude)/90 
X 
Non-work days sun exposure time (number of days worked x amount of time 
outdoors in sun) 
 
The resulting sun exposure work and sun exposure non-work values for each job 
were then combined to give a Cumulative adult workday sun exposure total and a 
Cumulative adult non-work day sun exposure total. Reported Adult Sun Exposure 
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was determined as the total of Cumulative adult workday sun exposure and 
Cumulative adult non-workday sun exposure and was analysed as a continuous and 
categorical variable. As the values of the Reported Adult Sun Exposure variable were 
not normally distributed, the median (308.1) was used as the cut-off for “low” and 
“high” adult sun exposure. 
3.7.2 Clinical examination data  
Body Mass Index (BMI) was calculated from weight and height and was grouped for 
analysis to those < 25 kg/m2, 25–29.99 kg/m2, and those ≥ 30 kg/m2; i.e. normal, 
overweight or obese. Naevus burden was grouped into 0–9 naevi, 10–39 naevi, and ≥ 
40 naevi to reflect low, medium and high burden. Scores for freckling and solar 
lentigo density of the three sites were regrouped from four groups to three: “nil”, 
“few or some”, and “many”. Number of solar keratoses was treated as a continuous 
variable. 
Spectrophotometry 
Spectrophotometry measurements of L* a* and b* were reported from each of 3 
sites: the left upper inner arm (an unexposed body site), the left dorsal forearm and 
the central forehead, as individual continuous measurements. While lightness of skin 
is reported by L* and measured from 0 (black) to 100 (perfect white), the three 
measurements are more commonly used in skin pigmentation research according to 
previously defined combinations of these values to represent hue, chroma and ITA 
value.211 The hue angle211 represents the basic tint of the skin colour ranging from 
red (0°) to yellow (90°) and was calculated in Stata as ho = arctangent(b*/a*)*57.3. 
Chroma84 represents the saturation, or intensity of that colour tint and was calculated 
as C* = √( a*2 + b*2). Chroma scores are seen to increase as intensity of colour 
increases.84 The L* and b* values from the upper inner arm were used to calculate a 
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variable for “skin-type”, the individual topography angle (ITA) value.211 Using the 
formula:  
ITA = [arctangent((L*-50)/ b*)]*180/3.14159 
values ranging from 90° to -90° were generated and used to form six “skin type” 
groups (see Table 3.2). 
Table 3.2 ITA skin types  
ITA value Skin type 
 
> 55o to ≤ 90o Very light/very fair 
> 41o to ≤ 55o Light/fair 
> 28o to ≤ 41o Intermediate/medium 
> 10o to ≤ 28o Tanned/olive 
> -30o to ≤ 10o Brown/dark  
> -90o to ≤ -30o Dark/black 
218 
 
Only the three lightest ITA skin types were represented by the participants in this 
study. ITA skin type was included in the analyses as an ordinal categorical variable 
and hue, chroma and ITA value were included as continuous variables. ITA value 
was chosen as the representative variable for “skin type” in all modelling (reported in 
Chapter 5).  
3.7.3 Serum 25(OH)D and serum S-100β  
Serum 25(OH)D concentration (nmol/L) was reported as a continuous measurement 
in the raw data file. A priori I aimed to examine the markers of melanoma prognosis 
in relation to 25(OH)D as a continuous measure, to allow examination of the linear 
association between adverse outcomes and increasing levels of 25(OH)D. I also 
examined the effect of low vitamin D status: using both the 50 nmol/L cut-point 
endorsed by the IOM178 and the lowest quartile of 25(OH)D (less than 45.25 nmol/L) 
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in this sample. Furthermore, I investigated whether high vitamin D status (here the 
highest quartile (equal to or greater than 69.8 nmol/L), since only a few participants 
had 25(OH)D levels of 75 nmol/L or higher) was associated with melanoma 
prognostic indicators. Both low and high vitamin D status were investigated to 
identify if there was, in effect a dose-response i.e. an adverse effect of low 25(OH)D 
concentration or a beneficial effect of high 25(OH)D concentration.   
Serum S-100β level was reported and analysed as a continuous measurement. I had 
also intended to analyse S-100β as a binary variable of less than, or greater than or 
equal to 0.15 µg/L (range for healthy men and women), however as only one sample  
(0.24 µg/L) was greater than the cut-off point this was not possible. 
3.7.4 Histopathology  
Data for the outcome variables were recorded in the raw data files as follows: 
• Breslow thickness: continuous (millimetres) 
• Clark level: ordinal categorical (Levels 1–5) 
• mitotic rate: continuous (number of mitosis per mm2)  
• ulceration: binary (yes/no). 
Breslow thickness 
Initially it was anticipated that Breslow thickness should be analysed as a continuous 
variable, but due to the large number of in situ tumours (43%), Breslow thickness 
was recoded as a binary outcome (< 0.75 mm and ≥ 0.75 mm). This reflects the 
common cut-off depths for prognosis as reported in the literature.219 
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Clark level 
A small number (n = 2) of Clark level 5 melanomas were reported. To allow 
comparison to be made between in situ and invasive tumours, Clark level was 
recoded as a dichotomous categorical variable of Level 1 and Levels 2–5.  
Mitosis and ulceration 
Mitotic activity was reported in 23% of the melanomas. Mitotic rate, recorded in the 
raw data files as a continuous variable with zero representing “no mitotic activity”, 
was subsequently recoded as a binary outcome (absent or present). Ulceration was 
reported in only 5% of the tumours; therefore due to insufficient cell size it was not 
included as an outcome variable. 
Melanoma type 
Eleven different melanoma types and subtypes were described in the histopathology 
reports and recorded in the raw data Excel spreadsheet. Initially grouping was based 
on the method proposed by Clark et al,56 of three types ranging from least to most 
malignant, i.e. lentigo maligna melanoma, superficial spreading melanoma and 
nodular melanoma. Some lesions did not fit into that grouping, necessitating the 
formation of a fourth group: “other melanoma”. This group included situations where 
two types of melanoma were reported within a single lesion (e.g. “malignant 
melanoma of superficial spreading and lentigo maligna types”) and others that were 
simply reported as “malignant melanoma” and other sub types. 
Thus the four groups were:  
• Lentigo maligna melanoma (LM) 
• Superficial spreading melanoma (SSM) 
• Nodular melanoma (NM) 
• Other melanoma.  
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If participants had been diagnosed with more than one melanoma simultaneously, 
only the first melanoma reported in the histopathology for the biopsy specimen was 
included in the analysis. 
Melanoma site 
To simplify the raw data relating to the anatomic site of the melanoma, this was 
aggregated to form four anatomic regions commonly used to describe melanoma 
locales: head and neck, trunk, upper and lower extremities.219 Any shoulder lesions 
were classified as “upper extremity”.  
Solar elastosis 
Although all histopathological analyses were performed in one commercial 
pathology laboratory, the terminology used in some histopathology reports to 
comment on the degree of solar elastosis varied slightly from that requested, thus 
requiring some regrouping.  For example; “nil”, “no evidence of”, and “negligible”, 
were regrouped into “absent”.  Solar elastosis was subsequently recoded as a 
dichotomous variable of absent and present.  
 
3.8 DATA ANALYSES 
Summary descriptive statistics of frequency, measures of central tendency (mean and 
median), and dispersion (standard deviation and range) were reported for continuous 
variables, and number (n) and percentages (%) were reported for categorical 
variables. Frequency histograms were examined in Stata for all continuous variables 
to check for normality of distribution. Relationships between variables were tested 
using Chi-squared tests, Fisher’s exact test (if there was less than n = 5 in any cells), 
Kruskal-Wallis and independent t-tests. Multicollinearity checks were undertaken by 
examining simple pair-wise Pearson (r) correlations between the variables. Cut-off 
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values for “r” that confirm multicollinearity range from 0.7 220 to 0.9.221  “r” ≥ 0.9 
was used as the cut-off in this study and then further checks were undertaken for 
collinearity using the Variance Inflation Factor (Stata command “vif”) to check that 
all values were less than 10.222  
As the sample size was n = 100, percentages were reported to one decimal place 
according to guidelines adopted from Lang and Secic.223 All summary statistics 
(mean, standard deviation, median, range) were reported to one decimal point, with 
the exception of S-100β (values here were all less than one) that was reported to two 
decimal points. 95% Confidence Intervals (95% CI), coefficients and P-values were 
reported to two decimal places. The only exception to this rule was when the P-value 
was less than 0.001, in which case it was reported as P < .001.  
 
3.9 MODEL AND VARIABLE SELECTION   
Focussing on the aim of the study, an epidemiological approach to the analysis was 
used to examine the independent association between surrogate measures of 
melanoma prognosis (the outcomes) and serum 25(OH)D concentration at diagnosis, 
while adjusting for potential confounding factors. A subsidiary analysis explored the 
predictors of melanoma prognosis (here Breslow thickness, Clark level and presence 
of mitosis) within these data. Missing values were managed by excluding all the data 
on those people for the specific analysis using that variable. However, there were 
very few missing values. 
Association between 25(OH)D and melanoma prognosis 
I first examined the bivariate association between 25(OH)D concentration and each 
covariate under consideration using linear regression. Next, using logistic regression 
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I undertook a bivariate analysis of the association between each outcome variable 
and all covariates under consideration. In order to control for any potential 
confounding effects, potential confounders were identified if they were significant at 
α < 0.2 in the bivariate analyses for both the outcome under investigation and 
25(OH)D. A confounder is an independent risk factor for the outcome; it has a 
statistical association with the exposure of interest and it is not on the causal pathway 
between the exposure of interest and the outcome.224 The measure of association 
between an exposure and an outcome can become distorted by the presence of 
another variable–the confounder. 
To adjust for age (in years) and sex, both variables were also identified for inclusion 
in the multivariable models regardless of their level of significance in the bivariate 
analyses. Significant covariates were identified in the preliminary multivariable 
models (of the outcome and 25(OH)D concentration) if they were either a logical 
confounder or if their inclusion in the model changed the coefficient of the main 
exposure of interest (vitamin D) by 5% or greater (indicating a confounding effect). 
These significant covariates were then adjusted for in the final models.  
To ensure that the non-linear scale ratio on which odds ratios are measured did not 
impact on the 5% change rule, the raw coefficient, rather than the odds ratio for 
vitamin D, was used to gauge if there was a 5% or greater change. However, final 
results were reported as Adjusted Odds Ratios (AOR).  
Best predictors of melanoma prognosis 
The aim of this process was to build a predictive model of melanoma prognosis. As 
in many model-building situations in epidemiological studies the most significant 
problem faced in analysing these study data was to select, from a very large number 
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of covariates, those that should be in the model. Covariates were purposefully 
selected, initially by their “significance” in a bivariate analysis at α < 0.2 level. Then 
using a purposeful selection of covariates (PSC) approach outlined by Hosmer and 
Lemeshow,225 a preliminary multivariable analysis was undertaken as each 
potentially important covariate was introduced one at a time into the model. A 
synopsis follows. 
Step 1: Bivariate analysis 
Step 1 began with a bivariate analysis of the association between the outcome and 
each covariate under consideration using binary logistic regression.  
Step 2: Identify covariates for preliminary multivariable model 
Covariates with P-values of less than 0.2 in the bivariate analyses were identified, 
and other variables considered likely to be “important” were flagged. 
Step 3: Fit preliminary multivariable model 
Covariates identified in Step 2 were fitted into a preliminary multivariable model. 
Variables with P-values of 0.2 or greater were then removed from the model. 
Step 4: Selection of variables for best fitting preliminary model 
Individual covariates were reinserted into the preliminary multivariable model and 
likelihood ratio tests were used to examine whether included covariates improved the 
model fit. Covariates were retained if the P-value for the likelihood ratio test was less 
than 0.05. 
Step 5: Reintroduction of previously excluded variables 
Covariates that were not considered for inclusion in the preliminary multivariable 
model, but considered “important” were added back into this model (one at a time). 
Improvement of the model was again tested using likelihood ratio tests. 
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Step 6: Examine linearity of the continuous covariates included in the 
preliminary model 
The fracpoly, compare command in Stata was used to identify the best parametric 
form. 
Step 7: Effect modification  
Using a multiplicative term in the model, the preliminary multivariable model was 
then examined to identify if the magnitude of the effect was different for different 
groups (for example, males and females). 
Step 8: Fit main effects model 
To determine the best fit for the main effects model, the likelihood ratio test was 
used to examine whether the inclusion of identified covariates improved the model.  
----------------------------------------------------------------- 
 
3.10 ETHICS 
Prior to commencement of the research, all of the documentation for the QUT 
Melanoma Study was submitted, via a National Ethics Application Form (NEAF), to 
the Human Research Ethics Committee (HREC) of the Queensland University of 
Technology (EC00171). The study received approval from the HREC, confirming 
that it met the requirements of the NHMRC National Statement on Ethical Conduct 
in Human Research (Approval number: 0900000681) (see Appendix J). All 
participants signed written informed consent prior to participation in the QUT 
Melanoma Study. 
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3.11 CONFIDENTIALITY 
The de-identified hardcopy data for each participant, i.e. completed questionnaire 
and clinical examination results, were stored by I.D. number in a sequential filing 
system that was easily accessible to the researcher. To maintain total confidentiality, 
the hard copies of the histopathology reports and the originals of the consent forms 
were stored in a locked filing cabinet in a separate office accessible only by swipe 
card. Electronic data files were all de-identified. 
 
3.12 SUMMARY 
Based on the conclusions of the literature review, a cross sectional exploratory study, 
designed to identify the relationship between the serum 25(OH)D concentration of 
patients with newly diagnosed melanoma, and their outcome as predicted by 
histopathological features of the melanoma that are associated with prognosis, was 
implemented. The study design overcame the perceived limitations of previous 
studies and allowed the study objectives to be fulfilled by: 
•  recruiting patients with both non-invasive and invasive melanomas 
(Objective 1) 
• obtaining blood samples for vitamin D and S-100β analysis prior to wider-
excision surgery (Objectives 2 and 4) 
• recruiting the sample over a twelve month period (Objective 3)  
• obtaining copies of the histopathology reports for both the biopsy and 
wider excision surgeries (Objective 2) 
• administering a comprehensive questionnaire (demographics, sun exposure 
history, sun protection habits, history of skin cancer) (Objective 2), and  
• performing a clinical examination of each participant, including a naevi 
count and spectrophotometry (Objective 2).  
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To answer the research question and address the study objectives, data were 
subsequently analysed in Stata IC Version 11.2 215 to obtain descriptive statistics, and 
using the outcome measures of Breslow thickness (≥ 0.75 mm vs. < 0.75 mm), Clark 
level (Levels 2–5 vs. Level 1) and mitosis (present vs. absent), I examined vitamin D 
(continuous, lowest quartile, 50 nmol/L, highest quartile) as a risk factor for these 
outcomes. I further used a purposeful selection of covariate model building process 
to develop a predictive model for Breslow thickness. The results of the data analyses 
will be discussed in the following chapters.
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Chapter 4:  Preliminary results 
4.1 INTRODUCTION 
Results will be presented in two chapters. As discussed in Chapter 3, risk factor 
modelling was used to answer the research question: “What is the relationship 
between serum 25(OH)D concentration at time of diagnosis with melanoma, and 
histopathological features of melanoma that are associated with prognosis?” A 
purposeful selection of covariates model building process was used to develop a 
predictive model for Breslow thickness to elucidate the key predictors. 
In this chapter all relevant statistics considered necessary to “set the scene” for the 
modelling processes are presented. The data presented are not simply descriptive. To 
gain a more comprehensive understanding of the sample, relationships between 
variables of interest are also explored, allowing the secondary study objectives of:  
• describing seasonal variation in vitamin D status within the sample, and 
• identifying the relationship between S-100β level and the histopathological 
features of the tumours,  
to be achieved.  
The results of the modelling processes will then be reported in Chapter 5. 
Chapter 4 commences by describing, in Section 4.2 the study setting, response rate 
and general descriptive participant characteristics. Section 4.3 examines data related 
to the exposures of interest, before melanoma-related data are examined in Section 
4.4. Both sections present relevant descriptive data before interrelationships between 
variables within each section, including age and sex, are explored. Section 4.5 
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reports on relevant relationships between sun exposure-related variables and 
melanoma-related variables.  
 
4.2 DESCRIPTIVE STATISTICS – GENERAL 
4.2.1 Setting 
This study was conducted in Brisbane, Queensland, Australia. Brisbane is 
geographically situated at Latitude 27.5° South, Longitude 153° East and experiences 
a mean maximum temperature of 26.4°C (80°F) and mean minimum of 16.2°C 
(61°F) (Winter: 11°C to 21°C, Summer: 20°C to 28°C, Spring and Autumn: 15°C to 
25°C).  
4.2.2 Response rate 
106 patients with cutaneous melanoma presented to the two surgeons during the 
study period. Of these, 102 fulfilled the inclusion and exclusion criteria and were 
approached to take part in the study; 100 patients consented to participate. Due to 
patient privacy regulations the only data available for the two patients who declined 
to participate was that they were female. Histopathology from both the biopsy and 
wider excision surgeries was obtained for all participants, blood samples for serum 
25(OH)D and S-100β analyses were collected prior to wider excision for the entire 
sample, 99% of participants completed the questionnaire and 98% took part in the 
clinical examination.   
4.2.3 Participant characteristics 
Study participants had a median age of 62.5 and a mean age of 61.4 years. The 
youngest patient was 26 years old and the oldest 89 years. Males were marginally 
over-represented (56%) compared to females (44%). 89% of the sample was born in 
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Australia and 61% in Queensland. Three quarters (76%) were married or in a de-
facto relationship and 67% had completed technical or tertiary education. Four 
patients (4%) had not attended high school and had moved into the work force at age 
14. Ever smoking was reported by 40%, while 6% were current smokers. Average 
BMI was 27.28 kg/m2 (SD = 4.68). 65% of participants were either overweight or 
obese.  
 
4.3 EXPOSURE-RELATED DATA 
4.3.1 Descriptive data 
Overall, the QUT Melanoma Study sample had “sufficient” serum 25(OH)D levels, 
reporting a mean level of 58.2 nmol/L (see Table 4.1). Naevi burden and Reported 
Adult Sun Exposure were not normally distributed (see Table 4.1), and as described 
in Section 3.7.2 (page 69) naevi burden was subsequently analysed as an ordinal 
categorical variable and the median, rather than the mean was used as the threshold 
to categorise Reported Adult Sun Exposure in later analyses.  
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Table 4.1 
Summary descriptive statistics (frequency, mean, standard deviation, median and range) for 
continuous exposure variables        
Exposure (n) Mean  Std. Dev. Median Min.  Max. 
Serum 25(OH)D [nmol/L] (100) 58.2 19.2 58.6 15.8 114.0 
Height [centimetres] (97) 171.2 9.2 171.5 150.0 189.0 
Weight [kilograms] (97) 80.0 15.8 80.0 53.0 117.0 
BMI (97) 27.3 4.7 26.8 19.6 42.5 
Naevi burden at diagnosis (98) 34.0 41.0 19.5 0.0 210.0 
Inner arm L* (98) 69.2 2.7 69.6 61.2 76.3 
Inner arm a* (98) 5.7 1.5 5.7 1.6 10.5 
Inner arm b* (98) 15.9 2.4 15.8 10.4 22.1 
Forearm L* (98) 56.9 5.6 56.7 43.6 69.8 
Forearm a* (98) 9.8 1.9 9.6 4.4 14.5 
Forearm b* (98) 18.0 2.5 17.9 7.3 24.0 
Forehead L* (98) 61.1 3.4 61.3 52.9 69.1 
Forehead a* (98) 14.2 2.9 13.9 6.4 22.4 
Forehead b* (98) 16.3 2.0 16.5 11.2 21.2 
Inner arm chroma (98) 16.9 2.5 16.8 10.6 24.4 
Inner arm hue (98) 70.1 4.4 70.7 58.5 82.6 
Forearm chroma (98) 20.6 2.4 20.7 14.4 76.6 
Forearm hue (98) 61.4 6.1 61.7 29.7 72.0 
Forehead chroma (98) 21.8 2.4 22.0 14.6 70.7 
Forehead hue (98) 49.3 7.0 50.0 35.4 35.4 
ITA value (98) 50.3 6.8 50.2 28.1 67.5 
Reported Adult Sun Exposure (96)# 342.7 186.3 308.1 56.7 1206.0 
# Refer page 68 
 
Summary descriptive statistics (number and percentage) are provided in Table 4.2 for 
skin phenotype variables and other categorical variables that have previously been 
identified as potential risk factors for melanoma. Few participants reported having 
many freckles (4%) or moles (5.1%) as a teenager and less than one quarter (22.2%) 
reported teenage hair colour that was blonde, red, auburn or strawberry blonde. The 
percentage of participants in each sunburn category remained similar across the three 
time periods (primary school, secondary school and as an adult). 
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Table 4.2 
Summary descriptive statistics for categorical exposure variables 
Characteristics (n) Categories n (%) 
 
Freckle density as teenager (99) 
 
   
Nil 
Few/some 
Many 
37 (37.4) 
58 (58.6) 
4 (4.0) 
Naevus density as teenager (98) Nil 
Few/some 
Many 
27 (27.5) 
66 (67.4) 
5 (5.1) 
Hair colour as teenager (99) Black/ dark brown 
Light brown 
Blonde, red, auburn/sb*  
48 (48.5) 
29 (29.3) 
22 (22.2) 
Eye colour (98) 
     
 
Blue/grey 
Green/hazel  
Brown  
36 (36.7) 
48 (49.0) 
14 (14.3) 
Freckle density at diagnosis (98) Nil 
Few/some 
Many 
63 (64.3) 
21 (21.4) 
14 (14.3) 
Primary school sunburns (99) 0–5 burns 
6–20 burns 
20+ burns 
40 (40.4) 
44 (44.4) 
15 (15.2) 
Secondary school sunburns (95) 
 
0–5 burns 
6–20 burns 
20+ burns 
39 (41.1) 
44 (46.3) 
12 (12.6) 
Adult sunburns (99) 
 
0–5 burns 
6–20 burns  
20+ burns 
45 (45.5) 
39 (39.4) 
15 (15.1) 
*strawberry blonde 
 
Summary statistics provided in Table 4.3 show that 70% of the sample had ITA Type 
2 skin colour (light/fair skin), yet 73.7% reported that they tan deeply or moderately 
after spending several weeks at the beach in the sun without any sun protection. Over 
half (53%) of the participants reported that they mostly or always burn after 
unprotected exposure to the midday sun for 30 minutes for the first time in summer 
and almost three-quarters (72.6%) reported high levels of sun exposure during their 
school years. 
Examination of serum 25(OH)D levels in relation to categories of the other variables 
(see Table 4.3) showed that there was very little difference between males and 
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females for 25(OH)D level (P = 0.91), older adults had higher 25(OH)D levels (P = 
0.37) than the younger adults, while those with the lightest skin type had lower 
25(OH)D levels (P = 0.08) than the other skin types.  
Table 4.3 
Summary descriptive statistics (frequency, mean, median, standard deviation and range) of serum 
25(OH) concentration  (nmol/L) for categorical variables of interest 
 
 
Summary descriptive statistics for serum 25(OH)D concentration at season of 
diagnosis were also examined and are presented in Figure 4.1. The lowest average 
seasonal levels of 25(OH)D were reported during winter (52 .0 nmol/L) and the 
highest in summer (62.3 nmol/L).  
 
    Serum 25-hydroxyvitamin D 
concentration (nmol/L) 
  
 
Characteristics (n) 
 
Categories 
 
n (%) 
 
Mean  
 
SD 
 
Median 
 
Range 
Sex (100) 
 
Male  
Female  
56 (56.0) 
44 (44.0) 
58.4 
57.9 
17.6 
21.3 
59.3 
57.5 
21.1–114.0 
15.8–104.0 
Age group (100) < 60 years 
≥ 60 years 
40 (40.0) 
60 (60.0) 
56.1 
59.6 
17.8 
20.1 
55.2 
59.7 
20.9–104.0 
15.8–114.0 
BMI (97) < 25.0  
25–29.9  
≥ 30  
34 (35.0) 
36 (37.0) 
27 (28.0) 
60.0 
59.3 
53.4 
18.4 
22.1 
16.3 
61.3 
58.4 
51.3 
20.9–104.0 
15.8 –114.0 
24.5–89.6 
Burning tendency (99) 
  
Rarely/never   
Sometimes  
Mostly/always 
16 (16.2) 
30 (30.3) 
53 (53.5) 
55.9 
60.3 
57.5 
20.8 
21.5 
17.7 
49.9 
59.9 
58.6 
15.8–101.0 
20.9–114.0 
21.1–104.0 
Tanning tendency (99) 
     
Tan deeply/moderately 
Tan slightly/ does not tan 
73 (73.7) 
26 (26.3) 
58.8 
56.2 
18.2 
22.4 
58.6 
58.4 
15.8–114.0 
20.9–104.0 
ITA skin type (98) Very light/very fair  
Light/fair 
Intermediate/medium  
20 (21.0) 
70 (71.0) 
8 (8.0) 
53.4 
58.0 
67.5 
18.1 
17.6 
31.8 
58.4 
57.5 
60.8 
21.1–85.7 
20.9–104.0 
15.8–114.0 
School-years sun 
exposure (95) 
Low  
High  
26 (27.4) 
69 (72.6) 
57.4 
58.0 
22.7 
18.1 
57.5 
57.8 
15.8–104.0 
20.9–114.0 
Reported Adult Sun 
Exposure (96) 
Low  
High  
48(50.0) 
48 (50.0) 
57.6 
59.9 
20.0 
19.3 
53.7 
59.2 
15.8–114.0 
20.9–104.0 
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Figure 4.1. Serum 25(OH)D concentration (nmol/L) by season of diagnosis with melanoma 
 
Examination of the descriptive statistics for the exposure variables has provided 
some indications of the characteristics of the study sample. I now present the results 
of analyses of relevant inter-relationships between the various exposure variables. 
4.3.2 Interrelationships between exposure variables and age and sex 
As discussed in Chapter 2 (section 2.5), male sex and increasing age are both risk 
factors for being diagnosed with melanoma. Males are also reported to have higher 
mortality rates for melanoma when compared to females. Bivariate relationships 
between continuous exposure variables and sex and age (≥ 60 years vs. < 60 years) 
are presented in Table 4.4 (significant associations have been highlighted). 
Significantly higher naevi burden at diagnosis was seen in males compared to 
females (P = 0.03). The older age group (60 years or older) were significantly more 
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Exposure (P < 0.001), lower mean ITA value (P = 0.03) and higher chroma (greater 
intensity of colour) of an unexposed body site (P < 0.001), than those aged less than 
60 years. 
 
Table 4.4 
Relationships (logistic regression) between continuous exposure variables and sex and age (≥ 60 
years vs. < 60 years) 
 
 
 
Exposure (n) 
Males 
 
 
Mean (SD) 
Females 
 
 
Mean (SD) 
 
 
 
P 
Age  
(< 60 years) 
 
Mean (SD) 
Age  
(≥ 60 years) 
 
Mean (SD) 
 
 
 
P 
Naevi burden at 
diagnosis  (98) 
42.0 (49.9) 24.2 (22.0) 0.03 48.7 (47.4) 24.2 (32.5) 0.03 
BMI (97) 27.7 (3.5) 26.8 (5.9) 0.37 27.9 (5.9) 26.9 (3.6) 0.28 
Inner arm L* (98) 68.9 (2.9) 69.5 (2.3) 0.29 69.2 (2.9) 69.2 (2.5) 0.91 
Inner arm a* (98) 5.9 (1.5) 5.5 (1.4) 0.16 5.6 (1.6) 5.8 (1.4) 0.44 
Inner arm b* (98) 15.7 (2.5) 16.0 (2.3) 0.53 14.9 (2.6) 16.5 (1.9) < 0.001 
Forearm L* (98) 53.7 (4.6) 61.0 (3.7) < 0.001 58.2 (5.7) 56.0 (5.4) 0.06 
Forearm a* (98) 10.2 (2.0) 9.3 (1.7) 0.24 9.6 (2.2) 9.9 (1.7) 0.59 
Forearm b* (98) 17.2 (2.4) 19.1 (2.2) < 0.001 18.2 (2.3) 17.9 (2.6) 0.49 
Forehead L* (98) 60.2 (3.3) 62.1 (3.2) 0.01 61.4 (3.0) 60.8 (3.6) 0.43 
Forehead a* (98) 14.7 (2.8) 13.5 (2.9) 0.04 13.8 (3.0) 14.5 (2.8) 0.27 
Forehead b* (98) 16.1 (2.0) 16.6 (2.0) 0.20 16.3 (2.2) 16.4 (1.9) 0.86 
Inner arm chroma (98) 16.9 (2.6) 17.0 (2.4) 0.80 16.0 (2.8) 17.6 (2.0) < 0.001 
Inner arm hue (98) 69.4 (4.6) 71.1 (3.9) 0.06 69.4 (4.5) 70.6 (4.2) 0.20 
Forearm chroma (98) 20.1 (2.2) 21.3 (2.4) 0.01 20.7 (2.6) 20.5 (2.2) 0.71 
Forearm hue (98) 59.3 (6.6) 64.1 (3.9) < 0.001 62.3 (5.3) 60.8 (6.5) 0.25 
Forehead chroma (98) 22.0 (2.5) 21.6 (2.2) 0.49 21.5 (2.5) 22.0 (2.3) 0.36 
Forehead hue (98) 47.8 (6.3) 51.2 (7.3) 0.02 50.0 (7.6) 48.8 (6.5) 0.42 
ITA value (98) 50.1 (7.5) 50.6 (6.1) 0.74 52.1 (7.8) 49.1 (5.9) 0.03 
Reported Adult Sun 
Exposure (96) 
356.9 (221.1) 323.7 (221.1) 0.39 243.4 (127.8) 407.8 (190.7) < 0.001 
 
 
 
Sex was significantly associated with tanning tendency (χ2 = 6.26, P = 0.02), with a 
higher percentage of males compared to females reporting tanning deeply or 
moderately after spending several weeks at the beach in the strong sun (see Table 
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4.5). Sex was also significantly associated with sun exposure during school years (χ2 
= 6.51; P = 0.01) and with applying sunscreen five years ago (Fisher’s exact = 0.03). 
Males reported higher sun exposure during their school years and to using sunscreen 
more infrequently five years ago, than females. Age group (≥ 60 years vs. < 60 
years) was significantly associated with solar lentigo burden at time of diagnosis 
(Fisher’s exact = 0.02) and Reported Adult Sun Exposure (χ2 = 11.0; P < 0.001).  
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Table 4.5 
Relationships (χ2, or Fisher’s exact) between categorical exposure variables and sex and age (≥ 60 
years vs. <60 years) 
 
 
Exposure (n) 
Males  
 
n (%) 
Females 
 
 
n (%) 
 
 
P 
Age  
(< 60 years)  
 
n (%) 
Age  
(≥ 60 years)   
 
n (%) 
 
 
P 
BMI (97) 
  < 25.0  
  25–29.9  
  ≥ 30 
 
14 (35.9) 
12 (30.8) 
13 (33.3) 
 
20 (34.5) 
24 (41.4) 
14 (24.1) 
0.11  
14 (35.9) 
12 (30.8) 
13 (33.3) 
 
20 (34.5) 
24 (41.4) 
14 (24.1) 
0.66 
Season at diagnosis (100) 
  Winter  
  Spring  
  Summer  
  Autumn  
 
12 (21.4) 
17 (30.4) 
11 (19.6) 
16 (28.6) 
 
17 (38.6) 
8 (18.2) 
9 (20.5) 
10 (22.7) 
0.23  
14 (35.0) 
9 (22.5) 
7 (17.5) 
10 (25.0) 
 
15 (25.0) 
16 (26.7) 
13 (21.6) 
16 (26.7) 
0.75 
Naevi burden at diagnosis (98) 
  0–9 
  10–39 
  40 + 
 
13 (23.6) 
25 (45.5) 
17 (30.9) 
 
12 (27.9) 
20 (46.5) 
11 (25.6) 
0.52  
6 (15.0) 
16 (40.0) 
18 (45.0) 
 
19 (32.8) 
29 (50.0) 
10 (17.2) 
< 0.001 
Solar lentigo density at diagnosis (98) 
  Nil 
  Few/some 
  Many 
 
6 (10.9) 
19 (34.6) 
30 (54.5) 
 
6 (14.0) 
17 (39.5) 
20 (46.5) 
0.42  
8 (20.0) 
18 (45.0) 
14 (35.0) 
 
4 (6.9) 
18 (31.0) 
36 (62.1) 
0.02 
Burning tendency (99) 
  Rarely/never   
  Sometimes  
  Mostly/always 
 
12 (21.8) 
19 (34.6) 
24 (43.6) 
 
4 (9.1) 
11 (25.0) 
29 (65.9) 
0.07  
4 (10.0) 
11 (27.5) 
25 (62.5) 
 
12 (20.3) 
19 (32.2) 
28 (47.5) 
0.27 
Tanning tendency (99) 
  Tan deeply/moderately 
  Tan slightly/does not tan  
 
46 (83.6) 
9 (16.4) 
 
27 (61.4) 
17 (38.6) 
0.01  
28 (70.0) 
12 (30.0) 
 
45 (76.3) 
14 (23.7) 
0.49 
ITA skin type (98) 
  Very light/very fair  
  Light/fair 
  Intermediate/medium 
  
12 (21.8) 
37 (67.3) 
6 (10.9) 
 
8 (18.6) 
33 (76.7) 
2 (4.7) 
0.47  
13 (32.5) 
24 (60) 
3 (7.5) 
 
7 (12.1) 
46 (79.3) 
5 (8.6) 
0.05 
School-years sun exposure (95) 
  Low  
  High 
  
9 (17.0) 
44 (83.0) 
 
17 (40.5) 
25 (59.5) 
0.01  
11 (27.5) 
29 (72.5) 
 
15 (27.3) 
40 (72.7) 
0.98 
Reported Adult Sun Exposure (96) 
  Low  
  High 
  
31 (56.4) 
24 (43.6) 
 
25 (61.0) 
16 (39.0) 
0.65  
30 (79.0) 
8 (21.0) 
 
26 (44.8) 
32 (55.2) 
< 0.001 
Sunscreen use 5 years ago (99) 
  Most of time 
  Sometimes 
  Rarely/never 
 
1 (1.8) 
15 (27.3) 
39 (70.9) 
 
6 (13.6) 
16 (36.4) 
22 (50.0) 
0.03  
5 (12.5) 
12 (30.0) 
23 (57.5) 
 
2 (3.4) 
19 (32.2) 
38 (64.4) 
0.33 
Sunscreen use 10 years ago (99) 
  Most of time 
  Sometimes 
  Rarely/never 
 
0 (0.0) 
14 (25.5) 
41 (74.5) 
 
3 (6.8) 
14 (31.8) 
27 (61.4) 
0.09  
2 (5.0) 
12 (30.0) 
26 (65.0) 
 
1 (1.7) 
16 (27.1) 
42 (71.2) 
0.67 
Solar elastosis (48) 
  Absent 
  Present 
 
7 (25.9) 
20 (74.1) 
 
7 (33.3) 
14 (66.7) 
0.58  
7 (35.0) 
13 (65.0) 
 
7 (25.0) 
21 (75.0) 
0.45 
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4.3.3 Interrelationships between sun-related variables 
Further analyses were conducted to examine whether there was any relationship 
between levels of self-reported sun exposure at either school age, or as an adult, and 
the presence of solar elastosis (see Table 4.6). Due to the small sample size of 
melanomas reported by histology for solar elastosis, 95% Confidence Intervals are 
also included in this table. No significant associations were identified. 
Table 4.6 
Associations (Fisher’s exact) between reported levels of sun exposure and presence of solar elastosis 
                    Solar elastosis 
 
  
 Present Absent  
Characteristic (n) n (%; 95% CI) n (%; 95% CI)   P  
School-years sun exposure (46) 
  Low 
  High 
 
5 (62.5; 48.5, 76.5) 
27 (71.1; 58.0, 84.2) 
 
3 (37.5; 23.5, 51.5) 
11 (28.9; 15.8, 42.0) 
0.68 
Reported Adult Sun Exposure (47) 
  Low 
  High 
 
13 (61.9; 48.0, 75.8) 
20 (76.9; 64.9, 88.9) 
 
8 (38.1; 24.2, 52.0) 
6 (23.1; 11.1, 35.1) 
0.26 
 
 Of the self-reported skin phenotype characteristics, only burning tendency (P = 
0.03) and tanning tendency (P = 0.04) when unprotected in the summer sun were 
significantly associated with ITA skin type (see Table 4.7). 
 
 
 
 
 
 
 
 
 
 Chapter 4: Preliminary results 92 
Table 4.7 
Associations (Fisher’s exact) between ITA skin type and skin phenotype characteristics 
  ITA skin type 
 
  
 Very light/very fair Light/fair Intermediate/ 
medium 
 
Characteristic (n) n (%) n (%) n (%) P  
Burning tendency (98) 
  Rarely/never 
  Sometimes 
  Mostly/always 
 
1 (5.0) 
5 (25.0) 
14 (70.0) 
 
10 (14.0) 
22 (32.0) 
38 (54.0) 
 
4 (50.0) 
3 (38.0) 
1 (12.0) 
0.03 
Tanning tendency (98) 
  Tans deeply/moderately 
  Tans slightly/does not tan 
 
11 (55.0) 
9 (45.0) 
 
53 (76.0) 
17 (24.0) 
 
8 (100.0) 
0 (0.0) 
0.04 
Freckle density as teenager (98) 
  Nil 
  Few/some 
  Many 
 
5 (25.0) 
14 (70) 
1 (5.0) 
 
27 (39.0) 
40 (57.0) 
3 (4.0) 
 
4 (50.0) 
4 (50.0) 
0 (0.0) 
0.71 
Hair colour as teenager (98) 
  Black/dark brown 
  Light brown 
  Blond, red, s/b*, auburn 
 
8 (40.0) 
6 (30.0) 
6 (30.0) 
 
34 (49.0) 
20 (28.0) 
16 (23.0) 
 
6 (75.0) 
2 (25.0) 
0 (0.0) 
0.47 
Eye colour (98) 
  Blue/grey 
  Green/hazel 
  Brown 
 
8 (40.0) 
10 (50.0) 
2 (10.0) 
 
24 (34.0) 
36 (51.0) 
10 (15.0) 
 
4 (50.0) 
2 (25.0) 
2 (25.0) 
0.65 
Naevi burden at diagnosis (98) 
  0–9 
  10–39 
  40 + 
 
6 (30.0) 
8 (40.0) 
6 (30.0) 
 
17 (24.3) 
34 (48.6) 
19 (27.1) 
 
2 (25.0) 
3 (37.5) 
3 (37.5) 
0.92 
* strawberry blonde 
 
4.3.4 Interrelationships between exposure variables and serum 25(OH)D 
Serum 25(OH)D concentration was initially analysed in bivariate modelling as a 
continuous variable and is reported as such in the bivariate modelling in Chapter 5. 
Table 4.8 is provided to examine any relationships between vitamin D status 
categorised as “sufficient” (according to the threshold of 50 nmol/L) and sun 
exposure related factors. Season at diagnosis was significantly associated with 
vitamin D sufficiency (χ2 = 8.56, df = 3, P = 0.04), and proportionally more 
participants diagnosed with melanoma during summer and autumn had sufficient 
vitamin D status (≥ 50nmol/L) than those diagnosed in the other seasons of the year.  
No significant associations with other variables emerged.  
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Table 4.8 
Associations (χ2, or Fisher’s exact) between vitamin D status (< 50 nmol/L vs. ≥ 50 nmol/L) and 
variables of interest 
   Vitamin D status 
 
 
  < 50 nmol/L ≥ 50 nmol/L  
Characteristic (n) n (%) n (%) P  
Sex 
  Male (56) 
  Female (44) 
 
20 (35.7) 
16 (36.4) 
 
36 (64.3) 
28 (63.6) 
0.95 
Age group 
  < 60 years (40) 
  ≥ 60 years (60) 
 
14 (35.0) 
22 (36.7) 
 
26 (65.0) 
38 (63.3) 
0.87 
Education 
  University degree (44)  
  Diploma/trade cert. (23) 
  Primary/secondary school (32) 
 
18 (40.9) 
6 (26.1) 
12 (37.5) 
 
26 (59.1) 
17 (73.9) 
20 (62.5) 
0.48 
Season at diagnosis 
  Winter (29)  
  Spring (25) 
  Summer (20) 
  Autumn (26) 
 
15 (51.7) 
11 (44.0) 
3 (15.0) 
7 (26.9) 
 
14 (48.3) 
14 (56.0) 
17 (85.0) 
19 (73.1) 
0.04 
Body Mass Index 
 < 25.0 (34) 
 25–29.9 (36) 
≥ 30 (27)  
 
10 (29.4) 
13 (36.1) 
13 (48.2) 
 
24 (70.6) 
23 (63.9) 
14 (51.8) 
0.32 
ITA skin type 
  Intermediate/medium (8) 
  Light/fair (70) 
  Very light/very fair (20) 
 
2 (25.0) 
25 (35.7) 
9 (45.0) 
 
6 (75.0) 
45 (64.3) 
11 (55.0) 
0.58 
Reported Adult Sun Exposure 
  Low (48) 
  High (48) 
 
18 (37.5) 
17 (35.4) 
 
30 (62.5) 
31 (64.6) 
0.83 
Solar elastosis 
  Absent (14) 
  Present (34) 
 
8 (57.1) 
12 (35.3) 
 
6 (42.9) 
22 (64.7) 
0.16 
Tanning tendency 
  Tan deeply/moderately (73)   
  Tan slightly/does not tan (26) 
 
26 (35.6) 
10 (38.5) 
 
47 (64.4) 
16 (61.5) 
0.80 
Burning tendency 
  Rarely/never (16) 
  Sometimes (30) 
  Mostly/always (43)  
 
8 (50.0) 
9(30.0) 
19 (35.9) 
 
8 (50.0) 
21 (70.0) 
34 (64.1) 
0.40 
Sunscreen use 5 years ago 
  Most of time (7) 
  Sometimes (31) 
  Rarely/never (61) 
 
3 (42.9) 
11 (35.5) 
22 (36.1) 
 
4 (57.1) 
20 (64.5) 
39 (63.9) 
0.93 
Sunscreen use 10 years ago 
  Most of time (3) 
  Sometimes (28) 
  Rarely/never (68) 
 
2 (66.7) 
11 (39.3) 
23 (33.8) 
 
1 (33.3) 
17 (60.7) 
45 (66.2) 
0.48 
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4.4 MELANOMA-RELATED DATA 
4.4.1 Descriptive data 
In this section descriptive data are presented for melanoma and related factors, 
including anatomic site, histological features, season at diagnosis, history of NMSC, 
family history of melanoma and serum S-100β. 
Superficial spreading melanoma (SSM) was the most common form of melanoma in 
this study (see Figure 4.2), comprising 54% (n = 54) of all cases. 
 
 
 
Figure 4.2. Percentage distribution of the different types of melanoma in the QUT Melanoma Study 
LM: lentigo maligna melanoma; SSM: superficial spreading melanoma; NM: nodular melanoma; 
other MM: all other melanomas. 
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Approximately one third (37%) of all study melanomas were reported on the trunk, 
while the upper extremities were the least common site (12%) for melanoma (see 
Figure 4.3). 
 
 
 
 
Figure 4.3. Percentage distribution of melanomas by anatomic site 
 
 
 
Breslow thickness of melanomas ranged from 0 mm (43%) to 7.8 mm; ulceration 
was reported in 5% of cases and 4% of patients were diagnosed simultaneously with 
two melanomas.  
On examination at diagnosis, 51.1% of participants had a high (many) solar lentigo 
density. More than half (56%) of the sample had a previous history of NMSC, one-
third (33%) had a family history of melanoma, 57% of melanomas had been 
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participants had a doctor check their skin three or more times in the three years 
before diagnosis (see Table 4.9).  
 
Table 4.9 
Summary descriptive statistics for categorical variables related to melanoma 
Characteristics (n) Categories n  (%) 
 
Breslow thickness (100) < 0 75 mm 
≥ 0.75 mm 
83 (83.0) 
17 (17.0) 
Clark level (100)  Level 1 
Level 2 
Level 3 
Level 4 
Level 5 
45 (45.0) 
36 (36.0) 
8 (8.0) 
9 (9.0) 
2 (2.0) 
Mitosis Absent 
Present 
77 (77.0) 
23 (23.0) 
Naevi burden at diagnosis (98) 0–9 
10–39 
40 + 
25 (25.5) 
45 (45.9) 
28 (28.6) 
Solar lentigo density at diagnosis (98) Nil 
Few/some 
Many 
12 (12.2) 
36 (36.7) 
50 (51.1) 
Solar elastosis (48) 
 
Absent  
Present  
14 (29.2) 
34 (70.8) 
Sunscreen use 5 years ago (99) Most of time 
Sometimes 
Rarely/never 
7 (7.1) 
31 (31.3) 
61 (61.6) 
Sunscreen use 10 years ago (99) Most of time 
Sometimes 
Rarely/never 
3 (3.0) 
28 (28.3) 
68 (68.7) 
History of NMSC (99) No 
Yes 
43 (43.4) 
56 (56.6) 
Previous melanoma (98) 
    
No 
Yes 
85 (86.7) 
13 (13.3) 
Family history of melanoma (99) No 
Yes 
66 (66.7) 
33 (33.3) 
History of any internal cancer (97) No 
Yes 
83 (85.6) 
14 (14.4) 
Time since lesion was noticed (99) < 3 months  
3–12 months 
> 1 year 
57 (57.6) 
27 (27.3) 
15 (15.1) 
Skin checks by doctor in last 3 years 
(99) 
Never 
1 or 2 times 
3 or more times 
25 (25.3) 
28 (28.3)) 
46 (46.4) 
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4.4.2 Melanoma type in relation to sex, age, site and prognostic indicators 
Superficial spreading melanoma (SSM) was the most common type of melanoma 
diagnosed in both males (44.6%) and females (65.9%). Lentigo maligna melanomas 
(LM) were more common in males than females (see Figure 4.4), but sex was not 
significantly associated with melanoma type (P = 0.15). 
 
 
Figure 4.4. Percentage distribution (frequency distribution) of melanoma types according to sex. 
 
 
Participants with SSM ranged in age from 31 years to 88 years. The lowest mean age 
for any melanoma type was 54 years in patients with nodular melanoma, although 
here the sample size (n = 2) was very small (see Table 4.10).  There was little 
variation in the mean age of males and females according to melanoma type. 
Melanoma type was not statistically associated with age (F (3) = 0.38, P = 0.76). 
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Table 4.10 
Mean age (SD) and sex of patients according to melanoma type 
 
Statistically significant associations were noted between melanoma type and the 
outcome measures of Breslow thickness (χ2 =18.63, df = 3, P < 0.001), Clark level 
(χ2 = 16.93, df = 3, P < 0.001) and mitosis (χ2 = 10.74, df = 3, P = 0.01) (see Table 
4.11). All lentigo maligna melanomas had a Breslow thickness less than 0.75 mm 
and both nodular melanomas had a Breslow thickness equal to or greater than 0.75 
mm (see Table 4.11). 
 
Table 4.11 
Associations (χ2 or Fisher’s exact) between melanoma type and histological characteristics of the 
melanomas 
 
 
 
Melanoma type 
(n = 100) 
Frequency 
(%)  
Mean age 
(SD) 
Mean age (males) 
(SD) 
Mean age (females) 
(SD) 
 
Lentigo maligna 29 (29.0) 62.9 (10.0) 64.1 (9.4) 59.5 (11.2) 
Superficial spreading 54  (54.0) 60.9 (13.4) 61.8 (13.8) 60.1 (13.2) 
Nodular 2 (2.0) 54.0 (1.4) 55.0 (-) 53.0 (-) 
Others 15 (15.0) 61.5 (15.1) 60.2 (16.2) 63.5 (14.4) 
    Melanoma types 
 
   
 LMM SSM NM Other  
Characteristics n (%) n (%) n(%) n (%) P 
Breslow thickness 
  < 0.75 mm 
  ≥ 0.75 mm 
 
29 (34.9) 
0 (0.0) 
 
44 (53.1) 
10 (58.8) 
 
0 (0.0) 
2 (11.8) 
 
10 (12.1) 
5 (29.4) 
< 0.001 
Clark level 
  Level 1 
  Level 2–5 
 
22 (48.9) 
7 (12.7) 
 
19 (42.2) 
35 (63.7) 
 
0 (0.0) 
2 (3.6) 
 
4 (8.9) 
11(20.0) 
< 0.001 
Mitosis 
  Absent 
  Present 
 
25 (32.5) 
4 (17.4) 
 
43 (55.8) 
11 (47.8) 
 
0 (0.0) 
2 (8.7) 
 
9 (11.7) 
6 (26.1) 
     0.01 
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4.4.3 Anatomic site of melanomas in relation to sex, age, melanoma type and 
prognostic indicators 
 
In males, melanomas were reported more often on the head and neck (34%) and 
trunk (41%); in females the trunk (32%) and legs (32%) were the most common 
sites. Figure 4.5 displays the percentage distribution of the anatomic sites of the 
melanomas according to sex and shows that a higher percentage of the melanomas of 
the head and neck, and trunk, were found in males, while the females reported a 
higher percentage of melanomas on the arms and legs. In the QUT Melanoma Study, 
the anatomic site of the melanomas was significantly associated with sex (χ2 = 6.18, 
df = 1, P = 0.01). 
 
 
Figure 4.5. Percentage distribution (frequency distribution) of the anatomic sites of melanomas 
according to sex. 
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Melanomas on the upper extremities were reported at the lowest mean age (55.8 
years) and melanomas on the trunk at the highest mean age (65.9 years) (see Table 
4.12).  
Table 4.12 
Mean age (SD) and sex of participants according to anatomic site of melanoma 
 
Melanoma anatomic site was also significantly associated with age group (≥ 60 years 
vs. < 60 years) (χ2 = 8.07, df = 3, P = 0.04) and 75.7% of melanomas located on the 
trunk were reported in the older age group (≥ 60 years).  
Both nodular melanomas were found on the upper extremities; 62% of all head and 
neck melanomas were lentigo maligna melanomas, and 88% of melanomas on the 
lower extremities were of the superficial spreading type (see Figure 4.6). There was a 
significant association between anatomic site and type of melanoma (χ2 = 44.05, df = 
9, P < 0.001). 
 
 
 
 
              Mean age (SD) 
 
 
Anatomic site 
 
Frequency (%) 
 
Sample 
 
   Males 
 
   Females 
Head and neck 27 (27.0) 58.7 (14.3) 57.0 (15.6) 62.6 (10.4) 
Trunk 37 (37.0) 65.9 (10.1) 67.5 (9.5) 63.1 (10.9) 
Upper extremities 12 (12.0) 55.8 (8.4) 57.5 (5.2) 55.0 (9.8) 
Lower extremities 24 (24.0) 60.5 (14.1) 62.2 (10.1) 59.2 (16.6) 
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Figure 4.6. Percentage distribution of each melanoma type according to anatomic site. 
 
The anatomic site of the melanomas was not significantly associated with the 
outcome measures of Breslow thickness, Clark level or mitosis (see Table 4.13).  
 
 
Table 4.13 
Associations (χ2, or Fisher’s exact) between anatomic site and histological characteristics of the 
melanomas 
 
 
          Anatomic site 
 
   
 Head & neck Trunk Upper 
extremities 
Lower 
extremities 
 
 
Characteristics 
 
n (%) 
 
n (%) 
 
n (%) 
 
n (%) 
 
P 
Breslow 
  < 0.75 mm 
  ≥ 0.75 mm 
 
24 (28.9) 
3 (17.6) 
 
31 (37.4) 
6 (35.3) 
 
9 (10.8) 
3 (17.7) 
 
19 (22.9) 
5 (29.4) 
0.69 
Clark level 
  Level 1 
  Level 2–5 
 
14 (31.1) 
13 (23.6) 
 
19 (42.2) 
18 (32.7) 
 
4 (8.9) 
8 (14.6) 
 
8 (17.8) 
16 (29.1) 
0.39 
Mitosis 
  Absent 
  Present 
 
19 (24.7) 
8 (34.8) 
 
32 (41.5) 
5 (21.8) 
 
9 (11.7) 
3 (13.0) 
 
17 (22.1) 
7 (30.4) 
0.38 
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4.4.4 Interrelationships and associations between S-100β and sex, age and 
histological characteristics of the study melanomas  
The fourth objective of the QUT Melanoma study was to identify any relationship 
between S-100β level and histological features of the melanomas. Mean and median 
serum S-100β levels were 0.05 µg/L (SD = 0.04; range < 0.02 to 0.24). Summary 
descriptive statistics for serum S-100β levels and variables of interest are displayed 
in Table 4.14. Crude associations analysed using the General Linear Model, are also 
displayed. Melanoma type, mitosis (present vs. absent) and age group (≥ 60 years vs. 
< 60 years) were noted to be significantly associated with S-100β level.  
 
Table 4.14 
Summary descriptive statistics (frequency, mean, median, standard deviation and range) of serum S-
100β (µg/L) and associations (General Linear Model) for variables of interest 
      Serum S-100β concentration (µg/L)    
 
Characteristic 
 
n (%) 
 
Mean  
 
SD. 
 
Median  
 
Range 
 
P  
Sex 
  Male  
  Female 
 
56 (56.0) 
44 (44.0) 
 
0.05 
0.06 
 
0.02 
0.05 
 
0.05 
0.05 
 
< 0.02 – 0.10 
< 0.02 – 0.24 
0.09 
Age group 
  < 60 years 
 ≥ 60 years 
 
40 (40.0) 
60 (60.0) 
 
0.04 
0.06 
 
0.03 
0.04 
 
0.04 
0.05 
 
< 0.02 – 0.14 
< 0.02 – 0.24 
0.05 
Anatomic site 
  Head & neck  
  Trunk  
  Upper extremities 
  Lower extremities 
 
27 (27.0) 
37 (37.0) 
12 (12.0) 
24 (24.0) 
 
0.05 
0.05 
0.06 
0.06 
 
0.03 
0.02 
0.04 
0.05 
 
0.05 
0.05 
0.06 
0.05 
 
< 0.02 – 0.10 
< 0.02 – 0.09 
< 0.02 – 0.14 
< 0.02 – 0.24 
0.22 
Melanoma type 
  LM 
  SSM 
  NM  
  Other melanomas 
 
29 (29.0) 
54 (54.0) 
2 (2.0) 
15 (15.0) 
 
0.05 
0.05 
0.06 
0.07 
 
0.03 
0.05 
0.01 
0.05 
 
0.05 
0.05 
0.06 
0.06 
 
< 0.02 – 0.10 
< 0.02 – 0.14 
  0.05 – 0.06 
< 0.02 – 0.24 
0.05 
Breslow thickness 
  < 0.75 mm 
  ≥ 0.75 mm 
 
83 (83.0) 
17 (17.0) 
 
0.05 
0.06 
 
0.03 
0.05 
 
0.05 
0.05 
 
< 0.02 – 0.14 
< 0.02 – 0.24 
0.17 
Clark level 
  Level 1 
  Level 2–5 
 
45 (45.0) 
55 (55.0) 
 
0.04 
0.06 
 
0.02 
0.04 
 
0.04 
0.06 
 
< 0.02 – 0.10 
< 0.02 – 0.24 
0.06 
Mitosis 
  Absent 
  Present 
 
77 (77.0) 
23 (23.0) 
 
0.03 
0.06 
 
0.03 
0.04 
 
0.05 
0.06 
 
< 0.02 – 0.14 
< 0.02 – 0.24 
0.05 
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A higher than normal level of S-100β (≥ 15 µg/L) was found in one patient (1%), a 
female aged 89 years who presented with a Level 4, 3.98 mm thick, ulcerated lesion 
(described as a “malignant melanoma”) on the lower leg. The histopathologist 
reported the presence of seven mitotic figures per square millimetre. Her serum 
25(OH)D level was 85.7 nmol/l. 
 
4.5 RELATIONSHIPS BETWEEN VARIABLES FROM SECTIONS 4.3 
 AND 4.4 
In this section, I present initial data for relationships between variables from the sun 
exposure related data and the melanoma related data. Table 4.15 presents descriptive 
statistics and crude associations for serum 25(OH)D concentration, melanoma site 
and histological characteristics. A non-significant association between higher mean 
serum 25(OH)D concentration and Breslow thickness less than 0.75 mm is noted.  
Table 4.15 
Summary descriptive statistics (frequency, mean, median, standard deviation and range) of serum 
25(OH)D (nmol/L) and associations (General Linear Model) with histological characteristics of the 
melanomas  
  25-Hydroxyvitamin D concentration 
(nmol/L) 
    
 
Characteristic (n) 
 
n (%) 
 
Mean  
 
SD. 
 
Median 
 
Range 
 
P  
Anatomic site  (100) 
  Head & neck  
  Trunk  
  Upper limbs  
  Lower limbs 
 
27 (27.0) 
37 (37.0) 
12 (12.0) 
24 (24.0) 
 
56.8 
59.1 
64.3 
55.1 
 
16.6 
17.1 
23.5 
22.9 
 
58.6 
58.9 
61.6 
54.9 
 
21.1–99.6 
37.9–114.0 
24.3–104.0 
15.8–101.0 
0.87 
Melanoma type (100) 
  LM  
  SSM 
  Nodular  
  Other melanomas 
 
29 (29.0) 
54 (54.0) 
2 (2.0) 
15 (15.0) 
 
59.9 
57.5 
73.3 
55.2 
 
17.7 
20.6 
43.5 
14.3 
 
59.8 
58.6 
73.3 
52.7 
 
21.1–99.6 
15.8–114.0 
42.5–104.0 
32.8–85.7 
0.55 
Breslow thickness (100) 
  < 0.75 mm 
  ≥ 0.75 mm 
 
83 (83.0) 
17 (17.0) 
 
59.7 
50.7 
 
18.0 
23.4 
 
59.0 
42.5 
 
15.8–114.0 
24.3–104.0 
0.08 
Clark level (100) 
  Level 1 
  Level 2–5 
 
45 (45.0) 
55 (55.0) 
 
60.8 
56.0 
 
20.7 
17.9 
 
59.6 
53.3 
 
15.8–114.0 
24.3–104.0 
0.22 
Mitosis (100) 
  Absent 
  Present 
 
77 (77.0) 
23 (23.0) 
 
58.9 
55.6 
 
18.8 
20.9 
 
58.6 
57.8 
 
15.8–114.0 
24.5–104.0 
0.47 
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Interrelationships between solar elastosis and anatomic site 
After noting that there was no association between the absence or presence of solar 
elastosis and levels of previous sun exposure (Table 4.6, page 91), I investigated 
whether there was any evidence of a relationship between solar elastosis and the 
anatomic site of the melanoma. While no significant associations were noted, all  
melanomas (n = 7) situated on the upper extremities (and histologically examined for 
solar elastosis) showed evidence of solar elastosis (see Table 4.16).   
Table 4.16 
Presence of solar elastosis and association (Fisher’s exact) with the anatomic site of melanoma 
                  Solar elastosis 
 
 
     Absent       Present  
Anatomic site (n =48) n (%; 95% CI) n (%; 95% CI)    P 
 Head & neck 
Trunk 
Upper extremities 
Lower extremities 
2 (25.0; 12.8, 37.3) 
9 (47.4; 33.3, 61.5) 
0 (0.0; 0.0, 0.0) 
3 (21.4; 9.0, 33.0) 
6 (75.0; 62.8, 87.3) 
10 (52.6; 38.5, 66.7) 
7 (100.0; 1.0, 1.0) 
11 (78.6; 67.0, 90.2) 
0.11 
 
 
Interrelationships between ITA skin type and prognostic outcome measures 
for melanoma 
Although ITA value will be examined at all bivariate stages of the analysis in 
Chapter 5, the details of the relationship between ITA skin type and the three 
outcome measures are presented in Table 4.17. Of particular interest is that no 
melanomas with Breslow thickness greater than or equal to 0.75 mm were reported 
in participants with an intermediate skin type. Breslow thickness (P = 0.03) and 
mitosis (P = 0.02) were both significantly associated with ITA skin type. 
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Table 4.17 
ITA skin type and associations (Fisher’s exact) with the three outcome measures for melanoma 
prognosis 
                            ITA skin type 
 
   
Outcome  
(n = 100) 
Intermediate 
n (%) 
Light/fair 
n (%) 
Very light/very fair 
n (%) 
   
P   
     
Breslow thickness 
   < 0.75 mm  
   ≥ 0.75 mm 
 
8 (100.0) 
0 (0.0) 
 
61 (87.1) 
9 (12.9) 
 
13 (65.0) 
7 (35.0) 
  0.03 
Clark level 
  Level 1 
  Level 2–5 
 
5 (62.5) 
3 (37.5) 
 
33 (47.1) 
37 (52.9) 
 
6 (30.0) 
14 (70.0) 
  0.24 
Mitosis 
  Absent 
  Present 
 
8 (100.0 
0 (0.0) 
 
57 (81.4) 
13 (18.6) 
 
11 (55.0) 
9 (45.0) 
  0.02 
 
4.6 SUMMARY 
Chapter 4 has presented descriptive statistics for the study population, main 
exposures of interest, the melanomas and has also explored relationships between 
variables of interest.  The following points provide a brief summation of the findings: 
• mean age of participants: 61.4 years 
• mean 25(OH)D concentration: 58.2 nmol/L 
• mean BMI: 27.34 kg/m2 
• most common type of melanoma: superficial spreading melanoma (SSM)  
 
In addition, the third and fourth study objectives have been achieved: 
• Season at diagnosis was found to be significantly associated (P = 0.04) 
with serum 25(OH)D concentration 
• S-100β level was significantly associated with melanoma type and mitosis. 
Chapter 5 will now address the research question and examine the predictors of 
Breslow thickness. 
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Chapter 5: Results of Model Building 
5.1  INTRODUCTION 
Chapter 5 presents the risk factor model building process designed to answer the 
research question: “What is the relationship between serum 25(OH)D level at time of 
diagnosis with melanoma, and histopathological features of melanoma that are 
associated with prognosis?” An analysis of the key predictors of Breslow thickness is 
also provided in this chapter. 
Relationship between serum 25(OH)D level and melanoma prognosis 
The process, as outlined in Chapter 3, involved building models for each of the 
outcome variables of Breslow thickness, Clark level and mitosis in relation to 
measures of vitamin D. As discussed in section 3.9, covariates satisfying the 
conditions of a confounder were identified for inclusion in the preliminary 
multivariable models. Age (in years) and sex were retained in all models. 25(OH)D 
was first modelled as a continuous variable, and then according to cut-points for low 
vitamin D status and high vitamin D status (as described in section 3.7.3). If the 
addition of any covariate to the preliminary multivariable models (outcome and 
vitamin D) resulted in a change to the vitamin D coefficient of 5% or more, this was 
regarded as evidence of confounding, and that covariate was then retained in the 
multivariable model with age (in years) and sex. In order to provide results that were 
more clinically relevant, all subsequent analyses report serum 25(OH)D per 10 
nmol/L, rather than by one nmol/L. Preliminary analyses are presented in terms of 
beta coefficients; final results of the modelling are presented as adjusted odds ratios 
(AOR).  
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The chapter begins by examining bivariate associations between 25(OH)D 
concentration and each covariate. The results for the risk factor modelling to examine 
the association between serum 25(OH)D and each prognostic outcome commences 
with the Breslow thickness model, before presenting the results for Clark level and 
mitosis. Results from the risk factor modelling for categories of vitamin D status are 
also presented (at the conclusion of each 25(OH)D concentration examination). The 
chapter concludes by presenting a predictive model for Breslow thickness. 
 
5.2 BIVARIATE ANALYSIS OF SERUM 25(OH)D CONCENTRATION 
AND COVARIATES 
The bivariate associations between the main outcome of interest, serum 25 (OH)D 
concentration (continuous variable) and each covariate were examined using the 
General Linear Model (see Table 5.1). Coefficients represent the mean difference in 
25(OH)D concentration per unit increase in the covariate from the referent. Nine 
spectrophotometric skin pigmentation variables (including ITA value), BMI, adult 
sunburns, solar elastosis, when the spot was noticed and taking supplements were all 
associated with serum 25(OH)D concentration at α < 0.2 level. As discussed in 
Section 3.7.2 (page 70), ITA value was chosen as the representative covariate for 
“skin type” in all modelling. 
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Table 5.1  
Bivariate linear regression for serum 25(OH)D concentration and all covariates 
Variable Coefficient 95% CI P  
Age  0.17 -.14, 0.47 0.28 
Sex 
  Male 
  Female 
 
 
-.43 
 
referent 
-8.16, 7.29 
 
 
0.91 
Melanoma type 
  LMM 
  SSM 
  NM 
  Other 
 
 
-2.39 
13.34 
-4.76 
 
referent 
-11.22, 6.44 
-14.72, 41.40 
-16.96, 7.45 
 
 
0.59 
0.35 
0.44 
Anatomic site 
  Head & neck 
  Trunk 
  Upper extremities 
  Lower extremities 
 
 
2.29 
7.43 
-1.68 
 
referent 
-7.42, 12.0 
-5.88, 20.74 
-12.44, 9.08 
 
 
0.64 
0.27 
0.76 
Season at diagnosis 
  Winter 
  Spring 
  Summer 
  Autumn 
 
 
6.40 
10.28 
9.82 
 
referent 
-3.93, 16.69 
-.70, 21.27 
-.39, 20.02 
 
 
0.22 
0.07 
0.06 
S-100β 65.97 -42.25, 174.20 0.23 
ITA value -.66 -1.22, -.11 0.02 
Inner arm L* -1.33 -2.77, 0.10 0.07 
Inner arm a* 2.83 0.22, 5.44 0.03 
Inner arm b* 1.72 0.11, 3.32 0.04 
Forearm L* -.94 -1.61, -.27 <0.001 
Forearm a* 3.25 1.33, 5.16 <0.001 
Forearm b* 0.49 -1.08, 2.05 0.54 
Forehead L* -.10 -1.25, 1.06 0.87 
Forehead a* 0.52 -.82, 1.86 0.44 
Forehead b* -.06 -2.01, 1.89 0.95 
Inner arm chroma 1.80 0.28, 3.32 0.02 
Inner arm hue -.42 -1.31, 0.47 0.35 
Forearm chroma 1.47 -.15, 3.09 0.07 
Forearm hue -.69 -1.33, -.07 0.03 
Forehead chroma 0.54 -1.11, 2.20 0.52 
Forehead hue -.18 -.74, 0.38 0.54 
BMI -.72 -1.55, 0.11 0.09 
Naevi burden at diagnosis  -.04 -.13, 0.06 0.45 
Freckle density at diagnosis 
  Low 
  Medium 
  High 
 
 
6.67 
1.95 
 
referent 
-2.97, 16.30 
-9.34, 13.24 
 
 
0.17 
0.73 
Solar lentigo density at diagnosis 
  Low 
  Medium 
  High 
 
 
4.69 
1.94 
 
referent 
-8.13, 17.51 
-10.42, 14.31 
 
 
0.47 
0.76 
Eye colour 
  Brown 
  Green/hazel 
  Blue/grey 
 
 
2.98 
6.32 
 
referent 
-8.67, 14.62 
-5.76, 18.40 
 
 
0.61 
0.30 
Burning tendency 
  Rarely/never burns 
  Sometimes burns 
  Mostly/always burns 
 
 
4.39 
1.56 
 
referent 
-7.56, 16.33 
-9.44, 12.57 
 
 
0.47 
0.78 
Tanning tendency 
  Tans deeply/moderately 
 
 
 
referent 
 
 
 Chapter 5: Results of Model Building 110 
Variable Coefficient 95% CI P  
  Tans slightly/does not tan -2.55 -11.33, 6.23 0.57 
Hair colour as teenager 
  Black/dark brown 
  Light brown 
  Blonde, red, auburn, s/b*, blonde 
 
 
-3.73 
1.77 
 
referent 
-12.79, 5.32 
-8.14, 11.68 
 
 
0.42 
0.72 
Naevus density as teenager 
  Nil 
  Few/some 
  Many 
 
 
1.13 
-7.91 
 
referent 
-7.70, 9.97 
-26.75, 10.92 
 
 
0.80 
0.41 
Freckle density as teenager 
  Nil 
  Few/some 
  Many 
 
 
0.54 
-4.46 
 
referent 
-7.60, 8.67 
-24.81, 15.90 
 
 
0.90 
0.67 
School-years sun exposure 
  Low 
  High 
 
 
0.57 
 
referent 
-8.32, 9.46 
 
 
0.90 
Reported Adult Sun Exposure 
(continuous) 
 
53.16 
 
44.88, 61.45 
 
0.19 
Primary school sunburns 
  0–5 burns 
  6–20 burns 
  > 20 burns 
 
 
0.66 
-6.88 
 
referent 
-7.72, 9.04 
-18.49, 4.74 
 
 
0.88 
0.24 
Secondary school sunburns 
  0–5 burns 
  6–20 burns 
  > 20 burns 
 
 
-1.21 
-7.72 
 
referent 
-9.69, 7.27 
-20.45, 5.00 
 
 
0.78 
0.23 
Adult sunburns 
  0–5 burns 
  6–20 burns 
  > 20 burns 
 
 
-5.54 
-8.42 
 
referent 
-13.88, 2.81 
-19.79, 2.95 
 
 
0.19 
0.15 
Solar elastosis 
  Absent 
  Present  
 
 
9.63 
 
referent 
-3.69, 22.94 
 
 
0.15 
Sunscreen use 10 years ago 
  Wore sunscreen most of time 
  Wore sunscreen sometimes 
  Rarely/never wore sunscreen 
 
 
12.96 
8.63 
 
referent 
-10.35, 36.27 
-14.00, 31.26 
 
 
0.27 
0.45 
Sunscreen use 5 years 
  Wore sunscreen most of time 
  Wore sunscreen sometimes 
  Rarely/never wore sunscreen 
 
 
0.97 
-3.66 
 
referent 
-15.13, 17.06 
-19.00, 11.69 
 
 
0.91 
0.64 
When was spot noticed 
  Less than 3 months 
  3–12 months 
  > 12months 
 
 
1.68 
-10.25 
 
referent 
-7.17, 10.53 
-21.25, 0.74 
 
 
0.70 
0.07 
Family history of melanoma 
  No 
  Yes 
 
 
3.43 
 
referent 
-4.75, 11.62 
 
 
0.41 
History of previous melanoma 
  No 
  Yes 
 
 
-1.75 
 
referent 
-13.18, 9.68 
 
 
0.76 
History of other internal cancer 
  No 
  Yes 
 
 
-3.24 
 
referent 
-13.86, 7.39 
 
 
0.55 
Take supplements 
  No 
  Yes 
 
 
-8.92 
 
referent 
-18.38, 0.53 
 
 
0.06 
Ever smoked 
  No 
 
 
 
referent 
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Variable Coefficient 95% CI P  
  Yes 1.95 -5.93, 9.83 0.63 
Education 
  Primary/Secondary school 
  Trade/ Technical certificate 
  Tertiary education  
 
 
6.46 
4.01 
 
referent 
-3.41, 16.32 
-4.90, 12.92 
 
 
0.20 
0.37 
 *strawberry blond 
 
 
5.3 BRESLOW THICKNESS MODEL 
5.3.1 Step 1: Bivariate association between Breslow thickness and vitamin D 
Breslow thickness was not normally distributed due to the large number (43%) of in 
situ melanomas and was modelled as a categorical variable reflecting “thin” tumours 
(< 0.75 mm) and “thick” tumours (≥ 0.75 mm). A Breslow thickness of less than 0.75 
mm is the referent category in all analyses. Results are reported as beta-coefficients, 
95% confidence intervals and P-values based on a logit model. Higher 25(OH)D 
concentration was inversely associated with Breslow thickness (beta = -.03, 95% CI 
= -.06, 0.00, P = 0.08) . 
 
5.3.2 Step 2: Examination of each covariate in relation to the outcome, Breslow 
thickness  
Bivariate associations between Breslow thickness (≥ 0.75 mm vs. < 0.75 mm) and all 
covariates are presented in Table 5.2. Covariates identified as significantly associated 
with Breslow thickness at α < 0.2 level were S-100β, ITA value, inner arm chroma 
and BMI. 
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Table 5.2 
Bivariate logistic regression analysis for Breslow thickness (≥ 0.75 mm vs. < 0.75 mm) in relation to 
all covariates 
Variable  
 
Coefficient 95% CI P 
Age  -.01 -.05, 0.03 0.62 
Sex 
  Male 
  Female 
 
 
0.43 
 
referent 
-.61, 1.48 
 
 
0.41 
Melanoma type   0.24 (Fisher’s) 
Anatomic site 
  Head & neck 
  Trunk 
  Upper extremities 
  Lower extremities 
 
 
0.48 
0.98 
0.74 
 
referent 
-1.04, 1.92 
-.79, 2.75 
-.81, 2.30 
 
 
0.56 
0.28 
0.35 
Season of diagnosis 
  Winter 
  Spring 
  Summer 
  Autumn 
 
 
0.68 
0.10 
0.13 
 
referent 
-.72, 2.08 
-1.60, 1.66 
-1.71, 1.52 
 
 
0.34 
0.91 
0.87 
S-100β 9.39 -4.00, 22.78 0.17 
ITA value 0.11 0.02, 0.21 0.02 
Inner arm L* 0.14 -.08, 0.36 0.23 
Inner arm chroma -.35 -.60, -.10 < 0.001 
BMI 0.12 0.00, 0.23 0.05 
Naevi burden at diagnosis  -.00 -.02, 0.01 0.72 
Freckle density at diagnosis 
  Low 
  Medium 
  High 
 
 
-.12 
0.37 
 
referent 
-1.52, 1.27 
-1.08, 1.81 
 
 
0.86 
0.62 
Solar lentigo density at diagnosis 
  Low 
  Medium 
  High 
 
 
-1.13 
-1.12 
 
referent 
-2.66, 0.40 
-2.56, 0.32 
 
 
0.15 
0.13 
Eye colour 
  Brown 
  Green/hazel 
  Blue/grey 
 
 
-.17 
-.78 
 
referent 
-1.64, 1.30 
-2.43, 0.87 
 
 
0.82 
0.35 
Burning tendency 
  Rarely/never burns 
  Sometimes burns 
  Mostly/always burns 
 
 
-.41 
-.12 
 
referent 
-2.04, 1.23 
-1.57, 1.33 
 
 
0.63 
0.87 
Tanning tendency 
  Tans deeply/moderately 
  Tans slightly/does not tan 
 
 
0.64 
 
referent 
-.49, 1.77 
 
 
0.27 
Hair colour as teenager 
  Black/dark brown 
  Light brown 
  Blonde, red, auburn, s/b*, blonde 
 
 
0.98 
-.36 
 
referent 
-.20, 2.16 
-2.04, 1.33 
 
 
0.10 
0.68 
Naevus density as teenager 
  Nil 
  Few/some 
  Many 
 
 
0.14 
0.36 
 
referent 
-1.10, 1.38 
-2.07, 2.80 
 
 
0.83 
0.77 
Freckle density as teenager 
  Nil 
  Few/some 
  Many 
 
 
-.70 
0.19 
 
referent 
-1.81, 0.41 
-2.20, 2.58 
 
 
0.22 
0.88 
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Variable  
 
Coefficient 95% CI P 
School-years sun exposure   
  Low 
  High 
 
 
-.04 
 
referent 
-1.20, 1.29 
 
 
0.95 
Reported Adult Sun Exposure 
(continuous) 
 
0.00 
 
-.00, .00 
 
0.51 
Primary school sunburns 
  0–5 burns 
  6–20 burns 
  > 20 burns 
 
 
0.07 
0.35 
 
referent 
-1.11, 1.26 
-1.19, 1.88 
 
 
0.91 
0.66 
High school sunburns 
  0–5 burns 
  6 – 20 burns 
  > 20 burns 
 
 
0.20 
-.69 
 
referent 
-.96, 1.36 
-2.92, 1.53 
 
 
0.73 
0.54 
Adult sunburns 
  0–5 burns 
  6–20 burns 
  > 20 burns 
 
 
-.64 
0.52 
 
referent 
-1.92, 0.65 
-.86, 1.90 
 
 
0.33 
0.46 
Solar elastosis 
  Absent 
  Present  
 
 
0.25 
 
referent 
-1.49, 1.99 
 
 
0.77 
Sunscreen use 10 years ago   0.64 (Fisher’s) 
Sunscreen use 5 years 
  Wore sunscreen most of time 
  Wore sunscreen sometimes 
  Rarely/never wore sunscreen 
 
 
-.44 
0.38 
 
referent 
-2.87, 1.99 
-1.82, 2.60 
 
 
0.72 
0.73 
When was spot noticed 
  Less than 3 months 
  3–12 months 
  > 12months 
 
 
0.07 
-1.09 
 
referent 
-1.12, 1.25 
-3.23, 1.05 
 
 
0.91 
0.32 
Family history of melanoma 
  No 
  Yes 
 
 
-.47 
 
referent 
-1.70, 0.74 
 
 
0.44 
History of previous melanoma   0.12(Fisher’s) 
History of other internal cancer 
  No 
  Yes 
 
 
0.38 
 
referent 
-1.02, 1.79 
 
 
0.59 
Take supplements 
  No 
  Yes 
 
 
-.71 
 
referent 
-1.90, 0.49 
 
 
0.25 
Ever smoked 
  No 
  Yes 
 
 
-.15 
 
referent 
-1.25, 0.96 
 
 
0.80 
Education 
  Primary/Secondary school 
  Trade/ Technical certificate 
  Tertiary education  
 
 
0.50 
0.78 
 
referent 
-.93, 1.92 
-.47, 2.03 
 
 
0.50 
0.22 
*strawberry blond 
 
5.3.3 Step 3: Selection of potential confounders 
Potential confounders were first identified according to whether they were associated 
with the exposure AND the outcome (P < 0.2) in the bivariate analyses (see Table 
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5.3).  Apart from age and sex (retained for reasons noted previously), ITA value and 
BMI were the only covariates identified. 
Table 5.3  
Age, sex and covariates flagged at α < 0.2 level in serum 25(OH)D concentration AND Breslow 
thickness (≥ 0.75 mm vs. < 0.75 mm) bivariate analyses 
Covariates 
 
25(OH)D 
P 
Breslow 
P 
Age  0.28 0.62 
Sex 0.91 0.41 
ITA value 0.02 0.02 
BMI 0.09 0.05 
 
 
 
5.3.4 Step 4: Examine effect of potential confounding variables on association 
between 25(OH)D concentration and Breslow thickness 
Table 5.4 shows the effect on the 25(OH)D coefficient of introducing each of the 
potential confounders (identified in Table 5.3) into the model containing only 
Breslow thickness (outcome) and 25(OH)D concentration (exposure). As can be seen 
in Table 5.4, inclusion of either ITA value or BMI caused significant changes in the 
25(OH)D coefficient, confirming these covariates as confounders of the association 
between Breslow thickness and 25(OH)D concentration. Although the inclusion of 
age and sex into the basic model did not change the 25(OH)D coefficient, they were 
retained in the model as previously noted. Thus, in relation to the outcome of 
Breslow thickness the preliminary model included 25(OH)D, age, sex, ITA value and 
BMI. 
Table 5.4  
Effect of potential confounders on the association between Breslow thickness (≥ 0.75 mm vs. < 0.75 
mm) and 25(OH)D concentration (per 10 nmol/L) 
Model (n=98) Coefficient 
25(OH)D 
% change in 25(OH)D 
coefficient 
Breslow, 25(OH)D  -.293  
Breslow, 25(OH)D, age  -.286 -2.39 
Breslow, 25(OH)D, sex -.282 -3.75 
Breslow, 25(OH)D, ITA value -.255 -12.97 
Breslow, 25(OH)D, BMI -.238 -18.43 
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5.3.5 Step 5: Reassessing variables initially excluded 
The confounding effect of other key factors previously identified in other studies as 
being important predictors of either vitamin D status or melanoma risk, was tested 
and is summarised in Table 5.5. Only season at diagnosis was noted to have a greater 
than 5% effect on the 25(OH)D coefficient. 
Table 5.5 
Examination of additional potential confounders on the association between Breslow thickness (≥ 
0.75 mm vs. < 0.75 mm) and 25(OH)D concentration (per 10 nmol/L) 
Model (n=98) Coefficient 
25(OH)D 
% change in 25(OH)D 
coefficient 
 
* Preliminary model 
 
-.212 
 
                 
 
* Preliminary model, season at diagnosis 
 
-.245 
 
15.57 
 
* Preliminary model, naevi burden at diagnosis 
 
-.212 
 
0.00 
 
* Preliminary model, primary school sunburns -.211 1.42 
 
* Preliminary model = Breslow thickness, 25(OH)D, age, sex, ITA value, BMI 
 
 
5.3.6 Step 6: Final model for the association between 25(OH)D concentration 
and Breslow thickness  
On the basis of these analyses, the final model contained age, sex, ITA value, BMI 
and season at diagnosis. The results of the final model, for the association between 
25(OH)D concentration (per 10 nmol/L) and Breslow thickness (≥ 0.75 mm vs. < 
0.75 mm) are shown in Table 5.6. 
Table 5.6 
Relationship of 25(OH)D concentration (per 10 nmol/L) to Breslow thickness (≥ 0.75 mm vs.< 0.75 
mm), with adjustment for confounding factors  
Model (n = 98) 
 
Crude 
OR  
95% CI P Adjusted 
ORa  
 
95% CI P 
25(OH)D 0.75 0.54, 1.02 0.07 0.78 0.55, 1.11 0.17 
a adjusted for age, sex, ITA value, BMI, season at diagnosis 
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5.3.7 Step 7: Effect modification 
I assessed whether the association (above) between 25(OH)D concentration and 
Breslow thickness (≥ 0.75 mm vs. < 0.75 mm) varied according to age or sex. No 
significant interaction was noted (age: z = -.99, P = 0.32; sex: z = 0.82, P = 0.41). 
5.3.8 Final Breslow thickness and serum 25(OH)D models 
At the completion of the risk factor modelling process and after carefully examining 
and accounting for potential confounding factors (including age and sex), I 
determined that ITA value, BMI, and season at diagnosis (and therefore blood draw) 
were the only confounding factors in the association between 25(OH)D 
concentration at time of diagnosis and Breslow thickness (≥ 0.75 mm vs. < 0.75 
mm), an indicator of melanoma prognosis.  
I found that the risk of greater Breslow thickness decreased by 22% per 10 nmol/L 
increase in serum 25(OH)D concentration. While this was not statistically significant 
(P = 0.17), the results were suggestive of an adverse effect of lower 25(OH)D 
concentration, i.e. an association with higher Breslow thickness. As noted in the 
Methods, I had decided a priori to also investigate the effect of low vitamin D status 
and high vitamin D status. To explore any possible adverse effect of low vitamin D 
status, I examined both the lower quartile compared to all other quartiles, and 
vitamin D insufficiency (compared to vitamin D sufficiency), as defined by the 
IOM178. To explore a possible beneficial effect of higher vitamin D status, the 
highest quartile of 25(OH)D concentration was examined in comparison to all other 
quartiles. The crude and adjusted results for these analyses are presented in Table 5.7 
(n = 98).  
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After adjusting for age, sex, ITA value, BMI and season at diagnosis (the factors 
previously identified as confounders in the 25(OH)D concentration analysis), vitamin 
D insufficiency was significantly associated with a higher risk of having a Breslow 
thickness greater than 0.75 mm.  
Table 5.7 
Final models (crude and adjusted) of vitamin D status at three different thresholds for “sufficiency” 
and Breslow thickness (≥ 0.75 mm vs. < 0.75 mm) 
Vitamin D status Crude OR 95% CI P Adjusted ORa 
 
95% CI P 
≥ 45.25 nmol/L 
< 45.25 nmol/L 
Reference 
5.30 
 
1.72, 16.40 
 
0.01 
Reference 
5.03 
 
1.32, 19.09 
 
0.02 
 
≥ 50 nmol/L 
< 50 nmol/L 
Reference 
3.59 
 
1.18, 10.93 
 
0.03 
Reference 
3.82 
 
1.03, 14.14 
 
0.04 
 
≥ 69.8nmol/L 
< 69.8 nmol/L 
Reference 
0.97 
 
0.28, 3.34 
 
0.96 
Reference 
0.83 
 
0.19, 3.58 
 
0.80 
a adjusted for age, sex, ITA value, BMI, season at diagnosis 
The results show that at time of diagnosis with melanoma, low vitamin D status 
defined as either the lowest quartile, or vitamin D insufficiency as defined by the 
IOM, was associated with increased odds of having a higher Breslow thickness. 
Although the adjusted ORs were in a protective direction, i.e. less than 1.00, for 
higher vitamin D status, there was no evidence of a significant protective effect. 
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5.4 CLARK LEVEL MODEL 
5.4.1 Step 1: Bivariate association between Clark level and vitamin D 
Clark level was analysed as a dichotomous categorical variable of Level 1 and Levels 
2–5.  Clark Level 1 is the reference category in all analyses. Results, reported with 
beta coefficients, 95% confidence intervals and P-values, are based on a logit model 
and shown in Table 5.8. Higher 25(OH)D concentration was not associated with 
Clark level (beta = -.01, 95% CI = -.03, 0.01, P = 0.22). 
5.4.2 Step 2: Examination of each covariate in relation to the outcome, Clark 
level  
Table 5.8 shows the results of the bivariate logistic regression for Clark level and all 
covariates. Anatomic site, season at diagnosis, S-100β, ITA value, inner arm chroma, 
solar lentigo density at diagnosis, eye colour, hair colour as a teenager, secondary 
school sunburns, when the spot was noticed, histories of previous melanoma and 
other internal cancers, taking supplements and education level were all associated 
with Clark level at α < 0.2. 
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Table 5.8 
Bivariate logistic regression of Clark level (Levels 2–5 vs. Level 1) and all covariates  
Variable  Coefficient. 95% CI P 
Age  -.00 -.03,0.03 0.89 
Sex 
  Male 
  Female 
 
 
0.30 
 
referent 
-.50, 1.09 
 
 
0.47 
Melanoma type   0.01 
Anatomic site 
  Head & neck 
  Trunk 
  Upper extremities 
  Lower extremities 
 
 
0.02 
0.77 
0.77 
 
referent 
-.97, 1.01 
-.65, 2.19 
-.37, 1.90 
 
 
0.97 
0.29 
0.19 
Season of diagnosis 
  Winter 
  Spring 
  Summer 
  Autumn 
 
 
1.59 
-.20 
0.36 
 
referent 
0.37, 2.82 
-1.35, 1.08 
-.70, 1.42 
 
 
0.01 
0.74 
0.51 
S-100β 12.96 -.54, 26.49 0.06 
ITA value 0.05 0.01, 0.11 0.12 
Inner arm L* 0.05 -.11, 0.20 0.56 
Inner arm chroma -.17 -.34, 0.01 0.06 
BMI 0.01 -.81, 0.96 0.81 
Naevi burden at diagnosis  -.00 -.01, 0.01 0.95 
Freckle density at diagnosis 
  Low 
  Medium 
  High 
 
 
-.13 
0.65 
 
referent 
-1.12, 0.86 
-1.10, 1.23 
 
 
0.80 
0.91 
Solar lentigo density at diagnosis 
  Low 
  Medium 
  High 
 
 
-1.21 
-.86 
 
referent 
-2.67, 0.25 
-2.32, 0.11 
 
 
0.11 
0.24 
Eye colour 
  Brown 
  Green/hazel 
  Blue/grey 
 
 
0.73 
0.51 
 
referent 
-.15, 1.61 
-.74, 1.76 
 
 
0.10 
0.42 
Burning tendency 
  Rarely/never burns 
  Sometimes burns 
  Mostly/always burns 
 
 
0.02 
-.14 
 
referent 
-1.20, 1.24 
-1.26, 0.99 
 
 
0.98 
0.81 
Tanning tendency 
  Tans deeply/moderately 
  Tans slightly/does not tan 
 
 
0.61 
 
referent 
-.32, 1.54 
 
 
0.20 
Hair colour as teenager 
  Black/dark brown 
  Light brown 
  Blonde, red, auburn, s/b*, blonde 
 
 
0.97 
-.37 
 
referent 
-.03, 1.96 
-1.39, 0.65 
 
 
0.06 
0.48 
Naevus density as teenager 
  Nil 
  Few/some 
  Many 
 
 
-.04 
-.63 
 
referent 
-.94, 0.86 
-2.57, 1.31 
 
 
0.93 
0.53 
Freckle density as teenager 
  Nil 
  Few/some 
  Many 
 
 
-.38 
0.72 
 
referent 
-1.22, 0.45 
-.1.64, 3.07 
 
 
0.37 
0.55 
School-years sun exposure 
  Low 
  High 
 
 
0.20 
 
referent 
-.70, 1.11 
 
 
0.66 
Adult Reported Sun Exposure    
 Chapter 5: Results of Model Building 120 
Variable  Coefficient. 95% CI P 
(continuous) 8.41 -.80, 0.80 1.00 
Primary school sunburns 
  0–5 burns 
  6–20 burns 
  > 20 burns 
 
 
0.36 
-.50 
 
referent 
-.51, 1.23 
-1.71, 0.70 
 
 
0.41 
0.41 
Secondary school sunburns 
  0–5 burns 
  6–20 burns 
  > 20 burns 
 
 
0.92 
0.70 
 
referent 
0.04, 1.81 
-.61, 2.01 
 
 
0.04 
0.30 
Adult sunburns 
  0–5 burns 
  6–20 burns 
  > 20 burns 
 
 
0.23 
-.27 
 
referent 
-.64, 1.10 
-1.43, 0.90 
 
 
0.60 
0.65 
Solar elastosis 
  Absent 
  Present  
 
 
0.07 
 
referent 
-1.19, 1.33 
 
 
0.92 
Sunscreen use 10 years ago 
  Wore sunscreen most of time 
  Wore sunscreen sometimes 
  Rarely/never wore sunscreen 
 
 
0.69 
0.99 
 
referent 
-1.82, 3.21 
-1.46, 3.44 
 
 
0.59 
0.43 
Sunscreen use 5 years 
  Wore sunscreen most of time 
  Wore sunscreen sometimes 
  Rarely/never wore sunscreen 
 
 
0.35 
0.58 
 
referent 
-1.30, 2.00 
-.99, 2.17 
 
 
0.68 
0.47 
When was spot noticed? 
  Less than 3 months 
  3–12 months 
  > 12 months 
 
 
0.69 
-1.19 
 
referent 
-.29, 1.67 
-2.44, 0.07 
 
 
0.17 
0.06 
Family history of melanoma 
  No 
  Yes 
 
 
-.55 
 
referent 
-1.39, 0.29 
 
 
0.20 
History of previous melanoma 
  No 
  Yes 
 
 
-1.16 
 
referent 
-2.42, 0.09 
 
 
0.07 
History of other internal cancer 
  No 
  Yes 
 
 
1.22 
 
referent 
-.12, 2.57 
 
 
0.07 
Take supplements 
  No 
  Yes 
 
 
1.03 
 
referent 
0.01, 2.06 
 
 
0.05 
Ever smoked 
  No 
  Yes 
 
 
0.03 
 
referent 
-.76, 0.84 
 
 
0.94 
Education 
  Primary/Secondary school 
  Trade/ Technical certificate 
  Tertiary education  
 
 
0.54 
1.06 
 
referent 
-.48, 1.55 
0.11, 2.02 
 
 
0.30 
0.03 
*strawberry blond 
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5.4.3 Step 3: Selection of potential confounders 
Variables associated with both 25(OH)D concentration AND Clark level at P < 0.2 
in the bivariate analyses, were identified as potential confounders and are presented 
in Table 5.9. 
 
Table 5.9 
Age, sex and covariates flagged at α < 0.2 level in serum 25(OH)D concentration AND Clark level 
(Levels 2 –5 vs. Level 1) bivariate analyses 
 
Covariates 25(OH)D 
P 
Clark level 
P 
Age 0.28 0.89 
Sex 0.91 0.47 
Season at diagnosis 0.06 0.01 
ITA value 0.02 0.12 
Supplements  0.06 0.05 
 
 
5.4.4  Step 4: Examine effect of potential confounding variables on association 
between 25(OH)D concentration and Clark level 
Table 5.10 shows that the inclusion of either season at diagnosis, ITA value or 
supplements into the 25(OH)D concentration (exposure) and Clark level (outcome) 
model significantly changed the vitamin D coefficient at α ≥ 0.05. These covariates 
were therefore confirmed as confounders of the association between 25(OH)D and 
Clark level. Neither age nor sex changed the 25(OH)D coefficient of the basic model, 
but they were retained as noted previously. Thus the preliminary model for the 
outcome of Clark level, included 25(OH)D concentration, age, sex, season at 
diagnosis, ITA value and supplements. 
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Table 5.10  
Effect of potential confounders on the association between Clark level (Levels 2 –5 vs. Level 1) and 
25(OH)D concentration (per 10 nmol/L) 
Model (n=98) Coefficient 
25(OH)D 
% change in 25(OH)D 
coefficient 
 
Clark, 25(OH)D  -.123  
Clark, 25(OH)D, age  -.125 0.81 
Clark, 25(OH)D, sex -.122 0.81 
Clark, 25(OH)D, season at diagnosis -.150 21.95 
Clark, 25(OH)D, ITA value -.088 -28.46 
Clark, 25(OH)D, supplements -.088 -28.46 
 
 
5.4.5 Step 5: Reassessing variables initially excluded 
The confounding effect of other key factors previously associated with either vitamin 
D status or melanoma risk was then tested. The effect of adding each of these 
variables to the preliminary model is shown in Table 5.11.  
Table 5.11 
Examination of additional potential confounders on the association between Clark level (Levels 2 –5 
vs. Level 1) and 25(OH)D concentration (per 10 nmol/L) 
Model (n=98) Coefficient 
25(OH)D 
% change in 25(OH)D 
coefficient 
 
* Preliminary model  
 
-.038 
 
 
 
* Preliminary model, BMI 
 
-.042 
 
0.53 
 
* Preliminary model, naevi burden at diagnosis -.036 
 
-7.89 
 
* Preliminary model, primary school sunburns 
 
-.072 92.11 
* Preliminary model = Clark level, 25(OH)D, age, sex, season at diagnosis, ITA value, supplements 
 
 
5.4.6 Step 6: Final model for the association between 25(OH)D concentration 
and Clark level  
On the basis of these analyses, the final model contained age, sex, season at 
diagnosis, ITA value, supplements, naevi burden at diagnosis and primary school 
sunburns. The result of the final model for the association between 25(OH)D 
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concentration (per 10 nmol/L) and Clark level (Levels 2–5 vs. Level 1) is presented 
in Table 5.12. 
Table 5.12 
Relationship of 25(OH)D concentration (per 10 nmol/L) to Clark level (Levels 2 –5 vs. Level 1), with 
adjustment for confounding factors  
Model (n = 98) 
 
Crude 
OR  
95% CI P Adjusted 
ORa  
 
95% CI P 
25(OH)D 0.88 0.72, 1.09 0.26 0.93 0.71, 1.22 0.60 
a adjusted for age, sex, season at diagnosis, ITA value, supplements, BMI, naevi burden at diagnosis, 
primary school sunburns   
 
5.4.7 Effect modification 
The association between Clark level and vitamin D concentration was examined to 
identify if it differed according to age or sex. No significant interaction was noted 
(age: z = -.93, P = 0.35; sex: z = 1.16, P = 0.25). 
5.4.8 Final Clark level and serum 25(OH)D models 
At the conclusion of the modelling process, season at diagnosis, ITA value, 
supplements, BMI, naevi burden at diagnosis and number of sunburns during 
primary school were confounders in the association between 25(OH)D concentration 
at time of diagnosis and Clark level (Level 2–5 vs. Level 1). Although I found that 
the risk of deeper Clark levels decreased by 7% per 10 nmol/L increase in 25(OH)D 
concentration, the association was not significantly significant (P = 0.60). Based on 
these results it would appear that in this study there was no suggestion that deeper 
Clark levels were associated with lower serum 25(OH)D concentration at time of 
diagnosis. 
As described previously in the Breslow thickness model, I further investigated if 
there was any effect of low and high vitamin D status on Clark level, adjusting for 
the factors identified as confounders in the association between 25(OH)D 
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concentration and Clark level (season at diagnosis, ITA value, supplements, BMI, 
naevi burden at diagnosis, primary school sunburns), and age and sex. The results are 
presented in Table 5.13 (n = 98).  
Table 5.13 
Final models (crude and adjusted) of vitamin D status at three different thresholds for “sufficiency” 
at time of diagnosis and Clark level (Levels 2–5 vs. Level 1) 
Vitamin D status Crude OR 95% CI P Adjusted ORa 
 
95% CI P 
≥ 45.25 nmol/L 
< 45.25 nmol/L 
Reference 
1.64 
 
0.64, 4.18 
 
0.30 
Reference 
1.28 
 
0.38, 4.33 
 
0.69 
 
≥ 50 nmol/L 
< 50 nmol/L 
Reference 
1.77 
 
0.76, 4.11 
 
0.19 
Reference 
1.83 
 
0.62, 5.44 
 
0.27 
 
≥ 69.8nmol/L 
< 69.8 nmol/L 
Reference 
2.05 
 
0.81, 5.23 
 
0.13 
Reference 
1.56 
 
0.48, 5.12 
 
0.46 
a adjusted for age, sex, season at diagnosis, ITA value, supplements, BMI,  naevi burden at diagnosis, 
primary school sunburns 
 
The results show that there was no significant association between low, insufficient 
or higher vitamin D status, and Clark level in the QUT Melanoma Study. 
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5.5 MITOSIS MODEL 
5.5.1 Step 1: Bivariate association between presence of mitosis and vitamin D 
The presence of mitosis was reported in 23% of the melanomas. Mitosis was 
modelled as a binary variable with two categories: present or absent. Results (beta 
coefficients, 95% confidence intervals and P-values) for the bivariate analysis 
between mitosis and each covariate are reported in Table 5.14.  
Higher 25(OH)D concentration was not associated with presence of mitosis (beta = -
.01, 95% CI = -.03, 0.02, P = 0.46). 
5.5.2 Step 2: Examination of each covariate in relation to the outcome, presence 
of mitosis 
Results for this step are presented in Table 5.14. They show that anatomic site, 
season at diagnosis, S-100β, ITA value, BMI, naevi burden at diagnosis and burning 
tendency were associated with mitosis at α < 0.2. 
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Table 5.14 
Bivariate logistic regression for mitosis (absent vs. present) and all covariates  
Variable  Coefficient 95% CI P 
Age  0.01 -.03, 0.05 0.62 
Sex 
  Male 
  Female 
 
 
-.50 
 
referent 
-1.47, 0.47 
 
 
0.31 
Melanoma type   0.02 (Fisher’s) 
Anatomic site 
  Head & neck 
  Trunk 
  Upper extremities 
  Lower extremities 
 
 
-.99 
-.23 
-.02 
 
referent 
-2.24, 0.26 
-1.78, 1.31 
-1.23, 1.18 
 
 
0.12 
0.77 
0.97 
Season at diagnosis 
  Winter 
  Spring 
  Summer 
  Autumn 
 
 
0.94 
-.85 
-.09 
 
referent 
-.26, 2.14 
-2.57, 0.86 
-1.42, 1.23 
 
 
0.13 
0.33 
0.89 
S-100β 12.60 -.64, 25.83 0.06 
ITA value 0.12 0.03, 0.20 0.01 
Inner arm L* 0.11 -.08, 0.30 0.25 
Inner arm chroma -.34 -.57, -.12 < 0.001 
BMI 0.09 0.01, 0.20 0.07 
Weight 0.03 -.00, 0.06 0.09 
Height 0.02 -.04, -.07 0.54 
Naevi burden at diagnosis  -.01 -.03, 0.01 0.19 
Freckle density at diagnosis 
  Low 
  Medium 
  High 
 
 
0.18 
0.43 
 
referent 
-.99, 1.36 
-.88, 1.74 
 
 
0.76 
0.52 
Solar lentigo density at diagnosis 
  Low 
  Medium 
  High 
 
 
 
-.51 
0.05 
 
 
referent 
-2.08, 1.06 
-1.40, 1.50 
 
 
 
0.53 
0.94 
Eye colour 
  Brown 
  Green/hazel 
  Blue/grey 
 
 
0.15 
-.54 
 
referent 
-.87, 1.18 
-2.23, 1.15 
 
 
0.77 
0.53 
Burning tendency 
  Rarely/never burns 
  Sometimes burns 
  Mostly/always burns 
 
 
1.70 
1.58 
 
referent 
-.48, 3.88 
-.53, 3.70 
 
 
0.13 
0.14 
Tanning tendency   0.00 
Hair colour as teenager 
  Black/dark brown 
  Light brown 
  Blonde, red, auburn, s/b*, blonde 
 
 
-.26 
-.34 
 
referent 
-1.31, 0.78 
-2.69, 2.02 
 
 
0.62 
0.78 
Naevus density as teenager 
  Nil 
  Few/some 
  Many 
 
 
-.26 
-.34 
 
referent 
-1.31, 0.78 
-2.69, 2.02 
 
 
0.62 
0.78 
Freckle density as teenager 
  Nil 
  Few/some 
  Many 
 
 
-.57 
0.99 
 
referent 
-1.57, 0.42 
-1.10, 3.08 
 
 
0.26 
0.35 
School years sun exposure  
  Low 
  High 
 
 
0.15 
 
referent 
-.98, 1.28 
 
 
0.79 
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Variable  Coefficient 95% CI P 
Reported Adult Sun Exposure 
(continuous) 
 
0.00 
 
-.00, 0.00 
 
0.12 
Primary school sunburns 
  0–5 burns 
  6–20 burns 
  > 20 burns 
 
 
0.57 
0.16 
 
referent 
-.48, 1.62 
-1.34, 1.67 
 
 
0.29 
0.83 
Secondary school sunburns 
  0–5 burns 
  6–20 burns 
  > 20 burns 
 
 
-.44 
-.54 
 
referent 
-1.49, 0.61 
-2.22, 1.14 
 
 
0.41 
0.53 
Adult sunburns  
   0–5 burns 
   6–20 burns 
  > 20 burns 
 
 
-.80 
-.49 
 
referent 
-1.89, 0.28 
-1.91, 0.93 
 
 
0.15 
0.50 
Solar elastosis 
  Absent 
  Present  
 
 
0.42 
 
referent 
-1.05, 1.90 
 
 
0.57 
Sunscreen use 10 years ago   0.50 
Sunscreen use 5 years 
  Wore sunscreen most of time 
  Wore sunscreen sometimes 
  Rarely/never wore sunscreen 
 
 
0.74 
0.49 
 
referent 
-1.53, 3.00 
-1.72, 2.69 
 
 
0.52 
0.67 
When was spot noticed 
  Less than 3 months 
  3–12 months 
  > 12months 
 
 
0.07 
-1.52 
 
referent 
-.98, 1.12 
-3.63, 0.60 
0.33(Fisher’s) 
 
0.89 
0.16 
Family history of melanoma 
  No 
  Yes 
 
 
-.09 
 
referent 
-1.10, 0.93 
 
 
0.86 
History of previous melanoma    
History of other internal cancer 
  No 
  Yes 
 
 
 
1.14 
 
 
referent 
-.05, 2.33 
 
 
 
0.06 
Take supplements 
  No 
  Yes 
 
 
-.18 
 
referent 
-1.33, 0.97 
 
 
0.76 
Ever smoked 
  No 
  Yes 
 
 
0.03 
 
referent 
-.94, 0.99 
 
 
0.96 
Education 
  Primary/Secondary school 
  Trade/ Technical certificate 
  Tertiary education  
 
 
0.84 
0.57 
 
referent 
-.36, 2.04 
-.57, 1.70 
 
 
0.17 
0.33 
*strawberry blonde 
 
 
 
5.5.3 Step 3: Selection of potential confounders 
Potential confounders that were associated with both 25(OH)D concentration AND 
mitosis at P < 0.2 in the bivariate analyses, are presented in Table 5.15. 
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Table 5.15 
Age, sex and covariates flagged at α < 0.2 level in serum 25(OH)D concentration AND mitosis 
bivariate analyses 
Covariates 25(OH)D 
P 
Mitosis 
P 
Age 0.28 0.62 
Sex 0.91 0.31 
Season at diagnosis 0.06 0.13 
ITA value 0.02 0.01 
BMI 0.09 0.07 
Reported adult sun exposure 0.19 0.12 
Adult sunburns 0.15 0.15 
 
 
 
5.5.4  Step 4: Examine effect of potential confounders on association between 
25(OH)D concentration and mitosis  
Table 5.16 shows the effect on the 25(OH)D coefficient when each covariate 
identified in Table 5.15 is introduced into the model of the outcome, mitosis (present 
vs. absent) and 25(OH)D concentration (exposure). All covariates (with the 
exception of age and sex) caused the 25(OH)D coefficient to change significantly, 
confirming that they were confounders of the association between 25(OH)D 
concentration and mitosis. Therefore, the preliminary model included 25(OH)D, age, 
sex, season at diagnosis, ITA value, BMI, reported adult sun exposure and adult 
sunburns. 
Table 5.16  
Effect of potential confounders on the association between mitosis (present vs. absent) and 25(OH)D 
concentration (per 10 nmol/L) 
Model (n=95) Coefficient 25(OH)D % change in 25(OH)D 
coefficient 
 
Mitosis, 25(OH)D  -.094  
Mitosis, 25(OH)D, age  -.097 3.19 
Mitosis, 25(OH)D, sex -.098 4.26 
Mitosis, 25(OH)D, season at diagnosis -.080 -14.89 
Mitosis, 25(OH)D, ITA value -.023 -75.53 
Mitosis, 25(OH)D, BMI -.052 -44.68 
Mitosis, 25(OH)D, reported adult sun 
exposure 
 
-.128 
 
36.17 
Mitosis, 25(OH)D, adult sunburns -.120 27.66 
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5.5.5 Step 5: Reassessing variables initially excluded 
The confounding effect of other key factors previously associated with either vitamin 
D status or melanoma risk, was then tested by adding each of these variables to the 
preliminary model (shown in Table 5.17).  
Table 5.17 
Examination of additional potential confounders on the association between mitosis (present vs. 
absent) and 25(OH)D concentration (per 10 nmol/L) 
Model (n=95) Coefficient 
25(OH)D 
% change in 25(OH)D 
coefficient 
 
* Preliminary model -.030  
* Preliminary model, naevi burden at diagnosis -.041 36.67 
* Preliminary model, primary school sunburns -.033 10.00 
* Preliminary model = mitosis (present vs. absent), 25(OH)D, age, sex, season at diagnosis, ITA 
value, BMI, reported adult sun exposure, adult sunburns 
 
 
5.5.6 Step 6: Final model for the association between 25(OH)D concentration 
and mitosis  
On the basis of these analyses, the final model contained age, sex, season at 
diagnosis, ITA value, BMI, reported adult sun exposure, adult sunburns, naevi 
burden at diagnosis, and primary school sunburns. The results of the final model, for 
the association between 25(OH)D concentration (per 10 nmol/L) and mitosis (present 
vs. absent) are shown in Table 5.18. 
Table 5.18 
Relationship of 25(OH)D concentration (per 10 nmol/L) to Mitosis (present vs. absent), with 
adjustment for confounding factors  
Model (n = 95) 
 
Crude 
OR  
95% CI P Adjusted 
ORa  
 
95% CI P 
25(OH)D 0.91 0.71, 1.17 0.47 0.96 0.70, 1.33 0.82 
a adjusted for age, sex, season at diagnosis, ITA value, BMI, reported adult sun exposure, adult 
sunburns, naevi burden at diagnosis, primary school sunburns 
 
Possible effect modification due to age or sex was examined, but no significant 
interaction was noted (age: z = -1.72, P = 0.09; sex: z = 0.44, P = 0.66). 
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5.5.7 Final mitosis and serum 25(OH)D models 
After examining and accounting for potential confounding factors (including age and 
sex), season at diagnosis, ITA value, BMI, reported adult sun exposure, adult 
sunburns, naevi burden at diagnosis, and primary school sunburns were found to be 
the only confounding factors in the association between 25(OH)D concentration at 
time of diagnosis with melanoma and mitosis (present vs. absent). 
The results show that there was a 4% reduction in risk for the presence of mitosis per 
10 nmol/L increase in serum 25(OH)D concentration, but this was not statistically 
significant (P = 0.82). I therefore concluded that in the QUT Melanoma Study there 
was no association between 25(OH)D concentration at time of diagnosis and mitosis. 
The effect of low vitamin D status and high vitamin D status (using the lower 
quartile, IOM “insufficiency” and the higher quartile) was then examined as 
described in section 5.3.8. The crude and adjusted results for these analyses are 
presented in Table 5.19 (n = 95). The adjusted model included any factors previously 
identified as confounders (in the mitosis and 25(OH)D concentration analysis). 
After adjusting for age, sex, season at diagnosis, ITA value, BMI, reported adult sun 
exposure, adult sunburns, naevi burden at diagnosis, and primary school sunburns, 
vitamin D insufficiency was not associated with a higher risk of having presence of 
mitosis and there was no evidence of a significant protective effect of higher vitamin 
D status. 
 
 
 
 Chapter 5: Results of Model Building 131 
Table 5.19 
Final models (crude and adjusted) of vitamin D status at three different thresholds for “sufficiency” 
at time of diagnosis and mitosis (present vs. absent) 
Vitamin D status Crude OR 95% CI P Adjusted ORa 
 
95% CI P 
≥ 45.25 nmol/L 
< 45.25 nmol/L 
Reference 
2.47 
 
0.89, 6.80 
 
0.08 
Reference 
2.21 
 
0.56, 8.68 
 
0.26 
 
≥ 50 nmol/L 
< 50 nmol/L 
Reference 
1.60 
 
0.61, 4.21 
 
0.34 
Reference 
2.12 
 
0.72, 6.19 
 
0.17 
 
≥ 69.8nmol/L 
< 69.8 nmol/L 
Reference 
0.40 
 
0.27, 2.39 
 
0.70 
Reference 
0.40 
 
0.10, 1.69 
 
0.21 
a adjusted for age, sex, season at diagnosis, ITA value, BMI, reported adult sun exposure, adult 
sunburns, naevi burden at diagnosis, primary school sunburns 
 
 
5.6 PREDICTIVE MODELLING 
At the conclusion of the risk factor modelling, Breslow thickness (≥ 0.75 mm vs. < 
0.75 mm) was the only histological outcome variable for melanoma prognosis 
significantly associated with vitamin D insufficiency. I now provide an analysis of 
the key predictors of Breslow thickness in this dataset, using the PSC approach 
outlined in the Methods. 
Step 1: Bivariate analysis 
A bivariate analysis of the association between Breslow thickness (≥ 0.75 mm vs. < 
0.75 mm) and each covariate under consideration was undertaken using binary 
logistic regression and is provided previously in Section 5.3 (pages 112–113). 
Step 2: Identification of covariates for preliminary multivariable model 
Covariates significant at P < 0.2 in the bivariate analysis and other covariates 
considered likely to be “important” were identified (see Table 5.20). 
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Table 5.20 
Covariates identified for inclusion in preliminary multivariable models 
Covariates 
 
Breslow 
P 
Significant at P < 0.2  
    25(OH)D concentration 0.08 
    S-100β 0.17 
    ITA value 0.02 
    BMI 0.05 
    Solar lentigo density at diagnosis 0.13 
    Hair colour as teenager 0.10 
Considered important  
    Age  0.62 
    Sex 0.41 
    Naevi burden at diagnosis 0.72 
 
Step 3: Fit preliminary multivariable model 
All covariates identified in Table 5.20 as significant at P < 0.2 were then fitted into 
the preliminary multivariable model for Breslow thickness. Table 5.21 shows the P-
value of the covariates in that model. 
Table 5.21 
Effect of covariates in the multivariable model  
Model (n=98) P-value 
of covariate 
P-value 
of model 
 
  0.03 
25(OH)D  0.32  
S-100β 0.11  
ITA value 0.10  
BMI 0.34  
Solar lentigo density at diagnosis 0.75  
Hair colour as teenager 0.38  
 
As described in the Methods, a P value greater than 0.2 was used as the criteria for 
removing covariates from the model. Based on this criterion, S-100β and ITA value 
were the only covariates retained in the model. 
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Step 4: Selection of variables for best fitting preliminary model 
Individual covariates excluded in the previous step were then reinserted (one 
covariate at a time) into the preliminary multivariable model of S-100β and ITA 
value, and likelihood ratio tests performed to examine if their inclusion improved the 
model fit (see Table 5.22). Covariates were considered to improve the model fit if the 
P-value for the likelihood ratio test was < 0.05. 
Table 5.22 
Effect of covariates on the preliminary multivariable model of S-100β and ITA value 
Model (n=98) P-value of likelihood ratio test 
 
25 (OH)D  0.09 
BMI 0.11 
Solar lentigo density at diagnosis 0.40 
Hair colour as teenager 0.07 
Age 0.85 
Sex 0.25 
Naevi burden at diagnosis 0.81 
 
The results presented in Table 5.22 show that none of the covariates improved the 
model fit, and the preliminary multivariable model was therefore S-100β and ITA 
value. 
Step 5: Reintroduce covariates previously excluded 
Age, sex and naevi burden at diagnosis, although excluded after the bivariate 
analysis, were identified as being “important”, and were then added back, one at a 
time, into the preliminary multivariable model. Improvement of the model was again 
tested using likelihood ratio test (see Table 5.23). 
Table 5.23  
Effect of excluded covariates on the preliminary multivariable model of S-100β and ITA value 
Model (n=98) P-value of likelihood ratio test 
 
Age 0.60 
Sex 0.32 
Naevi burden at diagnosis 0.95 
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Examination of Table 5.23 shows that none of the covariates significantly improved 
the model (at P < 0.05).   
Step 6: Examine linearity of continuous covariates included in the 
preliminary model 
To ascertain whether S-100β and ITA were linear in the logit, the fracpoly, compare 
command in Stata was used. Fractional polynomial modelling confirmed that there 
was no evidence of significant deviation from a linear fit. 
Step 7: Effect modification 
Using a multiplicative term in the model, the preliminary effects model of S-100β 
and ITA value was then examined to identify if the magnitude of the effect was 
different for males and females. The P-value for the interaction term was 0.13, 
indicating that there was no effect modification due to sex. 
Step 8: Main effects model 
To determine the best fit for the main effects model, the likelihood ratio test was 
used to examine whether the inclusion of identified covariates improved the model. 
At the conclusion of the predictive modelling process, the best predictors for Breslow 
thickness in this study (P-value for model = 0.01) were ITA value (P= 0.01) and low 
vitamin D status (P = 0.01). 
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Chapter 6: Discussion 
6.1 INTRODUCTION 
The aim of this research project was to identify and explore the nature of any 
relationship between the serum 25(OH)D level at diagnosis of patients at the time of 
diagnosis with melanoma, and the outcome for those patients as predicted by the 
histopathological indicators of melanoma prognosis. To my knowledge this is the 
first Australian study to do so. In this chapter the study findings will be discussed in 
the context of current theory, current practice and the conduct of the QUT Melanoma 
study. Strengths and limitations will be acknowledged and any potential biases 
identified. Formal conclusions will not be drawn to this chapter, as these will be 
reserved for the final chapter. 
 
6.2 OVERALL STUDY FINDINGS 
The QUT Melanoma study found that although there was no significant association 
between 25(OH)D concentration at time of diagnosis and any of the prognostic 
indicators for melanoma, the risk of greater (≥ 0.75 mm) Breslow thickness was 
observed to decrease by 22% per 10 nmol/L increase in serum 25(OH)D 
concentration (P = 0.17). Further investigations found that lower vitamin D status, 
either in absolute terms or relative to others in the study cohort, was adversely 
associated with Breslow thickness. After adjustment for age, sex, ITA value, BMI 
and season at diagnosis, vitamin D insufficiency, whether this was as less than an 
absolute cut-off of 50 nmol/L (OR = 3.82, 95% CI: 1.03, 14.14, P =0.04) or the 
lowest quartile of 45.25 nmol/L (OR = 5.03, 95% CI: 1.32, 19.09, P = 0.02), was 
significantly associated with an increased odds of having a Breslow thickness of 0.75 
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mm or greater. The importance of low vitamin D status to Breslow thickness was 
confirmed in a predictive model. 
I had anticipated that the results for vitamin D status and Clark level (Levels 2–5 vs. 
Level 1) might be quite similar to that seen for Breslow thickness, simply due to the 
fact that the basement membrane was breached in both comparative groups i.e. those 
with Breslow thickness of greater than 0.75 mm and those with Clark levels of 2–5. 
The lack of association between vitamin D insufficiency and higher Clark level, but 
positive association between vitamin D insufficiency and greater Breslow thickness 
may reflect the assignment to different categories of a number of Clark level 2 
tumours that were less than 0.75 mm in depth - the inclusion of these is the only 
difference between the Clark model and the Breslow thickness model. This 
suggestion is supported by results from additional analysis of Clark Level as an 
ordinal categorical variable with three categories of Level 1, Level 2 and Levels 3–5 
(see Appendix K). Here there was an adverse association with vitamin D 
insufficiency that approached statistical significance: OR = 2.17, 95% CI: 0.96, 4.94, 
P = 0.06. Further larger studies would be needed to explore these associations with 
adequate statistical power. 
Higher levels of serum 25(OH)D were also examined for association with melanoma 
prognosis, using the highest quartile of 69.8 nmol/L as the threshold for “higher 
levels”. Modelling with Breslow thickness, Clark level and mitosis suggested that 
there was no effect on prognosis of higher levels of serum 25(OH)D. These results 
are consistent with an hypotheses that it is insufficient vitamin D status at time of 
diagnosis with melanoma that is associated with a poorer prognosis, rather than high 
vitamin D status being associated with better prognosis. 
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Interpretation of overall study findings 
The results from the QUT Melanoma study add to the mounting body of evidence 
that supports sufficient vitamin D status as beneficial for good health, wellbeing, 
cancer incidence and prognosis. The overall findings are in agreement with those of 
three previously identified Northern Hemisphere studies that have investigated the 
association between serum 25(OH)D levels and melanoma prognosis. The 
prospective cohort study by Newton-Bishop et al,24 reported that higher Breslow 
thickness was associated with lower serum 25(OH)D levels in patients with invasive 
melanoma, while a more recent study by Gambichler et al23 found that decreased 
serum 25(OH)D levels were associated with increased tumour thickness and stage. 
Similarly, in their 2009 case-control study, Nurnberg et al25 identified that patients 
with advanced melanoma were at a higher risk of having serum 25(OH)D levels 
lower than 50 nmol/L. 
When comparing my results to these studies, the three key differences in study 
design should be revisited. First, in this cross-sectional study, melanoma stage (see 
Chapter 2, page 30) was not identified as a determinant of prognosis; instead the 
known histological prognostic features of melanoma - Breslow thickness, Clark level 
and mitosis - were used as proxies for prognosis. Secondly, in contrast to other 
studies, The QUT Melanoma study included melanoma in situ as well as invasive 
melanomas, and thirdly, serum samples for 25(OH)D were obtained at diagnosis; i.e. 
within approximately four days of the provisional diagnosis of melanoma by 
histopathological report and prior to wider-excision surgery, rather than at various 
times after diagnosis. The last point is considered to be the most notable difference, 
as patients diagnosed with melanoma have been shown to have both increased sun 
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awareness and sun protection behaviour205,206 and any ascertainment of vitamin D 
status after diagnosis may reflect this behaviour change. 
While studies investigating associations between vitamin D and melanoma prognosis 
are limited, the QUT Melanoma Study findings also agree with recent 
epidemiological studies of associations between serum 25(OH)D levels and 
prognosis for other cancers.226-229 In a retrospective study of 197 patients diagnosed 
with gastric cancer, Ren et al228 found that post-diagnosis vitamin D insufficiency (< 
50 nmol/L) was associated with poorer prognosis for gastric cancer (P = 0.02), while 
Peppone et al229 examined blood taken from 194 women 30.1 days (mean) prior to 
breast cancer surgery and reported that patients with worse prognostic indicators (OR 
= 3.15, 95% CI = 1.05, 9.49) and more aggressive cancers (P = 0.04) had lower mean 
serum 25(OH)D levels compared to women with less aggressive disease. Similar 
findings have been reported in prostate cancer.  
Gilbert et al226 investigated the association between 25(OH)D concentration and 
advanced versus localised prostate cancer (n = 1,447) and found that higher levels of 
serum 25(OH)D were protective for advanced prostate cancer (OR = 2.33, 95% CI = 
1.26, 4.28), while in 2011, Fang et al227 had provided evidence that higher pre-
diagnostic 25(OH)D levels may be associated with localised prostate cancer stage. 
Although the results of this cross-sectional study are suggestive of insufficient 
vitamin D status as a risk factor for thicker melanomas, causality cannot be inferred. 
I considered if the association could be due to reverse causality, with deeper tumours 
causing low vitamin D status (as an indicator of the health status of the individual). 
In the design of the QUT Melanoma Study, I aimed to minimize the risk of reverse 
causality by taking serum for 25(OH)D measurement at the time of diagnosis, before 
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disease-related changes in sun exposure behaviour – and therefore 25(OH)D 
concentration – had occurred. 
The strongest association between vitamin D status and melanoma prognosis in this 
study, was in relation to Breslow thickness. There are a number of possible pathways 
through which vitamin D could affect melanoma thickness. For example, cell biology 
research has shown that vitamin D (1,25(OH)2D) can inhibit tumour invasiveness in 
melanoma cell lines in vitro191 and suppress melanoma growth in rodents.191,193  
Thus, having sufficient serum 25(OH)D levels could inhibit the vertical progression 
of the melanoma by adjusting the 1,25(OH)D concentration in the surrounding 
microenvironment. Notably however, in this study, high vitamin D status was not 
associated with thinner tumours.  
Here I measured serum 25(OH)D as a marker of vitamin D status. Yet there is 
considerable evidence that local production of the active hormone occurs and may be 
of primary importance to suppression (or not) or tumour growth.230 As such, serum 
25(OH)D is only a crude proxy for levels of the active hormone both systemically 
and locally, and as a marker for activity of the vitamin D pathway.  
The vitamin D receptor (VDR) is a vital link in that pathway,165,231 as the mediator 
for the action of 1,25(OH)D. As mentioned in Chapter 2, others197 have shown that 
vitamin D receptor (VDR) expression is significantly decreased in melanoma 
metastases and melanoma when compared to normal skin, and that normal skin 
surrounding melanomas has also been observed to have significantly decreased VDR 
expression. This may signify that the reduction or absence of VDRs is implicated in 
the progression of melanoma, and it would be therefore intriguing to identify any 
relationships between VDR expression patterns of both melanoma tissue and 
surrounding healthy skin (from the wider-excision) from the QUT Melanoma Study 
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samples, and the corresponding serum 25(OH)D concentrations obtained at time of 
diagnosis, in relation to markers of melanoma prognosis. 
Future implications of main finding  
A case-control study recruiting melanoma patients as both the cases (Breslow 
thickness greater than 0.75 mm) and controls (melanoma in situ or melanomas with 
Breslow thickness less than 0.75 mm) from the approximately 1500 melanoma 
patients presenting to all plastic surgeons in Brisbane over a 12 month period, would 
have the potential to provide more definitive evidence to either support or refute the 
findings generated by this study. Yet the larger sample size, while providing more 
statistical power, would still not confirm if insufficient vitamin D status is actually a 
risk factor for, or a potential outcome of poor melanoma prognosis. The exact 
processes responsible will only be elucidated once the biological interactions 
between vitamin D, melanoma and other factors are further understood. 
Based on the single serum sample obtained at diagnosis I cannot extrapolate from my 
study data that vitamin D supplementation after diagnosis would be beneficial for 
melanoma patients in terms of disease progression. Indeed, there is no evidence in 
this study that high 25(OH)D levels were associated with benefit, although shifting 
those with vitamin D insufficiency to a sufficient status may be worthwhile. That 
would require a randomized trial of vitamin D supplementation in patients with 
melanoma. While this would not address the question of why low levels of serum 
25(OH)D prior to, or at diagnosis with melanoma might be related to melanoma 
prognosis, it would, if successful prove to be invaluable as a treatment for all patients 
diagnosed with melanoma. In the meantime, if we were to assume that the odds ratio 
reported in the QUT Melanoma Study approximates the relative risk (melanoma is a 
rare disease) and that the prevalence of the risk exposure in the population (low 
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vitamin D status) is 30%, approximately 18% of the incidence of thick melanomas in 
people with melanoma can be attributable to insufficient vitamin D status (less than 
50 nmol/L). This suggests that rather than wait for further studies to be undertaken, it 
may be prudent to simply encourage the population to maintain an adequate vitamin 
D status while practicing sensible sun safety. This would be particularly applicable to 
those at a higher risk of developing melanoma. 
   
6.3 SERUM 25(OH)D CONCENTRATION IN CONTEXT WITH OTHER 
STUDIES 
Approximately one-third (36%), of the QUT Melanoma study population was 
observed to be vitamin D deficient (25(OH)D concentration less than 50 nmol/L).  
Nurnberg et al25 found 78.1% of patients had a serum 25(OH)D concentration less 
than 50 nmol/L and Gambichler et al23 reported 73.8%.  Newton-Bishop et al24 found 
that 64% of their study participants had levels less than 60 nmol/L. The three studies 
all obtained serum for 25(OH)D at various times after diagnosis.23-25 The timing of 
blood sampling; i.e. at diagnosis, to ensure that sun exposure patterns did not change 
in response to the diagnosis of melanoma, may partly explain the difference between 
the reported percentage of patients with less than optimal (50 nmol/L) serum 
25(OH)D levels in the QUT Melanoma study, compared to other studies.23-25 
The sub-tropical study setting (27° South) of the QUT Melanoma study is a further 
possible explanation for the lower prevalence of vitamin D deficiency, as the other 
studies had been conducted at latitudes higher than 49° North. According to data 
from the United States and Canada,232 cutaneous production of vitamin D is minimal 
at and above latitude 42° North from November to February, or from mid-October 
until mid-April from latitude 52° North and higher. One of the studies that examined 
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serum 25(OH)D status in relation to melanoma prognosis25 collected serum samples 
during this time frame, so that the high levels of vitamin D insufficiency reported are 
perhaps unsurprising. Median 25(OH)D levels were reported by Nurnberg et al25 and 
Gambichler et al23 of 35.75 nmol/L and 30.75 nmol/L, respectively, while a study of 
older Finnish men also obtained blood samples from previously diagnosed melanoma 
patients at a similar time of the year, and reported median serum 25(OH)D levels of 
33.1 nmol/L.204  In comparison, the median level serum 25(OH)D concentration in 
the QUT Melanoma Study was 58.6 nmol/L.  
Seasonal variation 
Another possible explanation for the difference between vitamin D status and median 
25(OH)D levels reported in the QUT Melanoma study compared to other studies, is 
that serum was obtained over a 12 month period. This enabled the study’s third 
objective of describing seasonal variation in vitamin D status in the sample to be 
investigated. Modest seasonal variation was seen in serum 25(OH)D levels; mean 
serum 25(OH)D levels were, as to be expected, highest in summer (62.3 nmol/L) and 
lowest in Winter (52 nmol/L), although this difference was not statistically 
significant (P = 0.09). The lack of significance may be a reflection of the sample 
size, as vitamin D status (≥ 50 nmol/L vs. < 50 nmol/L) was significantly associated 
(χ2 = 8.56, df = 3, P = 0.04) with season.  
In situ melanomas 
The difference in the proportion of the sample with vitamin D insufficiency in the 
QUT Melanoma Study compared to other studies was not due to the inclusion in the 
former of in situ melanomas, as there was no statistically significant difference in 
vitamin D status according to whether the melanoma had breached the basement 
membrane or not (χ2 = 1.81, df = 1, P = 0.18). 
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Vitamin D assays 
It should not be overlooked, and is important to note, that the differences in serum 
25(OH)D levels between the studies may also be due at least in part, to poor 
agreement between the various assays used for vitamin D analysis. This has been 
widely reported182,233 and until standardised measures are agreed, inter-assay 
variability will remain an issue when comparing studies. 
 
6.4 SERUM 25(OH)D LEVELS IN COMPARISON TO AUSTRALIAN 
DATA 
The distribution of vitamin D status in the QUT Melanoma Study was comparable to 
that reported in a large Australian study (Australian Diabetes, Obesity and Lifestyle 
study (AusDiab)) of 11,247 adults.26  In that Australia-wide study, vitamin D 
deficiency (< 50 nmol/L) was observed in 31% of participants compared to 36% of 
the QUT Melanoma Study participants.26 Mean (63 nmol/L) and median (60 nmol/L) 
serum 25(OH)D concentrations were higher in the AusDiab study26 as compared to 
the QUT Melanoma study (58.2 nmol/L and 58.6 nmol/L respectively). Serum 
25(OH)D levels are reported to decrease with increasing age, so at least part of the 
difference in 25(OH)D levels between the two studies may be explained by the 
difference in age distribution of participants in the two studies, as participants in the 
QUT Melanoma Study (mean age = 61.4 years) were, on average, 13 years older than 
those in the AusDiab study (mean = 47.6 years in males, 48.9 years in females).26 In 
addition, participants in the QUT Melanoma Study were recruited from the Brisbane 
area, unlike the AusDiab participants who were recruited Australia-wide. Variation 
in 25(OH)D assays across Australia is widely reported234,235 and may also have 
accounted for some of the differences seen between the studies. 
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6.5 SERUM 25(OH)D LEVELS AND COVARIATES 
In bivariate analyses, the only covariates significantly associated (P = 0.05) with 
serum 25(OH)D concentration were seven of the “skin type” variables generated 
from the spectrophotometric output (see Table 5.1, page 109). While these crude data 
must be interpreted with caution, some variables negatively associated with serum 
25(OH)D concentration are suggestive of increased serum 25(OH)D levels in 
participants with greater sun exposure to an exposed body site and also in those 
participants with an intermediate skin type. While an intermediate skin type is still in 
the “light” skin range, this result probably reflects that these skin types may spend 
more time outdoors due to their better sun tolerance. 
Others have looked at the association between 25(OH)D levels and ITA value in 
multiethnic samples of New Zealanders, with contrasting results. Nessvi et al236 
reported an increase of 2–3 nmol/L per 10% increase in ITA value (this association 
almost disappeared after adjusting for ethnicity), while Rockell et al237 found a 5% 
decrease in 25(OH)D for every 10° increase in ITA value. Yet to the best of my 
knowledge there has not been any prior research conducted to identify associations 
between the specific spectrophotometric skin pigmentation characteristics (L*, a*, 
b*, chroma and hue) and serum 25(OH)D levels. While not an original objective of 
the QUT Melanoma study, these data provide some hereto unknown insight (albeit at 
the crude level) into the relationship between skin phototype and vitamin D status, 
but more research needs to be undertaken before any association is clearly 
understood.  Interestingly, none of the self-report measures of skin phenotype were 
associated with serum 25(OH)D concentration, even at the α < 0.2 level.   
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6.6 SKIN TYPE CHARACTERISTICS  
6.6.1 Spectrophotometry and melanoma prognosis: bivariate associations 
One particularly interesting outcome of the QUT Melanoma Study was the apparent 
association between two of the prognostic indicators and various measures of skin 
phototype. Detailed analysis of skin type in relation to melanoma prognosis is 
outside the scope of this current thesis, so the bivariate associations that I consider 
here require confirmation in more detailed analyses. Significant positive bivariate 
associations were observed with respect to the ITA value (skin colour value) of the 
unexposed upper arm and both Breslow thickness (OR = 1.12, P = 0.02) and mitosis 
(OR = 1.12, P = 0.01), suggesting that as ITA values increased (and the skin became 
lighter) prognosis was poorer. While it is not possible to comment on the relationship 
between the ITA groups and either Breslow thickness, or mitotic activity due to 
empty cells, no participant with an intermediate skin type presented with a melanoma 
with either a Breslow thickness equal to or greater than 0.75 mm, or with mitotic 
activity present.  
Although there is an abundance of studies reporting fair skin type as a risk factor for 
melanoma, the observations seen in this study, albeit in a modest sample size, do 
suggest a possible trend to a protective effect of a darker skin type for melanoma 
prognosis and may warrant further investigation in a larger sample, or a more 
detailed analysis in this sample to adjust for confounding. In the predictive modelling 
undertaken in this study, the importance of ITA value to Breslow thickness was 
confirmed. 
While ITA value was chosen as the representative variable of objective skin type, 
other variables derived from the spectrophotometer readings were associated, at the 
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bivariate level, with melanoma prognosis. Chroma (the saturation or intensity of 
colour) of the inner arm was negatively associated with Breslow thickness (beta = -
0.35, 95% CI: -0.60, -0.10, P < 0.001) and mitosis (beta = -0.34, 95% CI:  -0.57, -
0.12, P < 0.001). These results indicate that the odds of a poorer prognosis increased 
as the skin colour intensity decreased, or became fairer.  Others84 have found that 
chroma of an unexposed site is associated with increased risk for melanoma at a 
bivariate level, and I suggest that, based on results from the QUT Melanoma study, 
chroma could also be a risk factor for prognosis and does warrant further 
investigation in larger studies or further analysis in this study. 
In other studies, L* (lightness coefficient of the skin) has been validated as being 
highly associated with the melanin content of the skin.238 While it was not possible to 
determine the melanin content of the skin in the QUT Melanoma study, L* at the 
inner arm was not associated at the bivariate level with any of the outcome measures 
of prognosis: Breslow thickness, Clark level or mitosis. This may be explained in 
part by the fairly homogenous study sample in terms of depth of skin colour, as all 
study participants met the criteria for “low pigmentation” (L* > 60).  
6.6.2 Self-report measures of skin phenotype and melanoma prognosis 
Certain skin phenotype characteristics are considered to be risk factors for melanoma 
incidence and also for cutaneous production of serum 25(OH)D, yet only one self-
report measure of skin phenotype (“hair colour as a teenager” in the Clark level 
model) was significantly associated (beta = 0.88, P = 0.05) with an outcome measure 
of melanoma prognosis. In retrospect, rather than examine the relationship between 
individual self-report measures of skin phenotype in relation to melanoma prognosis, 
there may have been more benefit in amalgamating the self-report measures and 
allocating each participant to one of the Fitzpatrick skin types, as the sample size 
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may not have been sufficiently large to support analyses of the individual 
characteristics.  
6.6.3 Spectrophotometry versus self-report 
Bivariate relationships between ITA skin types and self-report measures of skin 
phenotype were examined (see Table 4.7, page 92) to identify if there was agreement 
between the two measures. The self-report measures of propensity to burn (P = 0.03) 
and propensity to tan (P = 0.04) were the only reported phenotypic characteristics 
significantly associated with ITA skin type groups. Even though 71% of the sample 
was classified as having a light/fair skin type, 73.7% reported that they would tan 
deeply or moderately after spending several weeks at the beach in the sun without 
any sun protection.  These two statistics appear contradictory, possibly highlighting 
unreliability of self-report measures with respect to skin phenotype characteristics.239 
Spectrophotometry clearly has value as an objective measure of skin pigmentation, 
although self-report remains important as a measure of perceived skin type – with 
importance for perceived need for use of sun protection – and for sun sensitivity, 
which is only loosely related to sun colour.240  
 
6.7 SERUM S-100β LEVELS 
The fourth study objective was to identify any relationships between S-100β levels 
and the histopathological features of the tumours. The median serum S-100β levels 
of 0.05 µg/L were similar (0.06 µg/L) to those obtained by others.213 High levels  
(≥ 0.15 µg/L) of S-100β were found in one patient (1%). Elevated serum S-100β 
levels are known to correlate with melanoma progression and poor 
prognosis,124,125,241 therefore as per the assay manufacturer’s instructions, the 
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suggested threshold of 0.15 µg/L was used to reflect non-pathological levels of S-
100β. If 0.20 µg/L had been used as the threshold in this study, as others have 
previously done,241  the results would not have changed, as 99% of participants had 
levels below both thresholds.  
As all serum samples were obtained prior to wider excision of the tumour, it was 
anticipated that the S-100β levels reported in the QUT Melanoma study could reflect, 
in part, the inflammatory response to the diagnostic biopsy or alternatively the 
presence of the primary tumour. A previous study had reported that serum collected 
with the primary tumour still in situ correlated with the Breslow thickness of the 
tumour.242 This may be the explanation for the lack of a significant association 
between Breslow thickness and S-100β levels (P = 0.17) seen here. 
On the basis of the single serum sample obtained at diagnosis, it was not possible to 
report on S-100β in relation to disease progression; but only on prognosis by using 
the proxies of Breslow thickness, Clark level and mitotic activity. While S-100β 
levels were found to be significantly associated with mitotic activity (P = 0.05), the 
results were not clinically meaningful as only one percent of the samples reached a 
pathological level. This is an indication that more power was needed to reach any 
conclusion about the utility of S-100β as a marker of melanoma prognosis when 
using the histopathological proxies for prognosis. Regardless of whether the 
histopathological indicators for diagnosis are to be used as proxies for prognosis in 
future studies, or melanoma patients are observed for disease progression over time, 
examination of S-100β serum levels at regular intervals after diagnosis is suggested.  
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6.8 PUBLIC HEALTH 
General implications 
From a public health perspective it was pleasing to note that almost half (46.5%) of 
the study sample had three or more full body skin checks by a doctor in the past 3 
years, with 74% reporting they had had at least one full body skin check by a doctor 
in that time.  This compares favourably to the 35.3% of Queensland melanoma 
patients who reported having a whole-body skin examination in the 3 years before 
diagnosis in the large survey by McPherson et al,105 and could be interpreted as an 
indication that public health messages with respect to skin examinations are being 
heeded. The regularity with which participants in the QUT Melanoma Study 
undertook full body skin checks, in addition to 57% reporting that their “spot” was 
noticed less than 3 months prior to excision, may explain the large number of in situ 
lesions (43%) observed in the study. This proportion is slightly higher than the 
Queensland figures for 2002 which show that 36% all melanomas diagnosed in that 
year were melanoma in situ.76 
 
6.9 LIMITATIONS 
There are several limitations to this study. Much of the self-report information 
relating to adult and school years sun exposure required significant long-term recall 
of places, dates, sunburns and sun behaviour patterns. Others160 have previously 
commented on the potential for bias in this area. The clinical examination at T2 
provided an opportunity to minimise potential bias in some of these “problem” areas. 
For example, self-reported recall of eye and hair colour in teenage years was assisted 
by use of visual aids (see Appendices G and H). The use of spectrophotometry to 
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gain an objective measure of skin phenotype characteristics was also a valuable tool 
to minimise potential self-report bias. 
The method of melanoma classification was a limiting factor with respect to the 
analysis of melanoma according to type, with 15% of all melanomas being 
necessarily included in a non-homogenous category of “other melanomas”. It is 
possible that this proportion may have been lower if the histopathologist had been a 
member of the study team and additional reporting could have been requested. 
Consideration was given to allocating melanomas with two reported types to the first 
type mentioned in the histopathology report, but in the interest of accuracy this was 
not followed through.  
The recoding of variables with Likert scales greater in number than four meant that 
information with respect to extreme values or responses was lost, or assimilated into 
other groups. The collapsing of categories, while a standard part of analysis, was 
more a reflection of the small sample size. To limit any misclassification bias, 
wherever possible the methods used to recode these variables were based on methods 
used by others, or according to clinical advice. I acknowledge that it is possible that 
participants may have responded differently if given fewer choices in the first 
instance.  
There is always the possibility that the observed association between serum 
25(OH)D and Breslow thickness could be explained by the presence of confounding 
or bias. While there may be confounders for melanoma prognosis that are as yet 
unknown, the study controlled for factors that are known to influence vitamin D 
levels or that may affect melanoma prognosis, in a rigorous analytical process.  
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One area of potential measurement bias was identified and relates to serum 25(OH)D 
concentration. As discussed in the literature review there is a lack of agreement with 
respect to the most appropriate and reliable method to use for measurement of serum 
25(OH)D concentration and until a “gold standard” method, and assay, is identified 
for this process, the potential will exist for conjecture with respect to correct 
measurements. This is more important in comparing absolute values across studies 
than in comparing results within a study, where the samples were assayed in batched 
analysis at study completion using a single assay within a single laboratory with 
excellent quality assurance performance.  
There were several recorded measures that could not be used in analyses due to 
uncertainty concerning their reliability. Questionnaire self-report of previous solar 
keratoses and skin cancers removed or treated by a doctor, were subject to conjecture 
as many patients were unclear as to the actual nature of lesions that had been treated. 
For the same reason, age at time of diagnosis with the first skin cancer could not be 
included in analyses. In addition, during the clinical examination accurate 
quantification of solar keratoses was compromised as patients often presented with 
obvious signs of recent cryotherapy, or they reported having recently been to the 
dermatologist or GP and had “many” burnt off. For this reason, number of solar 
keratosis was also not included in any analyses. 
The sample size of 100 participants limited the comparisons between various sub-
groups and may be a possible explanation for the predominately null findings 
reported in this study. In addition, the study had low power to detect any effect 
modification, as in general the sample size required to detect this should be at least 
four times that required for the main effect.243 
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6.10 STRENGTHS 
Initial concerns that as this would already be a stressful time for the patient, and any 
further intrusions could be seen as unwelcome, proved to be unfounded as the study 
had a very high participation rate with 98% of patients approached agreeing to 
participate in the QUT Melanoma study. The sample size (n = 100) was therefore 
representative of the population approached to participate in the study (n = 102). 
Based on recent data from the Queensland Government,244 the study sample size (n = 
100) represents approximately 9% of the 1172 melanomas diagnosed annually in the 
Brisbane area in 2007–2009, and thus can also be considered representative of 
melanoma patients in the Brisbane population.  
Various attributes of the study melanomas confirm that the sample was 
representative with respect to the subtypes and anatomic sites of melanoma 
diagnosed in Queensland. The most common melanoma subtype seen in this study, 
superficial spreading melanoma (54%), was also the most commonly reported 
invasive melanoma subtype to the Queensland Cancer Registry in the period 1982–
2008 (54.9%).245  In the same period, the Queensland Cancer Registry reported that 
the trunk (33.5%) was the most common site for melanomas.245 Likewise, in the 
QUT Melanoma study melanomas were most commonly found on the trunk (37%).  
All serum samples were obtained at diagnosis and prior to wider-excision surgery 
over a 12 month recruitment period, which allowed for investigation of any effect of 
seasonal differences in serum 25(OH)D concentration on the relationships under 
investigation. 
Epidemiological studies often rely on self -assessment of skin colour and skin 
phenotype characteristics as a subjective guide to skin type. A positive finding from 
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this study was the value of reflectance spectrophotometry to objectively assess skin 
colour type and its features of brightness, chroma and hue. All skin type covariates 
satisfying the criteria for inclusion in the preliminary multivariable models were 
obtained from the spectrophotometric readings (although only ITA value was used in 
multivariable models). It is unlikely that these readings could have generated any 
measurement bias given that one person using one spectrophotometer according to 
the study protocol performed all examinations.  
Ultimately skin phototype (ITA value) was a confounder in the relationship between 
all the prognostic outcomes and vitamin D status, yet I was also able to demonstrate 
that there were significant associations between other skin colour variables and 
prognostic outcome variables and serum 25(OH)D concentration in bivariate 
analyses.  Further investigations that modelled these variables, in place of ITA value, 
could provide further interesting insight into the role of skin phototype characteristics 
in the association between vitamin D and melanoma prognosis. 
I was also able to measure the effect of a large number of possible confounders of the 
relationship between vitamin D status and melanoma prognosis. The failure to 
identify any significant associations in the Clark level and mitosis models, despite a 
number of risk factors common to both of these prognostic indicators and also to 
Breslow thickness, could have been due to low study power, or the true absence of 
association between the risk factors and Clark level and mitosis. This study was 
unable to distinguish between these explanations. 

Chapter 7: Conclusion 155 
Chapter 7:  Conclusion 
In conclusion, the aim of this study has been to identify and explore the nature of the 
association between serum 25-hydroxyvitamin D level at time of diagnosis and the 
outcome for those patients as predicted by the histological indicators of melanoma 
prognosis. The QUT Melanoma Study, a cross-sectional, observational study of 100 
melanoma patients in Brisbane, Queensland, provides new evidence to suggest there 
is a significant association between vitamin D insufficiency (< 50 nmol/L) at time of 
diagnosis with melanoma and thicker tumours (Breslow thickness ≥ 0.75 mm). The 
strength of this association increased when a lower threshold for vitamin D status 
(lower quartile of < 45.25 nmol/L) was examined. No evidence of any association 
between insufficient vitamin D status and the other prognostic markers of Clark level 
(Level 2-5 vs. Level 1) or mitosis (present vs. absent), or of any protective effect on 
melanoma prognosis of higher levels of serum 25(OH)D was observed. Given that 
thicker tumours are associated with a poorer prognosis; this finding suggests that 
insufficient vitamin D status at time of diagnosis with melanoma may be associated 
with a poorer prognosis.  
Blood sampling within days of the provisional diagnosis and prior to the wider-
excision of the tumour ensured that sun avoidance behavior did not impact on serum 
25(OH)D levels and allowed for accurate reporting of the participant’s vitamin D 
status prior to definitive wider-excision surgery. 
From a public health perspective, the reduction of mortality from melanoma is 
paramount and can only be achieved if melanoma is prevented or is diagnosed when 
very thin and preferentially when in situ. The QUT Melanoma Study was not 
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designed to examine vitamin D status and the “risks” for developing melanoma, so 
comment cannot be made with respect of the potential role of vitamin D in the 
prevention of melanoma. The study was instead concerned with 25(OH)D 
concentration and the outcome for melanoma – survival. While the QUT Melanoma 
Study adds to the knowledge of how vitamin D is associated with melanoma 
prognosis, the mechanism behind this association is yet to be elucidated. I suggest 
that other unmeasured factors in the vitamin D pathway, such as the VDR, could play 
a role as a result of their absence or reduced numbers within the melanoma and 
surrounding skin. Further, sufficient serum 25(OH)D levels may inhibit vertical 
growth of melanomas beyond a depth of 0.75 mm, as has been shown in animal 
models. The results presented here suggest that, if the findings are causal, ensuring 
that all members of the population were vitamin D sufficient (greater than or equal to 
50 nmol/L), would result in approximately 18% fewer thick melanomas – with their 
attendant poorer prognosis - being diagnosed.  
Queensland has the highest incidence of melanoma in the world; therefore the 
suggestion that sufficient levels of vitamin D might be protective for poorer 
melanoma prognosis could have wide ranging implications for the public health 
message with respect to both melanoma and vitamin D – regardless of the 
mechanism responsible. There may be inherent difficulties in devising an appropriate 
public health message that balances the need for optimal vitamin D status while at 
the same time avoiding too much sun exposure – and the risk of developing 
melanoma. Messages would require tailoring and this would be particularly 
important for indoor workers, fairer skin types, those with a family history of 
melanoma and the elderly. For example, rather than relying on sun exposure for 
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maintenance of adequate 25(OH)D levels, those with fairer skin types may be best to 
use vitamin D supplements. 
The mechanism of the potential benefit of sufficient levels of serum 25(OH)D for 
melanoma prognosis requires further study. Until then it would appear sensible for 
all Queenslanders to ensure that they maintain serum 25(OH)D levels greater than 50 
nmol/L. This would be particularly pertinent for those at a higher risk of developing 
melanoma – not to avoid developing a melanoma but to possibly protect against 
having a thicker tumour and thus a poorer prognosis. 
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Appendix A 
QUT Melanoma Study protocol 
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Appointment/Interview Guidelines 
 
Appointment 1 (T1) 
• Dr Cockburn/Cheng to give patient introductory letter  
• If patient wishes to be involved in the study, CW to meet and greet patient 
• Spend approximately 30 minutes with patient and give them a personal folder (identified with their study number) containing the PIS to read, the consent form to sign and the questionnaire to take home)  
• Give patient a copy of the consent form to place in their study folder 
• Make post-operative appointment and ask patient to bring the completed questionnaire with them to the post-operative appointment 
• Take patient down to Sullivan & Nicolaides collection room for first blood collection and introduce them to phlebotomist  
• If patients are ordered any other tests (e.g. scans), take them to the appropriate departments and organise tests for them 
 
Appointment 2 (T2) 
Prior to appointment 
• Organise patient folder (USE PENCIL TO RECORD DETAILS) 
• Ensure visual aids are present 
• Check alcohol wipes and skin wipes are available 
 
During appointment 
• Clarify any questions the participant may have regarding the study 
• Check completed survey and mark any queries with sticky tags 
• Ensure spectrometer is turned on and is blank against the paper 
 
Skin Reflectance Test 
• Prior to conducting test, ask participant about use of tanning products over the last month. Explain why the use of these products will negate need for testing at this interview  
• Wipe the skin sites with alcohol wipes and leave to dry for several minutes 
• While skin is drying ask hair, eye and skin colour questions 
• Take the readings at the left inner upper arm, left dorsum of forearm and the central forehead (as per collection instruction guidelines) 
• Write these readings down by hand on the clinical examination form 
• Explain, if asked, the meanings of these readings 
 
Naevi Count 
- Looking at freckle and lentigo counts 
- Solar keratoses – red, scaly rough texture; need to touch to identify 
- Naevi count 
• Check eyes for naevi 
• Check sun-exposed sites first always checking left side then right 
• Ask participant to stand under good light and check hand, forearm, upper arm, and then check neck front then back 
• Ask participant to remove shirt 
• Examine shoulders and upper back (leave bra on and count by lifting up straps)  
• Lower back – down to belt line/2.5 cms below umbilicus 
• Progress around to stomach, making sure not to count lesions twice 
• Count chest down to bra line, participant can put shirt back 
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Questions to ask: 
• Melanoma family history 
• solarium use 
• anatomic site of melanoma 
• hair as teenager (visual aids) 
• solar keratoses and skin cancers (clarify if patient is aware of differences) 
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Introduction to study letter  
 
 
 
   
 
The QUT Melanoma Study 
   Have you heard about vitamin D? Did you know that vitamin D levels in your blood may be affected by how much sun exposure you are getting? A new research study, The QUT Melanoma Study, is conducting a study to explore the relationship between sun exposure, vitamin D and melanoma in Australian adults.   Vitamin D has many roles in the human body and having adequate amounts of vitamin D is very important for building and maintaining a healthy skeleton throughout life. However, we also know that most of the vitamin D we need comes from the sun and the sun is considered to be a risk factor for the development of melanoma. In Queensland we have one of the highest rates of melanoma in the world, yet recent studies conducted in Brisbane have shown that almost one-third of the population may have low levels of vitamin D. This is one reason why we need to explore and understand more about the relationship between sun exposure, vitamin D and melanoma. The knowledge we gain may help in the fight against melanoma.  
 
We would like to invite you to participate in The QUT Melanoma Study.   
The QUT Melanoma Study has received full ethical approval (QUT ethics 
certificate number 0900000681). We are inviting adults aged over 18 years, who live in Queensland and who have been newly diagnosed with melanoma, to join the study.  Could you please let us know whether or not you would like to learn more about the study by signing on the reverse of this page? If you indicate that you are interested in reading more, we will give you an information sheet that explains in more detail why we are conducting The QUT Melanoma Study and what is involved in participating.   QUT research student, Candy Wyatt, will then contact you shortly after this to arrange a meeting at your convenience.  If you do not want to take part in this study we will not contact you again.  
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 Thank you for your consideration to support this important research.  
Yours sincerely,   Professor Michael Kimlin and Candy Wyatt (PhD Student)      AusSun Research Laboratory     Institute of Health and Biomedical Innovation Queensland University of Technology 60 Musk Avenue Kelvin Grove      QLD      4059 
 
CONFIDENTIAL   Date:  ____________  Name (please print):  ___________________________  Address (please print):  ________________________________________                    ________________________________________  Phone numbers:  ________________________________________  Email:    _______________________________________________     YES, I would like to know more about this study         
OR  
NO, I do not wish to be involved in this study.      
THANK YOU
 
 
PLEASE NOTE: Ticking this box does not commit you to anything at this stage. 
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QUT Melanoma Study consent form 
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CONSENT FORM for QUT RESEARCH PROJECT 
 
“The QUT Melanoma Study” 
 
Research Team Contacts 
Professor Michael Kimlin (Principal Researcher): 
Phone: 3138 5802 
Mobile: 0401 313 534 
Email: m.kimlin@qut.edu.au 
 
Candy Wyatt (Associate researcher/ PhD student): 
Phone: 3138 0275 
Mobile: 0418 748 172 
Email: candy.wyatt@qut.edu.au 
 
 
Statement of consent 
 
By signing below, you are indicating that you: 
• have read and understood the information document regarding 
this project 
• have had any questions answered to your satisfaction 
• understand that if you have any additional questions you can 
contact the research team 
• understand that you are free to withdraw at any time, without 
comment or penalty 
• understand that you can contact the Research Ethics 
Coordinator on +61 7 3138 2091 or ethicscontact@qut.edu.au if 
you have concerns about the ethical conduct of the project 
• agree to participate in the project 
• agree / disagree for testing, storage and re-testing of serum 
samples (please indicate by placing a cross in the appropriate 
box)  
I agree to the use of my blood and tissue samples for 
this project only (specific consent). 
 
      
   
Name 
I agree to the use of my samples for this project and for closely related projects in the future (extended consent). In this event I understand that my samples will be de-identified. I wish to be contacted if you intend to use my stored samples for future research. 
 
Signature  
Date  /  /   
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QUT Melanoma Study Participant Information Sheet 
 
 
 
 
PARTICIPANT INFORMATION for QUT RESEARCH PROJECT 
 
“The QUT Melanoma Study” 
 
Research Team Contacts 
Professor Michael Kimlin (Principal Researcher): 
Phone: 3138 5802 
Mobile: 0401 313 534 
Email: m.kimlin@qut.edu.au 
 
Candy Wyatt (Associate researcher/ PhD student): 
Phone: 3138 0275 
Mobile: 0418 748 172 
Email: candy.wyatt@qut.edu.au 
 
 
Description This study is being undertaken as part of a PhD project to look at the inter-relationships between sun exposure, vitamin D and melanoma. It is being conducted by a PhD research student based at the Queensland University of Technology’s Institute of Health and Biomedical Innovation (IHBI) AusSun Research Laboratory – Candy Wyatt.  There is very little information about how sun exposure and vitamin D levels might affect the development of melanoma in humans. This is an important gap in our understanding, given the high sun exposure of Australians in general and our growing interest in the role that vitamin D plays in many health outcomes. In this study we aim to examine how factors such as individual sun exposure and sun protection habits, personal characteristics (like skin, eye and hair colour, and number of naevi/moles) and vitamin D levels affect melanoma development and characteristics.   The research team requests your assistance because we require the participants in this study to be adults aged 18 years and over, with a diagnosed melanoma.  
 
Participation Your participation in this study is voluntary. If you do agree to participate, you can withdraw from participation at any time during the study without comment or penalty. Your decision to participate will in no way impact upon your current or future relationship with QUT (for example, your grades if you are a student there), or with your treating medical practitioner. 
 
If I decide to take part, what do I have to do?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Your involvement would include:   
• the collection of a venous blood sample prior to your surgery, 
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• completing a survey to provide basic data about you – your age, gender, education etc – and also about your skin type, past sun-exposure history, sun protection habits and any history of skin cancer, 
• an examination of your skin to count moles, freckles and sunspots (by a registered nurse)and  
• an assessment of your skin colour at three body sites (your inner-upper arm, hand and face), using a hand-held spectrophotometer (a painless test that shines light on the skin and measures reflected light), 
• having 2 more blood samples taken – one at 6 months and one at 12 months after your first sample was taken, 
• giving consent for our research team to examine some tissue samples from your melanoma. This does not involve you directly. The pathologist would send us the samples after they have completed their examination of the excised specimen. 
 
Who will take my blood and where will this be done? You will be able to have your blood samples taken by trained personnel at any Sullivan & Nicolaides Pathology collection room.  All other parts of the study will be conducted in your doctor’s rooms at your convenience. 
 
What happens to my blood and tissue samples? Blood samples: All of the blood samples will be stored in a freezer at QUT until the end of the data collection phase of the study. At that time, one portion of the initial blood sample will be tested for the level of vitamin D and a tumour biomarker called S100BB. Another portion of that blood sample will remain stored for possible future research looking at genetic risk factors for melanoma. The samples collected at 6 and 12 months will also remain stored for possible future research looking at levels of vitamin D and S100BB in relation to your melanoma.  Tissue Samples will be examined under the microscope to look for a number of different cells and proteins that may be present in melanoma tissue.   
All blood and tissue samples are stored securely, are only identified by a code and 
will be accessed only by qualified medical researchers. 
 
Expected benefits  
It is expected that this study will not benefit you. However, it may benefit the general population in the 
future. 
 
Will I find out the results of research using my samples? Due to the length of this study, the overall results will not be available for up to 18 months after you participate. Once these are available however, a summary will be posted on the AusSun website at http://www.uv.hlth.qut.edu.au/.   
Individual vitamin D results will also be posted on the website as numbers (e.g. M 007).  Use the number that is on the front of your “study folder” to identify your results, or simply contact Candy Wyatt. You are most welcome to share those results with your surgeon or General Practitioner.  
 
Future research using your samples After we have finished this particular study, if you have agreed, we will keep the information and remaining samples that you give us indefinitely. In the future we may match your information against other health registers and we may use your samples 
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for future biochemical or genetic studies. We may also contact you again to ask you to take part in a follow-up study but you will be under no obligation to do so. Any extra studies that use your samples will have to be approved by the Scientific and Ethics Committees at QUT and the institution carrying out the study, before your information and material can be used. Any information or material given to researchers will be identified by a code only, so it will not be possible for them to identify you in any way. You will not receive any notice of future uses of your information or samples, unless you have requested this on the consent form.  There is a chance that information derived from the samples that you are donating under this study may, in the future, have some commercial value, for example if they lead to the development of a commercial product. You will not be compensated for your participation in the study or for any future value that the sample you have given may be found to have. However, it is our intention that if money is generated as a result of research using your samples then some will be put into a special fund to be used for future research into skin cancer. 
 
Risks of this study There are no risks beyond normal day-to-day living associated with your participation in this project.  The project does require you to have venous blood samples taken by a person qualified to do so, and in some instances some minor adverse side effects and discomfort may occur. Minor risks are common to any venous blood sampling and include bleeding and/or minor bruising at the blood collection site, occasionally multiple punctures to locate veins, and temporary dizziness or fainting. In the very unlikely event that you experience one of the above side effects, prompt medical assistance will be provided.  Possible adverse effects of taking blood include bleeding and redness or swelling at the site, and in extreme cases fainting may occur. These risks will be minimised and managed by applying pressure to the puncture site and in the unlikely event of fainting, with prompt attention from clinical staff.  QUT provides for limited free counselling for research participants of QUT projects, who may experience discomfort or distress as a result of their participation in the research.  Should you wish to access this service please contact the Clinic Receptionist of the QUT Psychology Clinic on +61 7 3138 0999.  Please indicate to the receptionist that you are a research participant.  
Confidentiality All comments and responses are anonymous and will be treated confidentially.  The names of individual persons are not required in any of the responses.  The privacy of all volunteers in this research program is taken very seriously. When you fill out a survey or donate a sample of blood to this study we will make every effort to protect your privacy.  
• All your surveys and samples will be stored securely in such a way that they cannot immediately be identified as having come from you. They will be labeled with a unique barcode number so that they do not get confused with surveys or samples from someone else.  
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• Any identifying information (your full name, address etc.) will be stored separately from the samples and information you provide. Access to this identifying information is restricted to a small number of senior members of the study team.  
• No information that could be used to identify you or your family will be included in any report on the results of the study.   
 
Consent to Participate We would like to ask you to sign a written consent form (enclosed) to confirm that you understand what participation in this study entails and your agreement to participate.  
Questions / further information about the study 
Melanoma, sometimes referred to as malignant melanoma, is a cancer of pigmented cells in the skin. The number of people in Australia with melanoma has been increasing every year and Queensland has the highest rate of melanoma in the world. Men and women are equally at risk from developing melanoma.  
Ultraviolet radiation (UVR) reaches the earth from the sun. Excessive UV radiation from sun exposure is a major cause of various skin cancers.  
 
Vitamin D is important for building and maintaining a healthy skeleton throughout life. Some vitamin D is obtained through diet, but most vitamin D is obtained from exposure to the sun. Not getting enough sun exposure can cause low vitamin D levels. Recent studies conducted in Brisbane have shown that almost a third of the population may have low levels of vitamin D.  
How are vitamin D and UV from the sun linked? Vitamin D is produced when a substance in the skin cells is exposed to UVR from the sun. However, the amount of vitamin D produced is influenced by other factors such as skin colour, age, sunscreen use, season, time of day and latitude.  
 
Please contact the researcher team members named above to have any questions 
answered or if you require further information about the study. 
 
Concerns / complaints regarding the conduct of the study QUT is committed to researcher integrity and the ethical conduct of research projects.  However, if you do have any concerns or complaints about the ethical conduct of the project you may contact the QUT Research Ethics Coordinator on +61 7 3138 2091 or ethicscontact@qut.edu.au. The Research Ethics Coordinator is not connected with the research project and can facilitate a resolution to your concern in an impartial manner. This study has received full ethical approval from the University Human Research Ethics Committee (Approval Certificate number: 0900000681)
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Appendix E 
QUT Melanoma Study questionnaire 
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Appendix F 
QUT Melanoma Study Clinical Examination 
 
 
Clinical Examination       
Date:           /      /  
I.D:  ____________ 
 
Date of Birth:                                       dd          mm              yy  
1. Melanoma site 
 
 a. Where on the body was the INDEX melanoma found?  
 
  
 b. Draw on the figure below the position where the melanoma occurred: (if 
more than one melanoma, please draw these on the figure as well) 
 
   
 
2. Spectrophotometry 
Site L* A* B* 
Dorsal forearm    
Upper inner arm    
Forehead    
 
    /              / 
right right left left 
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3. BMI                        
 
Weight   ........  kgs     Height ..........  cms 
 
4. Skin Examination 
 
a. Naevi  
• brown to black pigmented macules or papules of any size which are darker 
than the surrounding skin 
 
Major Site 
 
 
Sub-Site 
Left-side 
Total      2- 5 mm    > 5 
mm 
Right-side 
Total     2- 5 mm    > 5 
mm 
Back and 
shoulders 
Lower back – 
subscapular 
      
 Upper back – 
suprascapular 
      
 Posterior neck       
Upper limbs Hand       
Palmar       
 Forearm       
 Upper arm       
Head and neck Face       
 Ear       
Anterior trunk Abdomen  
sub-costal 
      
 Chest       
 Anterior neck       
 
 
 
Iris naevi:  
Left iris Right iris 
 
 
 
b. Has the patient had any naevi previously excised?  1 Yes / 2 No 
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c. How many naevi have been excised?    . 
 
.................... 
 
d. Draw the positions of the excised naevi on the figure below: 
 
 
   
 
e. Freckles & lentigines 
 
• Freckles: irregular but sharply demarcated, usually small (<3/4 mm), 
uniformly pigmented macules (tan/light brown), occurring in clusters, 
usually on exposed body sites 
• Lentigo: irregular but sharply demarcated, size 4-10 mm, usually light 
brown to dark brown, tendency for confluence on sun damaged / sun 
exposed skin, sparse or scattered 
 
 
Site Freckles Lentigines 
Forearms   
Face   
Shoulders   
 
 
 Forearms                Face              Shoulders 
 0 1         2       3            0             1                2              3          0             1        
       
 
    2             3 
 
right right left left 
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f. Solar keratoses    
• superficial, rough scaly areas with erythematous background and ill defined 
margins. 
• if more than 50 at one subsite write “50+” 
 
Site Left-side Right-side 
Dorsum Hand  
 
 
Dorsum Forearm  
 
 
Forehead  
 
 
Cheek  
 
 
Nose  
 
 
Chin  
 
 
 
 
 
g. Hair colour   Natural?  1 Yes / 2 No 
  1 white/blonde       2 grey      3 light brown   4 dark brown  
  5 black                   6 red/blonde  7  red     
 other………………………… 
 
 
h. Eye colour Please tick one box 
 
  1 Blue    2 Grey     3 Hazel     4 Green      5 Brown     
  6 Other……………………………………………. 
 
 5. Family history of melanoma 
Do you have any relatives who have had a melanoma? 1 Yes / 2 No 
 
6. Solarium Use 
Did you ever use a solarium before 1980?   1 Yes/ 2 No 
Have you ever used a solarium since 1980?   1 Yes/ 2 No 
 
7. Previous melanoma 
Is this the first melanoma you have had?   1 Yes / 2 No 
Sites of previous melanoma:   
............................................................................................... 
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8. Other internal malignancies                                              1 Yes / 2 No 
Sites of other malignancies?   
................................................................................................. 
9. Vitamin D supplementation 
Do you take any vitamin D/calcium supplements?  1 Yes / 2 No 
Describe .......................................................................................................... 
10. CT scan 
Did you have a CT scan or a PET scan prior to your surgery? 1 Yes / 2 No 
11. Week-end activities 
Thinking back to your survey, did you/ do you play/supervise weekend sporting 
activities? 
1 Yes / 2 No 
Describe .................................................................................................................. 
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Appendix G 
Hair colour guide 
 
 
 
 
 
Black Dark brown  ‘Mousey’ blond Light blond 5. Red 
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Appendix H 
Eye colour guide 
 
 
 
 
        
         Brown         Hazel        Green      Blue/Grey 
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Appendix I 
Protocol for use of spectrophotometer 
 
 
 
 
SPECTROPHOTOMETRY 
 
N.B.  
• HANDLE WITH CARE AT ALL TIMES 
• DO NOT TOUCH WHITE DOT 
• REPLACE BLACK CAP AFTER CALIBRATION.  
• IF MACHINE IS TURNED OFF IT MUST BE RE-CALLIBRATED BEFORE 
USING AGAIN 
• WIPE WHITE DISC BETWEEN PATIENTS WITH ALCO WIPE 
• PLACE “BLUEY” UNDER ARM 
 
1) Place on flat surface & plug in at power point 
2) Turn on at rear of machine  
3) Take black cover off base of cradle 
4) Highlight “Condition 2” and Enter 
5) Highlight “Calibrate” and Enter 
6) Highlight “Zero” 
7) Hold up to natural light and press button once 
8) Wait for 3 clicks 
9) Menu automatically goes to “White” 
10) Press button again while in cradle  
11) For this study we are using “SCI” 
12) When measuring, seal but do not press against the skin 
13) Record L, A & B on clinical examination form 
14) Ensure numbers are recorded correctly  
15) Black cap on at end 
16) NEVER TOUCH WHITE
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Appendix J 
Ethics approval 
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Appendix K 
Serum 25(OH)D and Clark level (ordinal) modelling 
 
 
 
Ordinal logistic regression modelling for serum 25(OH)D concentration and           
Clark level 
 
Bivariate analysis 
Clark level was analysed as an ordinal categorical variable with three categories: 
Level 1, Level 2 and Levels 3–5, using ordinal logistic regression (proportional odds 
model). Results, reported with the coefficients, 95% confidence intervals and  
P-values are shown  in Table 1.1. 
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Table 1.1 
Bivariate ordinal logistic regression for Clark level (Level 1, 2 and 3–5) and all covariates  
Variable  Coefficient. 95% CI P-value 
25(OH)D (nmol/L) -.02 -.04, 0.00 0.12 
Vitamin D status 
  ≥ 50 nmol/L 
 < 50 nmol/L) 
 
 
0.67 
 
referent 
-.10, 1.44 
 
 
0.09 
Age  -.00 -.03,0.02 0.76 
Age group 
  < 60 years 
 ≥ 60 years 
 
 
-.40 
 
referent 
-1.15, 0.36 
 
 
0.30 
Sex 
  Male 
  Female 
 
 
0.34 
 
referent 
-.40, 1.08 
 
t 
0.37 
Melanoma type   0.00 
Melanoma site 
  Head & neck 
  Trunk 
  Upper extremities 
  Lower extremities 
 
 
0.04 
0.72 
0.72 
 
referent 
-.91, 0.99 
-.55, 1.99 
-.31, 1.76 
 
 
0.93 
0.27 
0.17 
Season of diagnosis 
  Winter 
  Spring 
  Summer 
  Autumn 
 
 
1.14 
-.06 
0.38 
 
referent 
0.14 2.15 
-1.20, 1.08 
-.64, 1..40 
 
 
0.03 
0.92 
0.46 
S-100β 10.78 0.38, 21.17 0.04 
Inner arm L* 0.07 -.07, 0.21 0.34 
Inner arm a* -.24 -.51, 0.03 0.09 
Inner arm b* -.25 -.42, 0.07 0.01 
Forearm L* 0.01 -.05, 0.08 0.69 
Forearm a* -.02 -.21, 0.17 0.84 
Forearm b* 0.03 -.12, 0.18 0.70 
Forehead L* -.01 -.12, 0.10 0.87 
Forehead a* -.06 -.19, 0.07 0.35 
Forehead b* 0.14 -.05, 0.33 0.15 
Inner arm chroma -.24 -.41, -.07 0.01 
Inner arm hue -.00 -.09, 0.09 0.98 
Forearm chroma 0.01 -.15, 0.17 0.90 
Forearm hue 0.01 -.05, 0.07 0.69 
Forehead chroma 0.01 -.14, 0.17 0.86 
Forehead hue 0.04 -.01, 0.09 0.14 
ITA 0.07 0.01, 0.13 0.02 
ITA group 
  Intermediate/medium 
  Light/fair 
  Very light/very fair 
 
 
0.73 
1.80 
 
referent 
-.72, 2.18 
0.17, 3.44 
 
 
0.32 
0.03 
BMI 0.05 -.03, 0.13 0.26 
BMI categories 
  < 24.9 
  25–29.9 
  30 + 
 
 
0.47 
0.51 
 
referent 
-.42, 1.35 
-.43, 1.46 
 
 
0.30 
0.29 
Weight 0.00 -.02, 0.02 0.94 
Height -.03 -.07, 0.01 0.16 
Naevi burden at diagnosis  -.00 -.00, 0.01 0.82 
Naevi burden at diagnosis 
  0–9 
  10–39 
  40+ 
 
 
-.20 
0.22 
 
referent 
-1.11, 0.71 
-.76, 1.20 
 
 
0.67 
0.65 
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Freckle density at diagnosis 
  Low 
  Medium 
  High 
 
 
-.03 
0.31 
 
referent 
-.97, 0.90 
-.80, 1.42 
 
 
0.95 
0.59 
Solar lentigo density at diagnosis 
  Low 
  Medium 
  High 
 
 
-1.41 
-1.10 
 
referent 
-2.68, -.14 
-2.32, 0.11 
 
 
0.03 
0.07 
Eye colour 
  Brown 
  Green/hazel 
  Blue/grey 
 
 
0.72 
0.74 
 
referent 
-.11, 1.54 
-.46, 1.94 
 
 
0.09 
0.23 
Burning tendency 
  Rarely/never burns 
  Sometimes burns 
  Mostly/always burns 
 
 
-.09 
-.06 
 
referent 
-1.22, 1.04 
-1.11, 0.99 
 
 
0.88 
0.91 
Tanning tendency 
  Tans deeply/moderately 
  Tans slightly/does not tan 
 
 
0.65 
 
referent 
-.19, 1.5 
 
 
0.13 
Hair colour as teenager 
  Black/dark brown 
  Light brown 
  Blonde, red, auburn, s/b*, blonde 
 
 
0.88 
-.32 
 
referent 
0.02, 1.75 
-1.31, 0.68 
 
 
0.05 
0.53 
Naevus density as teenager 
  Nil 
  Few/some 
  Many 
 
 
0.06 
-.40 
 
referent 
-.77, 0.89 
-2.31, 1.52 
 
 
0.88 
0.68 
Freckle density as teenager 
  Nil 
  Few/some 
  Many 
 
 
-.43 
1.13 
 
referent 
-1.20, 0.35 
-.90, 3.16 
 
 
0.28 
0.27 
School-years sun exposure 
  Low 
  High 
 
 
0.21 
 
referent 
-.64, 1.07 
 
 
0.62 
Adult Reported Sun Exposure 
(continuous) 
 
0.00 
 
-.00, 0.00 
 
0.59 
Adult Reported Sun Exposure   
  Low 
  High 
 
 
-.08 
 
referent 
-.83, 0.67 
 
 
0.84 
Primary school sunburns 
  0–5 burns 
  6–20 burns 
  > 20 burns 
 
 
0.35 
-.32 
 
referent 
-.44, 1.15 
-1.50, 0.87 
 
 
0.39 
0.60 
Secondary school sunburns 
  0–5 burns 
  6–20 burns 
  > 20 burns 
 
 
0.83 
0.41 
 
referent 
-.01, 1.67 
-.79, 1.61 
 
 
0.05 
0.50 
Adult sunburns 
  0–5 burns 
  6–20 burns 
  > 20 burns 
 
 
0.02 
-.07 
 
referent 
-.77, 0.82 
-1.23, 1.08 
 
 
0.96 
0.90 
Solar elastosis 
  Absent 
  Present  
 
 
-.03 
 
referent 
-1.20, 1.14 
 
 
0.96 
Sunscreen use 10 years ago 
  Wore sunscreen most of time 
  Wore sunscreen sometimes 
  Rarely/never wore sunscreen 
 
 
0.85 
1.09 
 
referent 
-1.58, 3.29 
-1.28, 3.46 
 
 
0.49 
0.47 
Sunscreen use 5 years 
  Wore sunscreen most of time 
 
 
 
referent 
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  Wore sunscreen sometimes 
  Rarely/never wore sunscreen 
0.31 
0.55 
-1.30, 1.92 
-.99, 2.08 
0.70 
0.49 
When was spot noticed? 
  Less than 3 months 
  3–12 months 
  > 12 months 
 
 
0.61 
-1.19 
 
referent 
-.24, 1.46 
-2.43, 0.05 
 
 
0.16 
0.06 
Family history of melanoma 
  No 
  Yes 
 
 
-.58 
 
referent 
-1.38, 0.22 
 
 
0.16 
History of previous melanoma 
  No 
  Yes 
 
 
-1.16 
 
referent 
-2.40, 0.08 
 
 
0.07 
History of other internal cancer 
  No 
  Yes 
 
 
0.76 
 
referent 
-.26, 1.77 
 
 
0.14 
Take supplements 
  No 
  Yes 
 
 
0.67 
 
referent 
-.36, 1.79 
 
 
0.21 
Ever smoked 
  No 
  Yes 
 
 
-.08 
 
referent 
-.83, 0.67 
 
 
0.84 
Education 
  Primary/Secondary school 
  Trade/ Technical certificate 
  Tertiary education  
 
 
0.52 
1.08 
 
referent 
-.44, 1.48 
0.21, 1.96 
 
 
0.29 
0.02 
*strawberry blond 
 
 
Selection of covariates for preliminary multivariable model 
Covariates whose p-value did not exceed α = 0.2 level in either bivariate model 
(Clark level and serum 25(OH)D concentration), were identified and are summarised 
below in Table 1.2. As explained previously, age (in years) and sex were also 
retained. Although serum 25(OH)D concentration was not significantly associated 
with Clark level at the bivariate level, there was moderate association (P = 0.12) and 
modelling continued to examine if negative confounding may be masking any 
relationships.  
 
 
 
 
 
 
 
 
 
 Appendices 239 
Table 1.2 
Age, sex and all covariates flagged at α < 0.2 level in the Clark (Level 1, Level 2 and Levels 3–5) and 
serum 25(OH)D concentration bivariate analyses 
Covariates 
 
25(OH)D 
P 
Clark 
P 
Age    
Sex   
Season at diagnosis 0.06 0.04 
Inner arm a* 0.03 0.09 
Inner arm b* 0.04 0.15 
Inner arm chroma 0.02 0.01 
ITA value 0.02 0.02 
 
 
 
Final model 
Missing values for skin phenotype statistics (2) were taken into account resulting in a 
model with 98 participants. As described above, age and sex were retained in all steps 
of the modelling process. The modelling followed the same method as was 
undertaken to examine the association between serum 25(OH)D concentration and 
Breslow thickness (≥ 0.75 nmol/L vs. < 0.75 nmol/L), Clark level (Levels 2–5 vs. 
Level 1) and mitosis (present vs. absent). At the completion of the process the final 
model (n = 98) contained age, sex, ITA value and primary school sunburns and is 
presented below in Table 1.3. 
 
Table 1.3 
Final models (crude and adjusted) of vitamin D status at three different thresholds for “sufficiency” at 
time of diagnosis and Clark level (Level 1, Level 2, Levels 3–5) 
Vitamin D status Crude OR 95% CI P Adjusted ORa 
 
95% CI P 
≥ 45.25 nmol/L 
< 45.25 nmol/L 
Reference 
2.36 
 
0.97, 5.70 
 
0.06 
Reference 
2.45 
 
0.95, 6.30 
 
0.06 
 
≥ 50 nmol/L 
< 50 nmol/L 
Reference 
2.01 
 
0.92, 4.39 
 
0.08 
Reference 
2.17 
 
0.96, 4.94 
 
0.06 
 
≥ 69.8nmol/L 
< 69.8 nmol/L 
Reference 
1.63 
 
0.65, 4.06 
 
0.30 
Reference 
1.51 
 
0.59, 3.89 
 
0.39 
a adjusted for age, sex, ITA value, primary school sunburns 
 
